


BIOTECH IN BAVARIA – MEDICINES OF TODAY AND THE FUTURE

**REPORT
2017/18**

including more than 300 company
profiles and contact details

managed by





*People are different and
so are diseases.*

That's why we are committed
to discovering and developing
personalised medicines and targeted
diagnostic tests to help people live
better, longer lives.



Bio^M – central point of contact for pharma and biotechnology in Munich and Bavaria

- consulting for founders-to-be, start-ups & SMEs
- grant & seed financing support
- pre-seed incubation & m⁴ award
- matchmaking, networking & partnering
- events, conferences & training
- representing Bavarian biotechnology world-wide
- investment opportunities
- central online platform: job exchange, company database and much more





invest
in
bavaria

Never stop exploring.

Be part of the digital future.

Right this way for R&D

Bavaria is the leading biotech and pharma location in Germany. With a high number of international pharma companies and new rising biotech stars, Bavaria offers the right environment and infrastructure for your company – especially when it comes to R&D.

In Bavaria you'll find the right ingredients: a wealth of potential partners and customers throughout the entire industry value chain and highly qualified personnel. Bavaria is the home of digital future and your perfect business location.

Discover the benefits of expanding your business to Bavaria. We do everything to get your business started: From arranging contacts with relevant players to identifying the perfect location for your company.

Our service is confidential and free of charge. Get in touch with us!

→ www.invest-in-bavaria.com

Imprint

Editorial staff: Dr. Almut Windhager,
Dr. Georg Kääb

Company Profiles: Dr. Christina Grimm

Data analysis was compiled together with
BIO-Deutschland e.V.

We thank the Bavarian companies and the regional
organizations of the Bavarian Biotechnology Cluster for
supporting this survey.

May, 2018

Contact

Prof. Dr. Horst Domdey, CEO Bio^M

Spokesman of the Bavarian Biotechnology Cluster

**The Bavarian and the Munich Biotechnology Clusters
are managed by:**

Bio^M Biotech Cluster Development GmbH

Am Klopferspitz 19 a

D-82152 Martinsried

Phone: +49 (0)89-89 96 79-0

Fax: +49 (0)89-89 96 79-79

E-Mail: info@bio-m.org

www.bio-m.org



Cover: iStock by Getty Images

The layout, graphics and other contents of this brochure
of the Bavarian Biotechnology Cluster are protected by
copyright law.

Layout-Design: MxM, Munich, www.mxm.de

Pictures copyright as indicated

Supported by the Bavarian Ministry of Economic
Affairs, Energy and Technology
www.stmwi.bayern.de/en/



VOSSIUS & PARTNER

Special ideas require special protection.

For over 50 years, VOSSIUS & PARTNER has been providing high-end consultancy for innovative companies in all fields of patent, trademark, design and copyright law. VOSSIUS & PARTNER works in your interest: competently, reliably, precisely and creatively.

Legal areas. Patents, trademarks and brands, design rights, copyrights, know-how protection, domains, competition law, anticounterfeiting, software and IT, law on employees' inventions, licensing, food law, distribution agreements, franchise agreements, R & D agreements, media law, right of publicity, antitrust aspects in licensing, supplementary protection certificates, pharmaceutical law.

Technical areas. Mechanical & electrical engineering, IT, physics, chemistry, biotechnology, pharmacology, life sciences.

Services. IP prosecution, IP litigation, IP searches, freedom to operate, contracts, annuities, arbitration, mediation, IP portfolio management, due diligence, strategic IP consulting, IP landscaping, IP valuation services.

It is not without reason that VOSSIUS & PARTNER is among Europe's most renowned law firms in the field of intellectual property.

CONTENT

Biotech in Bavaria is thriving	7
Prof. Dr. Horst Domdey – Spokesman Bavarian Biotechnology Cluster	
<hr/>	
Facts and Figures 2017	8
<hr/>	
Bavarian Biotech Cluster – Trends and Topics	14
<hr/>	
Highlights 2017	20
<hr/>	
Bio^M for BioEntrepreneurs	22
<hr/>	
International Affairs	24
<hr/>	
Biotech Centers in Bavaria	26
<hr/>	
New challenges for the Regensburg location	29
Dr. Thomas Diefenthal – CEO of BioPark Regensburg GmbH	
<hr/>	
Company Profiles	31

About this Study:


For the Bavarian Biotech Report, a biotechnology company has been defined as a company which develops and/or manufactures products on the basis of state-of-the-art molecular biological methods. Since conventional pharmaceutical companies are also increasingly using such methods, it is often difficult to differentiate between biotech and pharma.

The biotechnology companies were classified according to their size as either big biotech (more than 250 employees) or biotech SME (less than 250 employees). The classification into OECD and non-OECD biotech companies as found in previous reports has been dispensed with, as this does not accurately portray the diversity of the biotech pharma ecosystem.

The data were collected in cooperation with Bio-Deutschland e.V. It was possible to achieve a response rate to the survey of more than 50%. Possible deviations from previously published figures are the result of additional data gathered in this survey that also may refer to previous years. The period under review for this report is 2017.

There are about 300 company profiles listed in the appendix of this brochure (pp. 31). Not every company listed is also considered in this survey, for example some companies with very specific services, or selected medical engineering companies. Furthermore, some Bavarian biotech and pharma companies are included in the survey but have not activated their listing in the database of Bio^M. Also more than 500 Bavarian companies in medical engineering are not included in this survey.

Published in May, 2018




Bei Amgen
sind biologische
Arzneimittel in
Qualität
verwurzelt
und werden von
Zuverlässigkeit
genährt.

Eine solide Qualitätskontrolle und zuverlässige Versorgung sind genau so wichtig wie wissenschaftliche Innovationen.

Seit mehr als drei Jahrzehnten wird bei Amgen jedes Medikament mit Engagement, Leidenschaft und dem Streben nach Perfektion hergestellt.

Darum finden Sie bei Amgen die Biologika, die für die Behandlung Ihrer Patienten so enorm wichtig sind. Und das auch für die zukünftigen Generationen.

Weitere Informationen über Amgens Engagement für eine gleichbleibende Qualität und zuverlässige Versorgung finden Sie unter biotechnologybyamgen.de.



**BIOTECHNOLOGY
BY AMGEN®**

BIOTECH IN BAVARIA

is thriving

The current Bavarian Biotech Report relates to the significant rise in employment and solid growth. The suppliers of technologies and research reagents are particularly sought-after and they sell their innovations from Bavaria throughout the world. Young start-ups have access to a thriving environment of small and medium-sized companies, as well as big names in the healthcare industry, service providers, academic research institutes, investors, and support in founding a new business, not least thanks to Bio^M. Learning from one another is the secret to success, whether this is achieved by involving future operators and doctors or by close collaboration with experts in medical technology, as well as nutrition science. Bio^M is the catalyst which brings the key players together, thus accelerating the development of new and urgently needed therapies. Today, including a new drug in 2017, already nine therapeutics have been developed in Bavarian biotech SMEs and have reached markets and patients. Also, the Bavarian drug development pipeline is well-stocked and ready for the future (see pp 14).

I view the dawning age of digitization with great curiosity and optimism, as our field is based on knowledge and creativity. It is not yet possible to foresee the extent of the changes which will entail job losses in some sectors, yet I certainly



PROF. DR.
HORST DOMDEY
CEO of Bio^M; Spokesman Bavarian
Biotechnology Cluster

see more opportunities than threats in the field of pharmaceuticals and health. **P4 medicine** in particular - a concept to which Bavaria is committed - requires the momentum of digitization. I predict great opportunities for drug developers to identify new targets for **personalized medicine**. I expect that the impact of digitization on the pharmaceutical industry will be just as extensive as that of biotechnology during the past. Twenty-five years ago, a mere handful of enthusiastic start-ups had the idea of using knowledge of molecular biology both commercially and for the good of patients. Today, it goes without saying that biotech plays a central role in drug development, including antibodies and genetic tests. Equally, integration and big data analysis open up new avenues for **prevention** and **prediction**, and **participation** of informed patients is facilitated by digital possibilities. Although data protection is a challenge, we should not be deterred from seizing this opportunity before others do so first. I am delighted that Bavaria offers a multitude of initiatives, consortia, and start-ups with the energy and courage to advance digital medicine.

Bavaria is a promising location for the medicine of the future; everyone who believes in this vision and is striving towards this goal is cordially invited to participate.

Yours sincerely,
Horst Domdey

FACTS AND FIGURES 2017

Number of companies

In 2017, a total of approximately 364 companies were operating in Bavaria in the biotechnology and pharmaceutical industry. In Bavaria, the sector is particularly strong when it comes to small, innovative drug developers. There are 234 biotech companies, 40 pharmaceutical companies, 60 contract research organizations, and 30 suppliers. The 234 biotech companies comprise 180 Bavarian biotech companies and 54 international biotech companies. Companies counted as Bavarian biotech companies have their headquarters in Bavaria. With only two exceptions (**MorphoSys** and **Labor L+S**), these companies are small and medium-sized enterprises (SMEs) with less than 250 employees. For news updates, please refer to pp. 16. As international biotech companies, we count subsidiaries of a foreign parent company. The largest are **Roche** (6,000 employees in Penzberg), **Amgen** (600 employees in two separate divisions in Munich), and **Biogen** (350 employees), to cite some of the many famous names present in the region.

As for the 40 pharmaceutical companies, this category includes both subsidiaries of international companies such as **BMS**, **Daiichi Sankyo**, **GSK** or **MSD**, and stand-alone companies like **Bencard**, **Dr. Pfleger**, **Denk Pharma**, and many others.



JENS KLEIN

Managing, Director / CEO
AMSilk GmbH

AMSilk is the world's first industrial supplier of synthetic silk biopolymers. Sustainably produced using a patented biotechnological process. The high-performance biopolymers are distributed in the form of Silkbeads (microparticles), Silkgel (hydrogel) or Biosteel® fibers. In August 2017, AMSilk was named one of the 50 most innovative

companies worldwide by Technology Review and among the three finalists in the "Technology" category.

The 60 contract research organizations make an important contribution to the biomedical environment through their expertise in (pre)clinical studies. These organizations are service providers for both local and international drug developers and make Munich a leading center for clinical studies. Finally, 30 suppliers complete the picture by delivering material such as microscopy consumables.

Bavarian biotech SMEs are the main target group of BioM's networking activities and funding initiatives. These companies are focused on the development of new therapeutics and diagnostics, a field in which about 55 companies are active. The area is further strengthened by 39 providers of technology platforms, mainly assisting drug development. Likewise, the area of biotech devices and reagents is highly developed and features 27 companies providing specialized laboratory equipment, assay systems, and measuring instruments for research, among other things. In addition, biotech SMEs are active in the fields of industrial biotechnology, agriculture and food as well as bioinformatics and others.

Newly founded companies



In comparison to the previous year, the number of biotech companies grew on balance by +2. Here, 11 newly founded or relocated companies compensated for the closure or take-over of a total of 8 enterprises. The growth of more established companies, for example concerning the number of employees, more than counterbalanced the losses. According to our research, the fields of pharmaceuticals, CRO and supply also remained stable.

NEW COMPANIES (FOUNDED & RELOCATED)

COMPANY	CATEGORY	LOCATION
CatalYm GmbH	Therapeutics	Würzburg
Climedo Health GmbH	Bioinformatics	Munich
essentim GmbH	Devices	Munich
Inveox GmbH	Diagnostics	Munich
IRUBIS GmbH	Devices	Munich
lifespın GmbH	Diagnostics	Regensburg
T-CURX GmbH	Therapeutics	Würzburg
UroQuant GmbH	Diagnostics	Regensburg
ViGeneron GmbH	Therapeutics	Munich
Incyte Biosciences Germany GmbH	Therapeutics	Munich
Spark Therapeutics Germany GmbH	Therapeutics	Munich

Of the nine start-ups, seven were spin-offs from scientific research institutes. Six of the companies are active in the development of therapeutics and diagnostics; two are

The Bavarian Biopharma Sector – Number of Companies



involved in services for research and laboratory; and one in bioinformatics and data management. In Bavaria, around 30 start-ups actively participate in the upcoming field of digital medicine. However, many of them provide not only applications for biotech and pharma and, therefore, are not included in this report. The newly founded companies are located in Munich / Martinsried, Regensburg, and Würzburg. Many of them were supported by BioM's network and advice for founders (see p. 22). Further information about the individual companies can be found in the company profiles starting p. 31.

Employment

A total of 33,500 people are employed in the Bavarian biopharma sector, of which 14,500 are in biotechnology companies (+ 8%), around 13,500 are in pharma, 2,500 are in CRO and 3,000 are in supply. In comparison to the previous year, biotechnology companies demonstrate a steady growth of plus 8 %. This is primarily due to the growth of existing companies and is a reflection of the maturity of biotechnology in Bavaria. To the best of our knowledge, employment figures in pharma, CRO and supply are broadly stable.

In addition, around 10,000 scientists are employed in university or non-university research institutes of life sciences in Bavaria. When it comes to biomedicine or other fields of biotechnological application, no other location in Germany offers a comparable density of highly-qualified and highly-talented staff.

Funding

According to the inquiries conducted for the current 2017 Ernst & Young Biotech Report for Germany, EUR 627 million of external financing was poured into German biotechnology companies, of which around EUR 200 million flowed from Venture Capital (VC) and other financiers into private companies, around EUR 340 million was raised by listed companies through capital increase, and additionally, the company InflaRx's (Jena) international stock market launch with a considerable EUR 86 million. No new stock market launches were initiated in the Bavarian biotechnology scene in 2017. Bavarian companies could raise around EUR 140 million from VC or stocks, which amounts to a respectable 25% of the whole amount in Germany of EUR 540 million. More



DR. SIMON E. MORONEY

CEO
MorphoSys AG

In 2017, MorphoSys took an important step on its way to being an integrated biopharmaceutical company. A first milestone was the approval of Tremfya® by our license partner Janssen for the treatment of psoriasis, thus making the first drug of our antibody library available to patients. Another milestone was the FDA conferring the designation

Breakthrough Therapy to our antibody MOR208, and we were also able to publish clinical data on blood cancer which gives us hope for a bright future to come for this compound.

established companies - most notably the Freising-based company **Pieris** – could also generate upfront payments at around EUR 100 million with the aid of impressive cooperation agreements with big pharma.

Breath Therapeutics - a spin-off of the long-established Bavarian medical engineering and pharma company **PARI Pharma** with a strong involvement of the VC firms Gimv, Sofinnova Partners and Gilde Healthcare – raised more than EUR 40 million in financing negotiations.

Headlines were made when the US company Merck (operating as Merck Sharp & Dohme or MSD in Germany) bought the Martinsried based company **Rigontec**, which was originally founded in Bonn in Germany. MSD was willing to pay EUR 464 million - of which EUR 115 million was upfront and a further EUR 350 million upon reaching further milestones – which may be due to Rigontec's specific approach in the currently „hot“ field of immunotherapies.

Remarkably, a number of Bavarian companies have attracted so much interest that other companies have made strategic investments. The company Rentschler, for


The Bavarian Biopharma Sector – Employment

Employees in Biopharma companies






33,500

Employees in Life Sciences Research



10,000



example, purchased 10 % shares in the Martinsried-based **Leukocare**, and Janssen / Johnson&Johnson secured 10 % shares in the Bavarian-Danish enterprise **Bavarian Nordic** (listed on the Copenhagen Stock Exchange) by increasing capital.

Furthermore, the maturity of Bavarian drug developers was demonstrated by the number of small and medium-sized milestone payments obtained from numerous development partnerships with other biotech or pharma companies.

Drug pipeline

Bavarian biotech companies (Biotech SMEs and big biotech with Bavarian origins) are involved in a total of 206 development programs for new medicines. This amounts to approximately 30 % of the national biotech pipeline of active ingredients. Around 90 % of candidates developed in Bavaria are biopharmaceuticals.

Research is focused on new active ingredients to combat various forms of cancer (89 in total), as well as autoimmune diseases (29 in total). Further important indications include infections, diseases of the central nervous system and cardiovascular diseases.

An impressive 79 of the pipeline projects we count originate from **MorphoSys**, the largest Bavarian biotech company. Here, human or humanized antibodies are being developed, primarily in cooperation with big pharma companies like Janssen, Roche, Novartis, and GlaxoSmithKline, among others, though MorphSys also has its own development programs. The most advanced candidate is now tested in phase III against B-cell lymphoma. With its 13 of the 19 pipeline projects, **Bavarian Nordic** dominates the vaccine category. The company especially focuses on vaccines against smallpox and various forms of cancer. In the field of cell therapeutics, **Medigene**, **Multimmune** and **Apceth** are pursuing a total of 10 primarily oncological development programs. In the Bavarian drug development pipeline, 18 of the drug candidates are small molecules. The largest contribution is made by **4SC** with 11 candidates for oncology. Nine drugs developed by Bavarian biotech companies can already be found on the market.

Further information is given in the section 'Trends and Topics' starting p. 14.



DR. PHILIPP BAASKE

CEO
Nanotemper Technologies GmbH

The TOP100 Innovator of the Year award, the development of our new Tycho NT.6, a device designed for the measurement of protein quality, as well as the opening of our Sales & Service office in Boston were amongst our highlights of 2017. We were able to achieve these thanks to our outstanding team which has recently been strengthened by two very experienced

leaders. We are now particularly looking forward to 2018, the year in which we celebrate our 10th anniversary together with many partners and friends.



STEPHEN S. YODER


President and CEO
Pieris Pharmaceuticals GmbH

2017 was a transformative year, witnessing major partnerships and clinical progression in our two core therapeutic areas: immuno-oncology and respiratory disease. In the first half of 2017, we closed alliances with Servier in immuno-oncology and AstraZeneca in respiratory disease, while retaining US rights on several


programs. In the second half of 2017, our lead programs in these two areas (PRS-343 and -060) entered clinical development. With more than US-D 90 million earned from our partnerships in 2017, we will continue robust growth in Freising and Boston.

Drug Pipeline of Bavarian Biotech SMEs –

Number of Projects by Phase and Indication



Indications in Phases I-III



* not included are around 80 different antibody-programms by Morphosys in pre-clinic

TRENDS AND TOPICS

A Selection of Bavarian Activities



PROF. DR. DR. MICHAEL
VON BERGWELT

Director of the Dept. of Internal Medicine
III University Hospital Munich

Which research topic are you fascinated by?

My main area of interest is the role of B cells in tumors. We now know that B cells not only function as 'antibody producers', but also as master regulators that control other immune cells, including those in cancer. This results in considerable potential for the

direct therapeutic use of these cells, or their manipulation through certain drugs. The translation of our own research into therapeutic concepts for tumor patients is currently one of our main topics. This goal has been driving me for many years now and I am increasingly enthusiastic about our current progress.

What do you appreciate most about the Munich location?

Munich offers a critical mass of expertise in biomedicine that is unique in Germany, not only from the point of view of an immuno-oncologist. There are unique conditions for a science-driven development of new therapeutic standards here, starting from excellent basic research, moving on to very successful biotech and pharmaceutical companies, right up to world-leading clinical study groups and, finally, sustainable research and healthcare structures (e.g. all German Centers for Health Research, Comprehensive Cancer Centers, numerous international research alliances). My goal is very clear as I want to further expand our networks and thus create even more synergy and dynamics in order to translate possible cellular mechanisms into real therapeutic options.

Personalized medicine

The **Munich Biotech Cluster** is raising its profile as a location for personalized medicine. The concept "m⁴ – Personalized Medicine and Targeted Therapies" has become a strategic approach since it won the Leading-Edge Cluster Competition. Notably, Munich was also successful in the follow-up competition for the internationalization of leading-edge clusters: Having established the **InnoMuNiCH** project, Bio^M supports bi-national cooperation with Japan in the field of personalized medicine. Other current areas of focus include biomarker research and diagnostics, immunotherapy and digital medicine for application in cardiovascular diseases. Below you will find a selection of current highlights from business and science in 2017 and the first quarter of 2018:

Munich Leukemia Laboratory (MLL) as Germany's leading reference laboratory for leukemia has established a research cooperation with Illumina and IBM Watson. Together, the partners want to advance their approaches in diagnostics and personalized therapy for leukemia and lymphoma. To this end, 5,000 of a total of 500,000 samples from MLL's Biobank will be sequenced. The information obtained on genotype and phenotype will then be analyzed by artificial intelligence systems in the context of medical literature, guidelines and additional study results.

Exosome Diagnostics succeeded in market launch and reimbursement negotiations for the EPI test in the USA. This urine test is based on the analysis of RNA from exosomes and will help avoid unnecessary prostate biopsies. The European headquarters and a research location of the specialist for liquid biopsies are located in Martinsried.

The project group **Personalized Tumor Therapy in Regensburg** was changed into an individual division at the Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM), thus securing the steady financing by the Fraunhofer Gesellschaft. The group in Regensburg has special expertise in single cell analysis of disseminated cancer cells. Researchers are developing methods for the enrichment and detection of these cells as well as the analysis of their genome and transcriptome. In addition, they are working on diagnostic and predictive tests, in-vitro and in-vivo models for preclinical testing, and further projects.

The competition **m⁴ Award** was implemented by the leading-edge cluster m⁴ – Personalized Medicine. This pre-seed competition is intended to support founding teams from academia in the field of modern biomedicine. It has been held by the Bavarian Ministry of Economic Affairs since 2011. The funding is meant to support the development of a business idea to end up in a spin-off. Every two years, the amount of EUR 500,000 is awarded to each of five promising teams. The competition is coordinated by Bio^M start-up coaches who assist the winning teams during their incubation phase and beyond by passing on their expertise. Dr. Marcus Conrad and Dr. Bettina Proneth of the **Helmholtz Zentrum Munich** were among the five winners in 2017. Their idea is to use ferroptose – a cellular mechanism leading to regulated cell death – to fight against tumors. To this end, the researchers want to discover ferroptose inducing substances via a recently established screening platform and further develop their candidates for analysis in relevant tumor models.

Targeted therapies

Prof. Dr. Anja Bosserhoff und Prof. Dr. Claus Hellerbrand of the **Friedrich-Alexander-University Erlangen-Nuremberg** were also among the winners of m⁴ Awards. The researchers' aim is to find an orally administered drug against malignant melanoma. The active substance is meant to inhibit the protein MIA which is known to foster dangerous metastasis and inhibit the immune system fighting against the tumor.

Further award-winners include the team Tubulis Therapeutics, namely Dr. Jonas Helma-Smets, Dr. Dominik Schumacher und Prof. Dr. Heinrich Leonhardt of the **Ludwig-Maximilians-University Munich**, as well as Prof. Dr. Christian Hackenberger of the FMP Berlin. The group investigates antibody-drug-conjugates (ADC) for targeted cancer therapy. A molecular glue serves as a linker between the drug and the antibody and releases the toxin only inside the targeted tumor cells. A first ADC for the treatment of acute myeloid leukemia (AML) will be analyzed in preclinical tests which are funded by the m⁴ Award. Furthermore, the team won the Leibniz Founder Award in March 2018, and now is heading towards the registration as a GmbH by the end of the year.



Picture: FAU/David Hartfiel

PROF. DR. ANJA BOSSERHOFF

Chair in Biochemistry and Molecular Medicine, Institute of Biochemistry, Friedrich-Alexander University Erlangen-Nuremberg

Which research topic are you fascinated by?

I am fascinated by a precise understanding of cellular processes and interactions between different cells in our body. Many molecular pathways of healthy cells and tumor tissue are still not yet elucidated or known in detail. However, precisely this provides large potentials for

the prevention of diseases as well as their cure through targeted therapies. I am inspired by the possibility to contribute to this and apply our new findings in translational medicine.

What do you appreciate most about the Erlangen location?

As a full university, the Friedrich-Alexander-University offers a wide range of cooperation partners in different areas. This offers the possibility to look beyond one's own nose and integrate interesting new approaches into one's own research. As such, Erlangen is a very supportive location for a wide range of research projects.

ITM Isotopen Technologien München started its first phase III trial for targeted therapy against pancreatic and gastrointestinal tumors using radiopharmaceuticals. The active ingredient Solucin consists of two components, one of which is edotreotide, a somatostatin analogon which directs the injected active substance to the tumor. The second component is EndolucinBeta, a synthetic lutetium isotope which is taken up by cancer cells and has a cytotoxic effect.



Picture: Leopoldina, German National Academy of Sciences

Which research topic are you fascinated by?

My research on infectious diseases covers the analysis of RNA and will contribute to a better understanding and control of these diseases. The opportunities are particularly fascinating in times of growing antibiotic resistance and

PROF. DR. JÖRG VOGEL

Director Helmholtz-Institute for RNA-based Infection Research Würzburg and Professor and Director Institute for Molecular Infection Biology University of Würzburg

increasing importance of the microbiome.

What do you appreciate most about the Würzburg location?

Würzburg offers particularly strong research units investigating several infectious diseases. The short distances here are very supportive – both in terms of the close cooperation between medicine and biology, as well as the strong connection to the clinic.

MorphoSys in Martinsried has started its first pivotal study with an antibody from the company’s pipeline. This phase III trial investigates the efficacy of the antibody MOR208 against a certain subtype of blood cancer in combination with the chemotherapeutic agent Bendamustin. In addition, the first antibody developed by MorphoSys was authorized in the USA, Europe and other countries: Tremfya by the license partner Janssen is indicated for the treatment of psoriasis.

Immuno-oncology

Medigene focuses on personalized T cell-targeting immunotherapies and develops complementary platforms for cancer therapy. The company’s approaches in Dendritic cell (DC) vaccines, as well as T cell receptor modified T cells (TCRs), have been successful: Patient recruitment for the clinical DC vaccine trial for acute myeloid leukemia (AML) was finished in November 2017. In March 2018, the Martinsried-based company announced the start of the clinical phase I/II trial with their TCR immune cell therapy MDG1011, which is indicated for the treatment of various blood cancers.

Rigontec was acquired by MSD. Using the RIG-I linked metabolic pathway of the innate immune system, Rigontec follows a new approach for cancer immunotherapy. The company’s expertise will remain in Martinsried also after its acquisition by MSD.

Pieris Pharmaceuticals in Freising (now with headquarters in Boston) has again entered into several partnerships with pharmaceutical companies. Pieris focuses on anticalin-based therapeutic approaches. Anticalins are modified lipocalins, i.e. endogenous human proteins that naturally bind, store and transport a wide spectrum of molecules. In the field of immuno-oncology, Pieris signed a strategic development cooperation with Servier alongside a cooperation and licensing agreement with Seattle Genetics. An additional agreement with AstraZeneca was arranged concerning inhalative substances against asthma and other diseases.

Autoimmune diseases

Two further Bavarian research groups working on autoimmune disease therapies won m⁴ Awards. Prof. Dr. Matthias Mack und Dr. Kerstin Renner are investigating new therapeutic approaches for multiple sclerosis at the **University Hospital Regensburg**. They are looking into a combination therapy using steroids together with a specific humanized antibody which is directed against the surface protein CCR2. The idea is to transiently deplete immune cells to suppress neurotoxic immune reactions in the brain.

Dr. Valentin Bruttel und Prof. Dr. Jörg Wischhusen of the **University Hospital Würzburg** developed the platform technology AIM Biologicals. This platform allows for the

identification of autoimmunity modifying biologicals for an effective and targeted suppression of specific immune reactions. The m⁴ Award funding will be used to adapt and test the platform in the field of neuroinflammatory autoimmune diseases like multiple sclerosis (MS) or neuromyelitis optica (NMO).

Cellular therapy

Apceth has agreed on a new partnership for the production of cellular therapeutics and is now producing cancer vaccines for the Dutch company DCprime. Furthermore, the Munich-based company is driving its own approaches in cell-based gene therapy for the treatment of inflammation, autoimmune diseases and solid tumors.

TUMCells, the interdisciplinary center for cellular therapies at the Technical University Munich is another facility for the production of cellular therapies. This cooperation project of the Helmholtz Zentrum Munich, the Hospital Klinikum rechts der Isar (MRI), and the Technical University Munich has been established to support the translation of scientific projects to innovative cell and gene transfer medical products.

Regensburg is another location offering comprehensive competence in cellular therapy. **The Regensburg Center for Interventional Immunology (RCI)** develops Advanced Therapy Medicinal Products (ATMPs) against leukemia and solid tumors. A modern infrastructure including the José-Carreras-Center for somatic cell therapy enables a production for individualized immunotherapy.

Translational medicine

The **Center for Translational Cancer Research (TranslaTUM)** was opened at the Hospital Klinikum rechts der Isar in Munich in 2017. Here, a team of experts from medicine, engineering, electrical engineering and information technology, computer science and natural sciences works together to find new therapeutic approaches against cancer. Extensive exchange as well as the immediate proximity to the hospital will advance the translation into clinical practice.

The **Translational Research Center** in Erlangen also implements patient-oriented research and close cooperation with clinical physicians. Interdisciplinary



PROF. DR.
JULIANE WINKELMANN

Chair Neurogenetics Technical University
Munich and Director
Institute of Neurogenetics Helmholtz
Zentrum Munich

Which research topic are you fascinated by?

The clinical use of high-throughput technologies, genomics and other omics technologies, facilitates access to information on underlying molecular mechanisms in a more systematic way. This results in a completely new dimension for prediction and

prevention, diagnostics and individualized therapy. To me, this is one of the biggest opportunities and challenges of our time.

What do you appreciate most about the Munich location?

Munich is a unique research location, ranking first in many fields. This also applies to my fields of work, which include neurosciences and genomic research. I have high hopes that our new government will recognize and further promote these special conditions. As an important and internationally renowned research location, Munich will hopefully take part in the worldwide competition for top positions and the best brains.

projects enable the transfer of new findings from one indication to another, thereby developing therapeutic strategies for several diseases.

The **University of Würzburg** set up two new master courses in “Translational Medicine” and “Translational Neuroscience”. Course content such as experimental procedures, epidemiology and healthcare research will enable students to speed up the transfer of new findings from basic research into the clinic.



PROF. DR. CHRISTOPH
ANDREAS KLEIN

Chair of Experimental Medicine,
University of Regensburg, and
Fraunhofer-Institute for Toxicology
and Experimental Medicine ITEM,
Personalized Tumor Therapy

Which research topic are you fascinated by?

My main area of interest is the development of metastatic cancer. How do tumor cells manage to settle in distant organs and become a deadly threat for the patient? How can doctors intervene? To answer these complex questions, new technologies have

to be developed, the results have to be questioned and interpreted in the context of clinical reality, and finally new ground has to be broken in diagnostics and therapy.

What do you appreciate most about the Regensburg location?

Together with the university and colleagues from the surrounding hospitals (UKR, Caritas-Hospital St. Josef, Hospital Barmherzige Brüder) we have been able to create comprehensive translational research structures which are unique in Germany. This has largely been supported by the State of Bavaria and will make the ITEM-R rank first in clinical research.

Biomaterial is an indispensable resource for translational research. Therefore, in 2017 eleven biobanks joined forces in the German Biobank Alliance, which is funded by the German Federal Ministry of Education and Research (BMBF). **The Joint Biobank Munich (JBM)**, the **Interdisciplinary Bank of Biomaterials and Data Würzburg (ibdw)**, and the faculty of **Medical Informatics at the**

University of Erlangen-Nuremberg are participants from Bavaria. The aim is to facilitate a national and pan-European exchange of biosamples and data through harmonization and quality control.

Digitization

As in all areas of life, digitization is trend-setting in the healthcare industry. In recent years, numerous start-ups in the field of digital health have emerged in Bavaria and, particularly, in Munich. These include research service providers, such as **Climedo Health**, which offers software for clinical study management, or **Essentim**, which provides a wireless sensor system for the laboratory of the future. The company **Hellsicht** has set its focus on customised IT solutions for deep-learning applications, and **Bioviance** offers special expertise in data analysis for drug development. Further enterprises have specialized in the development of healthcare apps, for example **Thera Bytes** develops health-promoting games, or **Kaia Health** offers a digital training system against back pain.

The **Digital Health Accelerator**, initiated and funded by Roche, has also opted for Munich as a location for innovation. To this end, WERK 1 is the first accelerator for start-ups in the field of Digital Health to be funded by the State of Bavaria. This approach aims to promote digitization in the healthcare sector and mutual learning between industry and start-ups. In February 2018, five international start-ups whose products are already at a mature stage began a pilot phase. One of these start-ups is the Garching-based company **Inveox**, which offers a fully automated management system for biopsy preparation in the laboratory.

In 2018, the Bavarian government will launch the Initiative for Digital Medicine of the Future. One of the projects is **DigiMed Bayern**, which comprises more than 10 scientific partners under the leadership of the German Heart Center Munich and Bio^M. Using atherosclerosis as an example, data-based medicine is to be introduced in Bavaria. The aim is to make healthcare more predictive, preventive, personalized and participatory (P4 Medicine).

Technology platforms

Axolabs in Kulmbach was acquired by LGC. The contract research, development and manufacturing organization will continue the development of oligonucleotide-based therapeutics, combining it with LGC's GMP-compliant production of nucleic acid.

Proteros in Martinsried has entered into research cooperation with Janssen Biotech. The aim is to discover new lead substances against several epigenetic target structures in different types of cancer. Proteros uses its own technology platforms, as well as its expertise in structural biology and protein-small molecule interaction.

XL-protein in Freising has signed specific licensing and cooperation agreements with Horizon Pharma, AdAlta, and Jazz Pharmaceuticals. The agreements concern XL-proteins's PASylation technology for an extended substance half-life in plasma and increased efficacy of selected drug candidates.

As a leader in mRNA-based therapeutics, **Ethris** focuses on lung and liver diseases. The Martinsried-based company was able to arrange for strategic research cooperation with AstraZeneca which is scheduled for five years and relates to the indications asthma, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis.

NOT JUST ANOTHER CRO – WE FEEL RESPONSIBLE.

- ▶ Customized conduct of clinical trials for biotech and medical device companies
- ▶ Highest quality standards, accompanied by frequent and clear communication
- ▶ Combined know-how in all major indications through our 100+ in-house experts in Europe

fgk-cro.com

Owned and managed by:

Dr. med. Edgar J. Fenzl
+49 89 893 119-22
edgar.fenzl@fgk-cro.com

Dipl.-Stat. Martin Krauss
+49 89 893 119-25
martin.krauss@fgk-cro.com

Heimeranstrasse 35 · 80339 Munich · Germany

Delivering Reliability

 **FGK**
CLINICAL RESEARCH

HIGHLIGHTS 2017

Selected Bio^M Events

20 years Munich Biotech Cluster – 20 years Bio^M



350 guests from the industry, science and politics participated in the celebration „20 years Munich Biotech Cluster - 20 years Bio^M“. „Over the past two decades, we have created perfect conditions and a functioning network that give our life sciences companies the best start,“ said Prof. Dr. Horst Domdey, CEO of Bio^M. In his keynote lecture, Prof. Dr. Ernst-Ludwig Winnacker (see picture) honoured the achievements and potential of molecular biology, and the development of the Bavarian biotech industry.

Forum Science & Health



About 300 stakeholders from the health sector attended the first Forum Science & Health at the monastery of Fürstenfeldbruck in July. The special emphasis of this new event series is on basic medical research with an interdisciplinary view on respective subject areas. Many participants actively contributed to the numerous discussions and workshops. Nobel Prize winner Prof. Dr. Jules Hoffmann (see picture) opened the event with his insights into the evolution of the immune system. On behalf of the Bavarian State Ministry of Economic Affairs, Bio^M is organizing the next Science & Health Forum on 3-4 July, 2019.

Seminars and training courses



In 2017, Bio^M offered a total of ten training courses, workshops and seminars for the Bavarian Biotech Cluster. The certified Good Clinical Practice course, as well as the cooperation event with Johnson&Johnson on the topic of clinical development of biological therapeutics were amongst several events that met with great interest. The Bio^M Crash Course in Drug Development lasted several weeks and taught compact knowledge on topics from preclinical to regulatory affairs. The two-day practical course Fundamentals of Fermentation was held in cooperation with the Weihenstephan-Triesdorf University of Applied Sciences in February (see picture). In addition, numerous external partners rented Bio^M's seminar rooms to run their roadshows.

Bio^M Dinner



In December, the board members and managing directors of Bavarian biotechnology and pharmaceutical enterprises met for the traditional Bio^M Dinner at the Lenbach Palais in Munich. The speeches of then Minister of State Ilse Aigner as well as Han Steutel, Managing Director of Bristol-Myers Squibb Germany and Chairman of the Board of vfa, gave all participants food for thought during the subsequent networking. In the picture: Han Steutel, Bristol-Myers Squibb and vfa; Ilse Aigner, Bavarian State Ministry of Economic Affairs; Prof. Dr. Horst Domdey, Bio^M (from left to right)

Bio^M FOR BIOENTREPRENEURS


A Start-up Accelerator for the Future of Medicine

Bio^M supports Bavarian biotech companies through each stage of their business development. Bio^M has developed a unique support program which is customized for aspiring start-ups and entrepreneurs in the life sciences sector.

The around 50 experienced biotech and pharmaceutical experts in the **Mentor Circle** support aspiring start-ups and young entrepreneurs on a voluntary basis. Founding teams can polish their presentation and receive honest and constructive feedback in individual **Pitch Doctor** sessions. The intensive four-week training set-up of the **BioEntrepreneur Bootcamp** allows founding teams to validate their business concept, get in touch with potential customers and key opinion leaders and meet supportive field and investor representatives. Founders meet four to five times a year in the informal setting of the **BioEntrepreneur Lounge**, where they exchange ideas with other founders and learn from experienced counterparts. The **BioAngels** network improves the prospect of finding a suitable investor. Two to three times a year, pre-selected and well-coached founder teams are given the opportunity to present their business concept to around 30 investor representatives at BioAngels

events. Every second year, Bio^M coordinates the **m⁴ Award**, a pre-seed funding program of the Bavarian Ministry of Economic Affairs which focuses on medical biotechnology and supports innovative academic projects with spin-off potential. Additionally, Bio^M fosters a lively and closely connected environment for start-ups through numerous and inspiring networking and kick-off events such as the **BioEntrepreneurship Summit**.

Bio^M offers BioEntrepreneurs a unique virtual incubator for life sciences start-ups.





The first **BioEntrepreneurship Summit** brought together all relevant stakeholders of the bio-entrepreneurial and health tech ecosystems. From students and scientists in the life sciences, pre-seed teams and experienced life sciences entrepreneurs to supporters, investors and industry leaders – about 200 participants joined the successful event to learn, meet and expand their network. The next opportunity to take part in the BioEntrepreneurship Summit will be in October 2019.



The five winning teams of the **m⁴ Award 2017**. The Bavarian **m⁴ Award** supports academic research projects with spin-off potential in the pre-seed phase. The program was launched in 2011 and has an annual budget of EUR 2.5 million. The purpose is to enhance and validate research results in the area of medical biotechnology and to get ready for seed-funding. Successful projects receive not only financial support but also extensive coaching from Bio^M, the relevant technology transfer organizations, mentors and other experts.

INTERNATIONAL AFFAIRS

Support for Business Development

Bio^M is the central point of contact for companies, investors and other key players on national and global level seeking information and access to the Bavarian life sciences sector. Likewise, Bio^M offers Bavarian companies support in identifying financial and cooperation partners worldwide and in exploring international markets. Bio^M has formed close relationships in global key markets, with a particular focus on Japan in recent years.



Signing of an in-depth Partnership Agreement between Bio^M and the Osaka region. Left to right: Franz Josef Pschierer, then State Secretary (today Minister) of the Bavarian Ministry of Economic Affairs; Prof. Dr. Horst Domdey, CEO of Bio^M; Mayuko Nagano, Chief Senior Staff of Osaka Prefectural Government; Dr. Tamio Sugawara, Coordinator of Osaka Bio Headquarters.

Japan - a key partner country

2011 marked the start of a transnational biotech and life sciences cooperation agreement between Bio^M and the Osaka Prefecture in the Kansai region of Japan. The partnership involves an exchange of information about new technologies in each region, its industrial development and academic potential. Both cluster organizations regularly inform each other about their best practices in technology transfer and their support for small and medium-sized enterprises (SMEs) when going international. The intention is to pave the way for both industry-industry and industry-university cooperations between the two regions. The partnership with Japan is further strengthened by the project InnoMuNiCH, which is funded by the German Federal Ministry of Education

and Research (BMBF) in the context of internationalizing German leading-edge clusters. This project fosters the development of binational cooperation projects related to Personalized Medicine. Every year, Bio^M in collaboration with Bayern International organizes and supervises a joint booth at the expo BioJapan. This is preceded by an exclusive one-day B2B partnering event in Osaka, initiated and supported by Bio^M, hosted by Osaka Prefecture and the EU-Japan Center. The event offers partnering opportunities for European SMEs and Japanese business partners from pharma, biotech, medical engineering and life sciences research facilities.

Bio^M worldwide

The bioXclusters Alliance, which was started with support from the EU, offers further assistance in exploring various global markets. Bio^M and three European partner regions are working to facilitate life sciences SME access to challenging target markets. To this end, a total of 8 Gateway Agreements were signed in 2017, whereby a gateway indicates an organization in the target country, which acts as a point of entry for European SMEs. Services offered include market surveys, support with regulatory affairs, and the identification and fostering of contacts with relevant R&D partners, commercial partners or distributors. The target countries bioXclusters focuses on are Japan, USA, China, Brazil, South Korea, Australia and Canada. In 2017, around a dozen Bavarian companies were already using the aid of a gateway to gain access to new target markets.

European collaboration

In addition, Bio^M is involved in the Council of European BioRegions (CEBR), where Dr. Stephanie Wehnelt, Bio^M, was elected as President of the Board in March 2018. More than 30 European life science regions exchange information, optimize their services and team together to raise EU funding. Close connections to Genopole and Medicen in Paris also allow for valuable contacts and the exchange of new ideas for collaborations.



17 Bavarian companies, supported by Bio^M, were showcased in Bayern International's Bavarian Pavilion at BioJapan 2017.

“Bio^M's contacts and knowledge have been extremely valuable in driving forward the internationalization of our SpheroTests. In Asia in particular, it is very difficult to find suitable partners to place our 3D microtumor technology for the optimization of cancer therapy in this huge healthcare market.”

Dr. Barbara Mayer, CSO and co-founder SpheroTec GmbH

„To accelerate Japanese-German cooperations further, Bio^M is currently setting up a virtual R&D platform, connecting selected specialists and their networks in the field of biomedicine. Projects can be submitted by both countries and relevant potential partners will be identified.”

Prof. Dr. Horst Domdey, CEO Bio^M



Participants of the Council of European BioRegions (CEBR) Annual Meeting in March 2018 at Bio^M. Dr. Stephanie Wehnelt (top row, third from left), Head of International Affairs at Bio^M, was elected as President of the Board.

BIOTECH CENTERS IN BAVARIA

Regional Networks and Incubators

In Bavaria, a lively biotech sector has established at five locations. The neighborhood of scientific institutions, providers, technology parks, and support by cluster organizations creates winning environments for attracting and founding biotech companies. In the biotechnology regions of Würzburg, Regensburg and Munich, the focus lies on biotechnology and healthcare. The other two clusters, Freising-Weihenstephan and Straubing, are specialized more on “white” (industrial) applications of biotechnology. In order to support and make better use of the particularities and strengths of the different regions, individual network organizations are responsible for the management of the respective clusters. Bio^M Biotech Cluster Development GmbH manages the metropolitan region of Munich, ranging from the Alps in the South almost up to the river Danube in the North. The BioPark Regensburg GmbH manages the region in Eastern Bavaria and the IGZ Center’s organization represents the region of Würzburg and Northern Bavaria. The cluster organizations’ objective is the development and marketing of the respective locations in the interest of the founders, companies and scientists. Furthermore, they are building a network of companies, universities, research facilities, university hospitals, chambers and associations, investors, funding authorities, advisers, and other players in the clusters. Bio^M Biotech Cluster Development GmbH has been coordinating and networking the biotechnology activities and has made great efforts all over Bavaria since 2006.

Erlangen and Nuremberg

The European Metropolitan Area Erlangen-Nuremberg is an internationally leading location for medical technology.

Cluster organization:

Medical Valley

Incubator: Medical Valley Centers in Erlangen (>5,000 sqm) and Forchheim (>2,300 sqm)


www.medical-valley-emn.de



Munich

Bio^M is located in Martinsried, the heart of the Munich Biotech Cluster. The cluster has a strong focus on health, i.e. personalized medicine. The cluster organization Bio^M is the central point of contact for the biotechnology sector in Munich and Bavaria. Bio^M offers a wide range of services and events and has developed a comprehensive incubation programme for company founders in the field of biotechnology.

www.bio-m.org



IZB Martinsried and Freising

The Innovation and Start-up Center for Biotechnology (IZB) in Planegg-Martinsried (focus on medical biotechnology) and Freising-Weihenstephan (focus on bio, agricultural and nutritional sciences) has developed into one of the top biotechnology centers in the world and offers young biotech start-ups 26,000 sqm of optimal building infrastructure for biotechnology.

www.izb-online.de





Würzburg

The Innovation and Start-up Center close to the Julius-Maximilians-University offers lab space and has developed a comprehensive program for promoting start-up activities in the region. Cluster organization: Innovation- and Start-up Center (IGZ) Würzburg
Incubator: IGZ Würzburg (>5,000 sqm)
www.igz.wuerzburg.de



Regensburg

The Innovation center and Start-up Center on the campus of the University of Regensburg offers state-of-the-art laboratories as well as comprehensive technology services. Cluster organization: BioPark Regensburg / Healthcare Regensburg
Incubator: BioPark Regensburg (>18,000 sqm)
www.bioregio-regensburg.de



Straubing

The BioCampus in the port of Straubing focuses on creating value from biobased resources, biomass logistics and start-up management. In close vicinity to the TUM Campus Straubing for sustainability and industrial biotechnology, it offers lab space, offices, and business support. Cluster organization: BioCampus Straubing, Incubator: BioCubator (1,200 sqm, enlargement being planned)
www.hafen-straubing.de



Industrial Biotechnology in Bavaria

Managed by Industrielle Biotechnologie Bayern Netzwerk GmbH. Established in 2008, IBB Netzwerk GmbH catalyzes the implementation of innovative biotechnological processes and industrial procedures. The main task is to connect partners from large industry, small and medium-sized enterprises, and academia, to implement joint projects in Industrial Biotechnology and sustainable economy.
www.ibbnetzwerk-gmbh.com



THE SUCCESSFUL INNOVATION CENTRE

MADE IN REGENSBURG



A company of the City of Regensburg

Health Industry of Regensburg

- 1.4 billion Euro turnover
- 15,500 employees

Cluster BioRegio Regensburg

- 51 companies (Life Sciences)
- 3,863 employees

BioPark Regensburg

- 18.000 qm area
- 36 tenants
- 600 employees
- flexible leasehold concept & single offices
- comprehensive range of technology & services
- personal consulting and flair
- direct motorway connection
- located on the University Campus (Infrastructure)
- excellent location factors
- own day-care facility
- over 40 start-ups since 1999
- conference rooms and theatre for external rent
- accessible routes to the most important networks
- active location marketing

Member of  CLUSTER
BIOTECHNOLOGIE
BAYERN

BIOPARK
REGENSBURG GMBH

NEW CHALLENGES

For the Regensburg Location

BioPark Regensburg is consolidating its management activities in the healthcare sector with the new umbrella brand "Healthcare Regensburg". Interview with Dr. Thomas Diefenthal, CEO of BioPark Regensburg GmbH.

Why is the BioPark Regensburg interested in the healthcare sector?

Alongside our core life sciences business at our biotechnology location "BioRegio Regensburg" we work - and have done so for the past few years - at an interdisciplinary level. Our strength is our small regional cluster with short distances and clear players. Many of the products, projects and networks involved in BioRegio Regensburg already had a regional connection to the healthcare industry. It was an obvious step to extend BioRegio Regensburg in this direction.

You presented the Masterplan Healthcare in Regensburg in 2017, a project in which more than 100 partners were involved. How did you organize the collaboration?

First of all, it was very important to listen to all of the region's issues, problems and approaches. The key players - hospitals, healthcare facilities, medical practitioners, universities, government and administration - participated in a total of six workshops. All in all, we collected 266 ideas. Together with an external consulting firm, we elaborated common focal points and initial recommendations for action.

What is the idea of the Masterplan Healthcare in Regensburg?

The masterplan outlines challenges, potentials and recommended actions for Regensburg and the region. Alongside issues like 'aging society' and 'qualified professionals and training', topics such as 'innovation and start-ups' and 'location marketing' were of great interest to us. It is precisely in these areas that the BioPark can show its strengths. Together with our affiliated company TechBase, which is implementing a digital campaign promoting start-ups in the Oberpfalz/ Bavaria, we are also tackling the exciting topic of digitalisation in the field.

Which opportunities for health arise from digitalisation?

A multitude; just consider the administration and handling of medical data (see the electronic medical record) or the possibility of relieving the strain on the swiftly growing care sector (see electronic assistance systems). Some European countries such as Denmark or Lithuania are striking examples of what is possible in this area. This topic is very important at the BioPark, too, for example for the Tumor Center, the Regensburg Center for Interventional Immunology or the Fraunhofer Project Group.

What are the next steps?

As part of our remit to promote the economy, we want to extend and invigorate the **Cluster Healthcare Regensburg**. In addition, we have already launched the **Digital Health Initiative Regensburg**. Furthermore, we organize Innovation Days at our Regensburg location such as our recent event about digitalisation in care. We, the universities and the TechBase initiate start-up events on these topics. We also travel to national and international trade fairs with the key players and help to get started various projects.




DR.
THOMAS DIEFENTHAL
CEO of BioPark Regensburg GmbH



The Bavarian Biotech Cluster

Bavaria – top location for biomedical innovation



Cluster activities

- Bavarian biotech report: the annual survey of the biotechnology sector
- close collaboration of all Bavarian biotech locations
- representation at international trade fairs
- interlinking business and science
- innovation transfer

Company Profiles

2bind GmbH



Contact:

Am BioPark 11, BioPark III
D-93053 Regensburg
Phone: +49 (0) 941 20000890
E-Mail: info@2bind.de
Internet: www.2bind.de

BIOTECH DNA & PROTEIN ANALYTICS

Keywords: Small Molecules, Molecular Diagnostics, Peptide/Protein, Bioanalytics, Drug Development, R&D Service

2bind is a CRO (certified by NanoTemper) in the area of biophysical analytics to study molecular interactions with focus on early drug development (hit identification, hit validation and hit characterization). Four core technologies (MST, nanoDSF, BLI and ITC) allow our experts for studying molecular interactions in terms of classical binding parameters such as affinity, kinetics, thermodynamics and stoichiometry. We offer a broad portfolio of biophysical assays starting at High Throughput Screening, Binding analyses in biofluids (such as sera) up to competition assays. Our Biotech and Pharma customers benefit from a strong expertise in biophysical methods, from customized milestone-based projects with clear timelines and reliable cost structures. Be smart work with the experts!

4SC AG



Contact:

Dr. Anna Niedl

Fraunhoferstraße 22
D-82152 Martinsried
Phone: +49 (0) 89 700763-0
Fax: +49 (0) 89 700763-29
E-Mail: public@4sc.com
Internet: www.4sc.com

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Autoimmune Diseases, Small Molecules, Molecular Modelling, Medicinal Chemistry, Drug Development, Oncology

4SC focuses on the development of novel small molecule drugs that target key mechanisms of cancer development, such as the enzymes lysine-specific demethylase 1 (LSD1) or histone deacetylases (HDAC), for example. Such drugs are intended to provide patients with innovative treatment options that are more tolerable and efficacious than existing therapies and provide a better quality of life.

4SC's current product pipeline includes two programs in clinical development: resminostat and 4SC-202, as well as 4SC-208, which is in the preclinical stage of drug development.

4SC's goal is to advance its own drug development programs in order to increase the value of the Company as a whole through entering into valuable partnerships with pharmaceutical and biotechnology companies for the further development or commercialization of 4SC's drug candidates, and/or the eventual marketing and sales of approved drugs in select territories, such as Europe.

ABF GmbH

CRO

Keywords: Metabolomics, Analytical Chemistry, Biomarker Discovery & Development

ABF is an accredited (ISO 17025, GLP) bioanalytical contract research laboratory with almost three decades of experience in method development, validation and application in the field of biomarkers and biomonitoring. The lab has particular experience in the analysis of compounds within clinical and toxicological studies by application of LC-MS/MS and GC-MS(/MS). Clients are from the occupational, environmental, food, tobacco and pharma fields. Since end of 2001, ABF provides its services to corresponding industry, academic and governmental institutions. We can offer skills of a staff (10 employees), almost all of them with an academic background, with a wide range of know-how, allowing flexible working approaches. Our aim is to provide excellent, high quality services; meeting or exceeding our customers' expectations. Our service goes beyond sample analysis, we help customers to evaluate and interpret data. Additional keywords: Instrumental Analytics, LC-MS/MS, GC-MS(/MS), Method Development, Validation and Application.



Contact:
Dr. Max Scherer

Semmelweisstraße 5
D-82152 Planegg-Steinkirchen
Phone: +49 (0) 89 535395
E-Mail: max.scherer@abf-lab.com
Internet: www.abf-lab.com

abf diagnostics GmbH

PHARMA SUPPLIER & TRADE

abf diagnostics develops, manufactures and markets products and solutions for the collection, storage and onsite analysis of biological traces and samples. Our strategic focus lies on innovations in pre-analytics and de-centralized testing. Our second business area comprises contact-less digital methods for the detection, identification and documentation of biological or chemical traces.



Contact:

Raiffeisenstraße 34
D-85402 Kranzberg
Phone: +49 (0) 8166 9986 130
Fax: +49 (0) 8166 9986 140
E-Mail: info@abfdiagnostics.com
Internet: www.abfdiagnostics.com

Activoris Medizintechnik GmbH

MEDTECH

Keywords: Regulatory Affairs, Logistics, Pneumology, Devices, In-Vitro-Diagnostics

Activoris is a German outsourcing specialist for pharma, medtech and diagnostics companies. Activoris supports its clients with contract manufacturing, device developments, regulatory and business consulting as well as administration support. Activoris' clients are among both well-established corporations and life science startups. With Activoris, they achieve more flexible, cost-efficiency and a faster time-to-market.



Contact:

Wohraer Str. 37
D-35285 Gemünden
Phone: +49 (0) 6691 97990 0
Fax: +49 (0) 6691 97990 25
E-Mail: info@activoris.com
Internet: www.activoris.com



Contact:
Prof. Dr. Götz Münch

Fraunhoferstr. 9a
D-82152 Martinsried
Phone: +49 (0) 89 2000 204-10
Fax: +49 (0) 89 2000 204-20
E-Mail: info@advancecor.com
Internet: www.advancecor.com

advanceCOR GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Cardiovascular Diseases, Peptide/Protein, Drug Development, Inflammation

advanceCOR is a drug-developing biotech company which focuses on personalized medicine in cardiovascular diseases. They concentrate on innovative biological drugs in indications with unmet medical needs. One biological drug, Revacept is currently in phase II clinical development for the treatment of stroke and cerebral vascular syndromes, as well as for acute coronary. Revacept is a lesion-specific inhibitor of atherothrombosis. Further preclinical candidates are under development, i.e. CD39-GPVI, a fusion protein which provides further effector functions compared to Revacept alone. Cyclic peptides are being investigated for their potential to treat Graves' disease. Further, COR-5 allows for diagnostics of early platelet activation. advanceCOR is financed by the MIG AG, KfW Bank, Bayernkapital, HTGF and BioM AG. The founders and management of advanceCOR bring together knowledge and reputation in research and clinical medicine together with biotech experience.

Advanced Identification Methods - AIM GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: Agrobiotechnology, Laboratory, Molecular Diagnostics, NGS, PCR

We identify biological samples from animal sources quickly and reliably for you. We specialize in: Yard or forest pests, including larvae and eggs; Identification of insects from deadwood or ground samples by NGS; Insects from ecological assessment traps (e.g. Malaise traps); Samples from meat, fur, or skin; And much more for the identification, we use genetic DNA barcoding, a method in which we are leaders in Germany. We collaborate on the construction of an Internet-based genetic database of the German fauna. The skilled staff at AIM - Advanced Identification Methods GmbH - is hence performing species identification via routined DNA Barcoding protocols, fast, reliable & cost-efficient!



Contact:

Zenettistraße 37 RGB
D-80337 München
Phone: +49 (0) 8951 3089 89

E-Mail: info@aimmethods-lab.com
Internet: www.aimmethods-lab.com

Aenova Holding GmbH

PHARMA & CHEMICAL INDUSTRY, CMO

With a planned turnover of around EUR 760 million in the current financial year, the Aenova Group is one of the leading companies in the global pharmaceutical and healthcare industry. The group's portfolio of services covers the entire value chain for the development and production of all the main dosage forms and product groups in the field of medicines and dietary supplements. The Aenova Group's high standards of quality, innovative technologies and clear vision for the future have enabled it to become European market leader in the business-to-business field. The company, which has its headquarters near Munich, operates 28 sites in eleven countries throughout the world. More than 4,400 employees contribute to the group's success.



Contact:
Dr. Dr. Mohammad Naraghi

Berger Straße 8 - 10
D-82319 Starnberg
Phone: +49 (0) 8151 9987-001
Fax: +49 (0) 8151 9987-499
E-Mail: info@aenova.de
Internet: www.aenova-group.com

Agrobiogen GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: Agrobiotechnology, Bioanalytics, Laboratory

Agrobiogen focuses on and is experienced in the application of molecular-genetic techniques in livestock animals (especially molecular genetic diagnostics and gene transfer). Many transgenic rabbit lines and several cattle clones have been established. As a service for other biotech companies transgenic farm animals are generated using conventional microinjection procedures and nucleus transfer. Detection of pathogens like BVDV, as well as parentage control of animals, SNP genotyping and analysis of DNA markers are offered as a service for breeders, veterinarians and companies. Agrobiogen has developed a simple labour-saving system for collection of tissue samples and extraction of DNA from millions of animals for high-throughput analysis.



Contact:
Herr Dr. Lutz Plobner

Larezhhausen 3
D-86567 Hilgertshausen
Phone: +49 (0) 8250 9279040
Fax: +49 (0) 8250 9279049
E-Mail: info@agrobiogen.de
Internet: www.agrobiogen.de

Agrolytix GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Agrolytix is your competent partner around the themes of microencapsulation and micronization. The company specializes in the areas of agrochemicals and cosmetics. We are happy to assist in the development and production of your new products or offer you our technologies as services.



Contact:
Dr. Stefan Schwab

Cauerstr. 4
D-91058 Erlangen
Phone: +49 (0) 9131 85-29452
Fax: +49 (0) 9131 85-29449
E-Mail: info@agrolytix.com
Internet: www.agrolytix.com

Alexion Pharma Germany GmbH

PHARMA & CHEMICAL INDUSTRY



Contact:

Landsberger Straße 300
D-80687 München
Phone: +49 (0) 89 45 70 91 300
Fax: +49 (0) 89 51 51 87 21
E-Mail: alexion.germany@alexion.com
Internet: www.alexionpharma.com

Alexion operates a branch office in Germany to support patients locally. Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the innovation, development and commercialization of life-changing therapies. Patients with these diseases often have no effective treatment options, and they and their families suffer with little hope. Our goal is to deliver medical breakthroughs where none currently exist. We are driven because we know people's lives depend on our work. Alexion developed the world's first and only terminal complement inhibitor from laboratory through regulatory approval and commercialization for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and refractory generalized myasthenia gravis (refractory gMG). Alexion also has two highly innovative enzyme replacement therapies for the treatment of patients with hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D).

ALGORA Gesellschaft für Medizinstatistik und Vertriebssysteme mbH

CRO

Keywords: Infectious Diseases, Oncology



Contact:
Dr. Karl Fehnle

Münchner Str. 11
D-85540 Haar
Phone: +49 (0) 89 613727-0
Fax: +49 (0) 89 613727-20
E-Mail: cro@algora.de
Internet: www.algora.de

Algora is a niche CRO successfully operating on clinical trials in Germany. Services include phase II-IV trials as well as large observational studies and range from protocol development to final study reports. Algora manages complete study projects or delivers individual services, such as clinical monitoring, data management or statistical analysis. Experienced in oncology since the first days of the company in 1989, Algora always had a focus on innovative therapies, leading to close relationships to university hospitals and medical societies. Since 1995 another focus developed in large pediatric studies. Customers are pharmaceutical and medical device companies, independent research groups, and other CROs.

Altmann Analytik GmbH & Co. KG

PHARMA SUPPLIER AND TRADE

Keywords: Laboratory, Fine Chemicals/Reagents, Devices, Analytical Chemistry



Contact:
Tobias Thelen

Rupert-Mayer-Str. 46
D-81379 München
Phone: +49 (0) 89 724805-90
Fax: +49 (0) 89 724805-91
E-Mail: info@altmann-analytik.de
Internet: www.analytics-shop.com

Consumables for Chromatography (HPLC & GC), Spectroscopy (lamps & flow cells) and Sample Prep (syringe filters, vials and caps). For more than 30 years Altmann Analytik from Munich, Germany, has been your competent and independent partner for instrumental analytics. Our main areas are Chromatography, Spectroscopy, and Sample Prep. We provide more than 140,000 different lab supply products from more than 30 different high-quality manufacturers, such as Agilent Technologies, Chiral Technologies, Grace, Hamilton, Macherey Nagel, Merck, Millipore, PerkinElmer, Thermo Fisher, Waters, Whatman and YMC. Our products can be found and purchased online.

AMGEN GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Nephrology, Bone/Joint Diseases, Oncology

Amgen GmbH is an affiliate of Amgen Inc. (Applied Molecular Genetics). The US based company discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, osteoporosis and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives.



Contact:
Dr. Corinna Jacob

Riesstraße 24
D-80992 München
Phone: +49 (0) 89 149096-0
Fax: +49 (0) 89 149096-2000
E-Mail: corinna.jacob@amgen.com
Internet: www.amgen.de

AMGEN Research (Munich) GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Immune Therapy, Drug Development, Antibody, Oncology

Amgen Research (Munich) GmbH, former Micromet, puts novel concepts in immunotherapy to work. Using proprietary technologies, the company is building a strong pipeline of innovative drug candidates for the treatment of cancer, inflammation and autoimmune disease. It has established a powerful drug development platform: BiTE™ (Bispecific T cell engagers), a unique drug format that leverages the outstanding cytotoxic potential of T cells to precisely eliminate pathogenic cells. Amgen Research (Munich) is an affiliate of Amgen Inc. (Applied Molecular Genetics Inc.). The US based company discovers, develops, manufactures and delivers innovative human therapeutics.



Research GmbH

Contact:
Susanne Sporer

Staffelsestr. 2
D-81477 München
Phone: +49 (0) 89 895277-0
Fax: +49 (0) 89 895277-205
E-Mail: susanne.sporer@amgen.com
Internet: www.amgen.de

AmplexDiagnostics GmbH Gesellschaft für molekularebiologische Diagnostik

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Infectious Diseases, PCR, Clinical Diagnostics

AmplexDiagnostics GmbH is a privately held company for the development, production and distribution of In Vitro Diagnostics. Our aim is the improvement of the potential of the PCR-technology by implementing the main advantages of this technology into the diagnosis of bacterial infections. Founded in 2002 - Amplex developed its first product (hyplex® StaphyloResist) and entered the market already in 2003. Additional systems for the direct detection of multidrug-resistant bacteria (like VRE, ESBL, KPC and NDM-1) are completing our portfolio of PCR-screening tests for nosocomial infections causing „bugs“. Beside this we offer several PCR-based screening tests for sexual transmitted diseases, EHEC or TBC.



Contact:
Dr. Lars Wassill

Werkstr. 2
D-83555 Gars-Bahnhof
Phone: +49 (0) 8073 91693-0
Fax: +49 (0) 8073 91693-33
E-Mail: info@amplexdiagnostics.de
Internet: www.hyplex.info

AMS Advanced Medical Services



Contact:
Dr. Gerlinde Jänel

Rosa-Bavarese-Str. 5
D-80639 München
Phone: +49 (0) 89 2000074-100
Fax: +49 (0) 89 2000074-400
E-Mail: Medical.Science@ams-europe.com
Internet: www.ams-europe.com

CRO

Keywords: [Pharmacology](#), [Medical Writing](#)

AMS is a privately owned, independent mid-size CRO and a competent partner to the pharmaceutical and healthcare industry since 1997. Today over 250 employees work in the business areas Medical Science, Clinical Research and Marketing & Sales. As an experienced CRO, AMS offers 360° customer support in Clinical Trials phase II - IV and non-interventional studies, Data Entry, Data Management, Biostatistics, Pharmacovigilance/Clinical Safety and Medical Writing. In addition we offer Quality Management including the conduction of Audits and provide support in Regulatory Affairs and Market Authorization. AMS invented the first Internet-Pharmaschool with trainers and techniques offering tailor-made training concepts for staff in both clinical research and sales. AMS is a full-service CRO with significant experience in multiple therapeutic areas and strong medical expertise. The Medical Science Team of AMS combines years of experience in the global clinical development and benefit assessment of pharmaceuticals with the extensive knowledge in the field of pharmaceuticals and medical devices. We are an interdisciplinary team of more than 40 experts with profound experience in Biostatistics, Medical Writing, Health Economics, Public Health and Project Management. Our Team is supported by experts with over 15 years of experience in global clinical drug development. We are pioneers for the benefit assessment of pharmaceuticals since the German Act on the Reform of the Market for Medicinal Products came into effect in 2011. Due to our wide experience in methodological requirements we are also a strong European partner in the field of Health Technology Assessments (HTAs), Relative Effectiveness Assessments (rapid REAs) for pharmaceuticals and medical devices as well as method assessments for medical devices in Germany. Benefit from our extensive experience by choosing AMS as a competent and reliable partner for projects in the life cycle of your pharmaceutical or medical product.

AMSilk GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: New Materials, Industrial Biotechnology

AMSilk GmbH is the world's first industrial supplier of synthetic silk biopolymers and has its headquarters in Planegg near Munich, Germany. Sustainably produced using a patented biotechnological process, AMSilk high-performance biopolymers have the unique functional properties of the natural product they are based on. The organic high-performance material can be used in multiple ways, including in medical or technical products as well as cosmetic ingredients. AMSilk high-performance biopolymers give everyday products unique properties. Among other things, the polymers are biocompatible, breathable and especially robust. AMSilk high-performance biopolymers are distributed in the form of Silkbeads (microparticles), Silkgel (hydrogel) or Biosteel® (fibers). They are currently used in coatings for medical-technology products, in the textile industry and as an ingredient in personal care products.



Contact:
Jens Klein

Am Klopferspitz 19
D-82152 Planegg-Martinsried
Phone: +49 (0) 89 579 5393-0
Fax: +49 (0) 89 579 5393-30
E-Mail: info@amsilk.com
Internet: www.amsilk.com

amYmed GmbH Referenzzentrum für Amyloidkrankheiten

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, Antibody Production Service, Devices, Antibody

We provide high precision immunohistochemical classification of the diverse amyloid diseases with respect to specific and causal treatment as a service for patients and physicians. We are in the process of extending this service by producing and offering test kits in order to enable clinics and institutes of pathology to perform this classification by themselves.

Contact:
Prof. Dr. med. Reinhold P. Linke

Vinzenz-Schlüpfer-Straße 20a
D-81475 München
Phone: +49 (0) 89 745 022 73
Fax: +49 (0) 89 75 999 347
E-Mail: linke@amymed.de
Internet: www.amymed.de

apceth Biopharma GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS



Contact:
Dr. med. Christine Günther

Max-Lebsche-Platz 30
D-81377 München
Phone: +49 (0) 89 7009608-0
Fax: +49 (0) 89 7009608-130
E-Mail: contact@apceth.com
Internet: www.apceth.com

Keywords: Gene Therapy, Cell Therapy, Autoimmune Diseases, Drug Development, Respiratory Diseases, Inflammation, Oncology

apceth - The cell engineering company!

PROPRIETARY TECHNOLOGY & PRODUCTS

- Clinical stage biopharmaceutical company
- Leader in the development of cell-based gene therapies
- Genetically engineered mesenchymal stem cell therapeutics
- Immunomodulation, major chronic diseases, cancer

CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION

- Reliable, experienced and high-performance partner
- Complex cell-based and gene therapy products (ATMPs)
- Process, product and assay development
- Clinical and commercial GMP manufacturing
- GMP-certified since 2010

APEX GmbH

CRO

Keywords: Pharmacology, Drug Development, Pharmacokinetics, Diabetes, Hepatology, Nephrology



Contact:
Dr. med. Gertraud Haug-Pihale

Landsberger Str. 476
D-81241 München
Phone: +49 (0) 89 896016-0
Fax: +49 (0) 89 896016-33
E-Mail: apexpkpd@aol.com
Internet: www.apex-research.com

Our Concept...

APEX is a highly efficient combination of investigator and CRO. Our aim is to provide our clients with a service which combines the access to patients of an investigator with the expertise to perform a complex, high quality research project of a CRO. We combine high level phase 1 data quality with the typical phase 2/3 study population.

Our Service...

Is the clinical performance of pharmacokinetic and proof-of-concept / PKPD studies.

Our Study Population...

are patients with impaired renal or hepatic function and patients with other chronic stable diseases (diabetes, hypertension, asthma etc.). Since the patients come into our clinic, rather than us having to go to them via their GP's, the data we generate are more complete and accurate, fewer patients are required and the project can be completed faster.

Our Clients...

are international pharmaceutical companies from medium sized to members of the world's top ten.

AptaIT GmbH

BIOTECH BIOINFORMATICS

Keywords: Informatics, Genomics, Personalized Medicine

AptaIT is a bioinformatics company dedicated to develop advanced and user-friendly software solutions for sequence driven biomedical research. Next-generation sequencing (NGS) currently transforms the procedures of modern drug discovery. AptaIT has developed intelligent software algorithms with an emphasis to discovery platforms of novel biologics by in vitro selection strategies or analysing the adaptive immune repertoire and response. THE SOFTWARE ENABLES - intelligent and efficient analysis of next-generation sequencing data. - profound quality control of synthetic nucleic acid libraries. - accelerated identification of ligands in combinatorial approaches. - comprehensive profiling of the adaptive immune repertoire. - improved patenting strategies by profound sequence information.



Contact:
Dr. Raymund Buhmann

Am Klopferspitz 19A
D-82152 Martinsried
Phone: +49 (0) 89 21541721
Fax: +49 (0) 89 59918 125
E-Mail: info@aptait.de
Internet: ngsdataanalysis.com/

Assay.Works GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Medicinal Chemistry, Drug Development, Analytical Chemistry

Our mission is to accelerate our partner's research programs by developing and executing predictive and scalable assays to quantify the bioactivity of novel chemical and biological entities. We combine scientific rigor with our domain expertise in laboratory automation, informatics, and industry best practices to turn challenging assays into quantitative, reproducible results.



Contact:

Am BioPark 11
D-93053 Regensburg
Phone: +49 (0) 941 2000 1240
Fax: +49 (0) 941 2000 1241
E-Mail: contact@assay.works
Internet: www.assay.works

Astellas Pharma GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Inflammation, Infectious Diseases, Immune Therapy, Autoimmune Diseases, Allergy, Antibiotics, Drug Development

Astellas Pharma Inc. was formed in April 2005 from a merger with Yamanouchi and Fujisawa. Astellas Pharma ist Japan's second largest pharmaceutical company and is headquartered in Tokio. It has operations in Europe, Asia, North and South America, South Africa and Japan. Astellas is focused on the following key therapeutic areas: Transplantation, urology, dermatology, anti-infectives, pain and oncology. Astellas employs approx. 3,300 people in Europe across Sales & Marketing, Research & Development and Manufacturing. Astellas has 21 Sales & Marketing affiliates, 3 manufacturing plants and 1 R&D site in Europe. Astellas Europe is headquartered just outside London in Chertsey. The German headquarters are based in Munich. Located here are Sales, Marketing and Medical. The product portfolio includes therapies in transplantation, urology, oncology, dermatology, asthma/COPD, cardiology, infectious diseases, gastroenterology and pain. Astellas Pharma GmbH employs approx. 380 people including 230 sales representatives.



Contact:
Karina Oppitz

Georg-Brauchle-Ring 64-66
D-80992 München
Phone: +49 (0) 89 4544-1057
Fax: +49 (0) 89 4544-1329
E-Mail: info@de.astellas.com
Internet: www.astellas.de

Avergen Pharmaceutical GmbH (APG)

BIOTECH THERAPEUTICS & DIAGNOSTICS



Contact:

Am Klopferspitz 19
D-82152 Martinsried
E-Mail: marius.yildiz@avergen.com
Internet: www.avergen.com

Avergen Pharmaceutical GmbH (APG) creates long-term value through internal and collaborative innovative drug discovery programs based on novel drug targets. APG is using a platform to identify and develop protein-protein interaction (PPI) inhibitors. APG is dedicated on its core competences in neurodegenerative disease and oncology research. APG is focused on drug development until phase II clinical studies. The location of the company in Munich enables the access to experienced experts in the field of drug discovery and development, as well as business development and commercialization.

AMW GmbH, Arzneimittelwerk Warngau

PHARMA & CHEMICAL INDUSTRY



Contact:

Birkerfeld 11
D-83627 Warngau
Phone: +49 (0) 8024 470999 0
Fax: +49 (0) 8024 470999 29
Internet: www.a-m-w.eu

Keywords: Drug Delivery

Intelligent Pharmaceuticals AMW GmbH is an innovative, and steadily growing pharmaceutical company situated nearby Munich, the capital of the Free State of Bavaria in Germany. Although still a small to medium-sized enterprise, we already act globally by providing licensees to partners throughout the world. Our partnering resp. licensing focus is the development, manufacture and distribution of medicinal products for indications such as oncology, neurology and pain treatment. What drives us at AMW is the fact, that despite significant progress in the treatment of severe diseases with highly active drugs, there are still several unmet needs in various therapeutic areas. Thus we strive for the development of a leading technology platform to achieve the maximum benefit for the patient by significantly improving the patient's adherence to the prescribed course of treatment. The base of our technology is to provide a prolonged therapeutic effect with the benefit of having lesser side effects and lower consumption of the active pharmaceutical ingredients. One example from our portfolio is a biodegradable implant, that will be applied subcutaneously by an applicator with an automatic needle-retraction mechanism.

Axolabs GmbH

BIOTECH PRECLINICAL SERVICES

Keywords: RNAi & Antisense, Antisense/Nucleotides, Aptamer Technology, Pharmacokinetics, Pharmacology

Axolabs is a preclinical research organization for oligonucleotide therapeutics. Based on the foundations of the former Roche Center of Excellence for RNA Therapeutics, we leverage our world-leading know-how and 14+ years of experience to provide high-end preclinical solutions and consultancy tailored to your specific needs. Oligonucleotide Manufacturing: High-throughput up to large scale, sequence/ structure optimization, drug substance production for GLP-Tox, process development, regulatory documentation; Analytics and Bioanalytics: HPLC, UPLC, MS, CAD, CE, DSC, thermophoresis etc., pharmacokinetics and biodistribution, ADME and DMPK; Pharmacology: Lead identification and optimization, in vivo efficacy and early safety, delivery.



Contact:
Dr. Roland Kreutzer

Fritz-Hornschuch-Str. 9
D-95326 Kulmbach
Phone: +49 (0) 9221 82762-0
Fax: +49 (0) 9221 82762-99
E-Mail: info@axolabs.com
Internet: www.axolabs.com

baseclick GmbH

BIOTECH DEVICES & REAGENTS

Keywords: PCR, Nanobiotechnology, Chip/Array Technology, New Materials, Fine Chemicals/Reagents, Clinical Diagnostics

baseclick GmbH is an ISO9001:2015-certified company located in Neuried, Germany, and was founded in 2008 with the shareholders of BASF SE, Ludwigshafen and the LMU Munich. The core of the baseclick technology is the „click reaction,“ a Cu-catalyzed cycloaddition allowing virtually unlimited and highly efficient functionalization of nucleotides, small synthetic oligonucleotides and large gene fragments. The Scripps Research Institute patented the click chemistry of the inventor B. Sharpless, Nobel laureate 2001. Beside our own patents, baseclick holds an exclusive worldwide license for the use of this technology in the field of nucleic acids and offers this technology just as products like cell proliferation kits, modified oligonucleotides, FISH products, click reagents and many more.



Contact:
Dr. Thomas Frischmuth

Floriansbogen 2-4
D-82061 Neuried
Phone: +49 (0) 89 9699 3401
Fax: +49 (0) 89 9699 4696
E-Mail: info@baseclick.eu
Internet: www.baseclick.eu

Basilea Pharmaceutica Deutschland GmbH

PHARMA & CHEMICAL INDUSTRY



Contact:

Elsenheimerstraße 7
D-80687 München
Phone: +49 (0) 89 7857674-0
Fax: +49 (0) 89 7857674-100
E-Mail: basilea.info@basilea.com
Internet: www.basilea.com

Keywords: Drug Development, Antibiotics, Allergy, Dermatology, Infectious Diseases, Oncology

Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland. The company currently focuses on antibiotics and antifungal as well as oncology and dermatology drugs, targeting the medical challenge of rising resistance and non-response to current treatment options in the hospital and specialty care settings. Basilea Pharmaceutica Deutschland was founded 2007 in Munich. Skin diseases are an area of high medical need. Patients are suffering from disfiguring conditions such as hand eczema. Alitretinoin (Toctino®), a vitamin A derivative offers a significant quality of life improvement in the treatment of adults with severe chronic hand eczema unresponsive to topical corticosteroid.

Bavarian Nordic GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS



BAVARIAN NORDIC

Contact:

Francisco Lopez

Fraunhoferstr. 13
D-82152 Martinsried
Phone: +49 (0) 89 255446-030
Fax: +49 (0) 89 255446-333
E-Mail: derek.beggs@bavarian-nordic.com
Internet: www.bavarian-nordic.com

Keywords: Infectious Diseases, Vaccines, Drug Development, Immune Therapy, Oncology

Bavarian Nordic (BN) is a fully integrated biotechnology company focused on the development of innovative and safe therapies against cancer and infectious diseases. Using our live virus vaccine platform technology, MVA-BN®, we have created a diverse portfolio of proprietary and partnered product candidates intended to improve the health and quality of life for children and adults. We supply our IMVAMUNE® non-replicating smallpox vaccine to the U.S. Strategic National Stockpile and other government stockpiles. The vaccine is approved in the European Union (under the trade name IMVANEX®) and in Canada. In addition to our long-standing collaboration with the U.S. government on the development of IMVAMUNE® and other medical countermeasures, our infectious disease pipeline comprises a proprietary RSV program as well as vaccine candidates for Ebola, HPV, HBV and HIV, which are developed through a strategic partnership with Janssen. Additionally, in collaboration with the National Cancer Institute, we have developed a portfolio of active cancer immunotherapies. BN was founded in 1994 and is headquartered in Kvistgård, Denmark with subsidiary operations in Martinsried, Germany and Morrisville, NC, USA. The company has more than 400 employees and is listed on the Copenhagen Stock Exchange.

Baxter Deutschland GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Nephrology, Autoimmune Diseases, Oncology, Pain, Immune Therapy, Vaccines, Tissue Engineering/Cell Culture

Baxter International Inc. (NYSE: BAX), through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide.



Contact:
Lutz Knabe

Edisonstr. 4
D-85716 Unterschleißheim
Phone: +49 (0) 89 31701-0
Fax: +49 (0) 89 31701-177
E-Mail: info_de@baxter.com
Internet: www.baxter.de

Beckman Coulter Biomedical GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Devices, Nanobiotechnology, Automation, PCR

Beckman Coulter develops, manufactures and markets products that simplify, automate and innovate complex biomedical testing. Our diagnostic systems are found in hospitals and other critical care settings around the world and produce information used by physicians to diagnose disease, make treatment decisions and monitor patients. Scientists use our life science research instruments to study complex biological problems including causes of disease and potential new therapies or drugs. Hospital laboratories are our core clinical diagnostic customers. Our life science customers include pharmaceutical and biotechnology companies, universities, medical schools and research institutions. Beckman Coulter has an installed base of more than 200,000 clinical and research systems operating in laboratories around the world. Beckman Coulter has a leading position in Laboratory Automation. Research & Development as well as Production of our stand alone automation systems, the AutoMate 2500 Family (formerly known as OLA 2500), are located in Munich, Germany.



Contact:

Sauerbruchstr. 50
D-81377 München
Phone: +49 (0) 89 579589-0
Fax: +49 (0) 89 579589-3503
E-Mail: info@beckmancoulter.de
Internet: www.beckmancoulter.de

Bencard Allergie GmbH

PHARMA & CHEMICAL INDUSTRY



Contact:

Leopoldstraße 175
D-80804 München
E-Mail: info@bencard.com
Internet: www.bencard.de

Bencard Allergie GmbH is a subsidiary of the parent company Allergy Therapeutics, an international firm specialized on delivering diagnostic and therapeutic solutions for allergic diseases. With its 19 branches and selling offices, Allergy Therapeutics is represented on the entire globe.

In Worthing, a town located in the south of England, the allergen extracts and the formulations for diagnostics and therapeutics are produced according to the highest GMP-Standards. The company portfolio includes a broad spectrum of therapeutic and Prick-test solutions (a diagnostic test for allergic susceptibility) as well as over-the-counter formulations of symbiotic organisms which support the immune system through the intestinal flora. The recent research initiatives from Bencard Allergie include the development of other innovative adjuvants, as for example the Virus-like-Particles (VLPs). VLPs are developed through the Bencard-Adjuvant-Systems, a allergonomic program dedicated to the molecular characterization of the allergens. With its wide-ranging portfolio, its future oriented research activities and the increasing customers' trust; resulting also from a focused know-how built on 80 years of history. The strong company's growth occurred in the last 5 years confirms and mirrors the company's mindset.

bene-Arzneimittel GmbH

PHARMA & CHEMICAL INDUSTRY



Contact:

Dr. Günter Auerbach

Herterichstraße 1
D-81479 München
Phone: +49 (0) 89 74987-0
Fax: +49 (0) 89 74987-200
E-Mail: contact@bene-arzneimittel.de
Internet: www.bene-arzneimittel.de

Keywords: Pain, Drug Development

bene-Arzneimittel GmbH has been producing high quality pharmaceuticals in Munich for 65 years. As a traditional and innovative family business, people are always at the center of our actions. Our branded products are available in 30 countries with the highest standards of quality and compatibility. More than 100 employees are constantly working to develop new products, active ingredients, dosage forms and preparations for human health!

Bernina Plus GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS



Bernina Plus

Contact:

Dr. Felix Gropp

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 52388-740
Fax: +49 (0) 89 52388-333
E-Mail: gropp@berninaplus.de
Internet: www.berninaplus.de

Keywords: Drug Delivery, Liposomes, Nanobiotechnology

Bernina develops smart oral drug delivery systems for therapeutic peptides. The proprietary technology is based on artificial envelopes created by lipids. In addition, these nano-particulate natural and synthetic lipids are used in coating and drug elution processes.

betapharm Arzneimittel GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Pain, Drug Development

Betapharm was founded in 1993 in Augsburg. betapharm delivers generic drugs and is one of the leading generic companies in Germany. In 2006 the company was bought by globally active Dr. Reddy Laboratories, Hyderabad, India. With 75 employees Betapharm generates revenues of about EUR 180m.



Contact:
Michael Ewers

Kobelweg 95
D-86153 Augsburg
Phone: +49 (0) 821 74881-0
Fax: +49 (0) 821 74881-420
E-Mail: info@betapharm.de
Internet: www.betapharm.de

Bicoll GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Medicinal Chemistry, Oncology, Infectious Diseases, Natural Compounds, Small Molecules, Nutraceuticals

Bicoll is a biopharmaceutical company, offering pre-clinical support in the area of Drug Discovery from Natural Products and Medicinal Chemistry. To speed up drug discovery processes, Bicoll offers its drug like compound library BILOBAC N, consisting of already fractionated plant extracts, to global clients in drug discovery and related innovative fields. BILOBAC N provides enhanced probability of biological activity and reduced complexity of fine fractions, thus it's ready to use in client's screening systems. With innovative strategies and a proprietary technology platform, Bicoll is able to rapidly select only the best leads with superior drug-like profiles for further development. Subsequent medicinal chemistry and custom synthesis complete Bicoll's seamless substantial services.



Contact:
Dr. Kai Lamottke

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 820106-30
Fax: +49 (0) 89 529178
E-Mail: lamottke@bicoll-group.com
Internet: www.bicoll-group.com

BIOBANK der Blutspender Blutspendedienst des BRK

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, Autoimmune Diseases, Cardiovascular Diseases, Diabetics, Metabolic Diseases, Oncology

With its »Blood Donor BIOBANK«, the Bavarian Red Cross Blood Donor Service offers a unique resource for biomarker research: the world's first blood donor based biobank. A large pool of more than 400,000 active blood donors enables the identification of several thousands of diseased BIOBANK participants per year. Their serial, pre-diagnostic blood samples are a unique resource for investigating markers associated with the onset and progression of diseases. With a collection of more than 4 m plasma samples processed and stored using highly standardized, qualified processes (ISO9001:2008 certification) the »Blood Donor BIOBANK« is one of the largest biobank projects worldwide.



Contact:
Dr. Silke Martin

Herzog-Heinrich-Str. 2
D-80336 München
Phone: +49 (0) 89 5399-0
Fax: +49 (0) 89 5399-4505
E-Mail: biobank@blutspendedienst.com
Internet: www.biobank.de

BioClinica GmbH



Contact:
Dr. Michael Kersten

Landsberger Str. 155
D-80687 München
Phone: +49 (0) 89 202 444 97-0
Fax: +49 (0) 89 2024 4497-9
Internet: www.bioclinica.com

CRO

Former „CoreLab Partners“ is an imaging core lab, managing the complete imaging segment of clinical trials for the global pharmaceutical, biotechnology and medical device industries. Our expertise spans Phase I through IV and all major therapeutic areas. We are specialized in oncology trials but also do cardiovascular, musculoskeletal, CNS and medical device studies. Our radiologists, nuclear physicians and medical oncologists interpret data from all major modalities, including CT, MRI, X-ray, SPECT, Ultrasound, PET and PET/CT in a centralized and independent way. We assist in planning, tracking and implementation of studies and provide medical expertise, regulatory know-how and validated technologies. In 2013 BioClinica[®], Inc., (NASDAQ: BIOC), a global provider of clinical trial management services, announced that JLL Partners and Ampersand Capital Partners, two leading middle market private equity firms, have completed their acquisition of BioClinica and CoreLab Partners and have combined the two companies under the name BioClinica. This merger brings together two of the most experienced and trusted authorities in medical imaging management for clinical trials and creates a new standard in imaging core lab services, cardiovascular safety monitoring, and eClinical trial management solutions.

Biogen GmbH



Contact:
Stefan Schneider

Carl-Zeiss-Ring 6
D-85737 Ismaning
Phone: +49 (0) 89 99617-0
Fax: +49 (0) 89 99617-199
E-Mail:
stefan.schneider@biogen.com
Internet: www.biogen.de

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Rheumatoid Arthritis, Autoimmune Diseases, Dermatology, Neuro-Degeneration, Neurology, Drug Development

Biogen's mission is clear: we are pioneers in neuroscience. Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. Founded in 1978, Biogen is a pioneer in biotechnology and today the Company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including Alzheimer's disease, Parkinson's disease and Amyotrophic lateral sclerosis (ALS). Building on its heritage in biologics, Biogen also manufactures and commercializes high-quality biosimilars. The German affiliate is located in Ismaning.

Biogents AG

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: Infectious Diseases, Natural Compounds, Devices, Agrobiotechnology

Biogents develops, produces & sells innovative trapping systems against mosquitoes & flies, especially against dangerous vectors such as aedes aegypti, aedes albopictus & sand flies. These systems are already being used by leading health organisations (e.g. CDC, USA), several armed forces (e.g. „Bundeswehr“, Germany), other governmental bodies & public entities (incl. quarantine departments, research institutes & universities). Several consumer versions are marketed since 2009. The technology is protected by two granted patents and was awarded in 2007 by the world bank with money from the Bill & Melinda Gates Foundation. Biogents also offers a fee-for-service business for insect repellents and attractants. The company was started in 2003 as a spin-off from the University of Regensburg.



Contact:
Markus Siegers

Weißenburgstr. 22
D-93055 Regensburg
Phone: +49 (0) 941 5699 6947
Fax: +49 (0) 941 5699 2168
E-Mail: biogents@biogents.com
Internet: www.biogents.com

Biomax Informatics AG

BIOTECH BIOINFORMATICS

Keywords: Informatics, Data Management and Biostatistics, Data Management, Bioinformatics

Biomax provides computational solutions for better decision making and knowledge management in the life science industry. They focus on integrating information to enable a knowledge-based approach to develop innovative life science products. Their BioXM™ Knowledge Management Environment combines software products and knowledge resources to help customers eliminate the coding process, slash the implementation time of complex projects, harness the information overload and distill critical insights from data. The Viscovery® data mining software complements the BioXM system with tools to identify and validate diagnostic biomarkers. Biomax's worldwide customers include companies and research organizations in healthcare, drug discovery, diagnostics, fine chemicals, food and plant production.



Contact:
Dr. Philipp Krubasik

Robert-Koch-Str. 2
D-82152 Martinsried
Phone: +49 (0) 89 895574-0
Fax: +49 (0) 89 895574-825
E-Mail: info@biomax.com
Internet: www.biomax.com

Biomed Labordiagnostik GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Analytical Chemistry, ELISA/EIA, PCR, Clinical Diagnostics

Our core competence is the manufacture and distribution of CE marked products for clinical chemistry and quality control according to IVD Guidelines. Our area of activities covers also Infectious Disease Diagnostics. We are currently extending our focus to the Molecular Diagnostics field, for which we aim to develop and to market new products leveraging on our years of experience at home and abroad. Our success is tied to a continuous increase of know-how, an extensive expertise in the healthcare marketplace and specialized system solutions in the field of Laboratory Diagnostics.



Contact:
Claudia Caspers

Bruckmannring 32
D-85764 Oberschleißheim
Phone: +49 (0) 89 3157000
Fax: +49 (0) 89 3153242
E-Mail: info@biomed.de
Internet: www.biomed.de



Contact:
Dr. Urs Hänggi

Forst-Kasten-Str. 15
D-82152 Krailling
Phone: +49 (0) 89 12765-136
Fax: +49 (0) 89 12765-137
E-Mail: mail@Biomer.de
Internet: www.biomer.de

Biomer

BIOTECH NEW MATERIALS AND COMPOUNDS

Biomer develops and produces raw materials such as PHB (polyhydroxybutyrate) which can be processed and used in the same way as classic thermoplasts, but are fully biodegradable. Articles made of Biomer formulations can be disposed of by composting. Being made from renewable feed stocks they do not add to the carbon dioxide concentration of the atmosphere even when they are burned. The core competence covers the production of biopolymers in microorganisms and formulation of the extracted polymers into resins for use by plastics processors.



Contact:
Sabine Zirngibl-Brandl

Im Gewerbepark B49
D-93059 Regensburg
Phone: +49 (0) 941 454 41
Fax: +49 (0) 941 461 68 31
E-Mail: info@biometric-gmbh.de
Internet: www.biometric-gmbh.de

Biometric GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: Analytical Chemistry

Biometric GmbH is a laboratory for microbiological and chemical analysis dealing with the analysis of water, hygienic control and providing microbiological analyses of pharmaceutical products, medical devices, cosmetics and food.



Contact:
Thomas Jaik

Kerschensteinerstr. 11-15
D-92318 Neumarkt
Phone: +49 (0) 9181 231-90
Fax: +49 (0) 9181 231-265
E-Mail: info@bionorica.de
Internet: www.bionorica.de

BIONORICA SE

PHARMA & CHEMICAL INDUSTRY

Keywords: Drug Development, Analytical Chemistry, Oncology, Respiratory Diseases, Pain, Neurology

Bionorica SE is one of the leading companies in the area of phytopharmaceuticals worldwide. The product range focuses mainly on diseases of the respiratory tract, urinary tract, gynaecological disorders and on medications for the treatment of pain. As an essential Bionorica follows the principle of phytonearing as gold standard in modern phytotherapy. Phytonearing combines the huge potential of natural active substances (phytos) with the knowledge and methodology of modern pharmaceutical research (engineering) in order to develop efficient and safe preparations. The expressed goal is to discover new active substances in order to develop effective drugs with minimized side effects. Bionorica has established an impressive network of scientists working in about 490 renowned universities, institutions and organisations worldwide.

BioNTech Small Molecules GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Immune Therapy, Oncology, Medicinal Chemistry, Analytical Chemistry, Small Molecules, 3D-Structural Analysis, Molecular

Modelling BioNTech Small Molecules is a 100% subsidiary of BioNTech AG (Mainz, Germany) offering integrated small molecule drug discovery services, from hit finding and chemical lead optimization through to early development candidates. Proprietary projects focus on discovery and development of new chemical entities in the field of cancer immunotherapy. The most advanced project presently undergoes preclinical evaluation. Cancer immunotherapy, immuno-oncology, molecular modelling, 3D-structural analysis, small molecules, analytical chemistry, medicinal chemistry.



Contact:
Dr. Stefan Strobl

Am Klopferspitz 19 a
D-82152 Martinsried
Phone: +49 (0) 89 8188802-0
Fax: +49 (0) 6131 9084-390
Internet: www.biontech.de

Biontex Laboratories GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Microscopy, Nanobiotechnology, Gene Therapy, RNAi & Antisense, Liposomes, Gene Transfer, Fine Chemicals/Reagents

Biontex Laboratories GmbH was launched in 1995 as an innovative biotech company in the field of genetic engineering, having been one of the technology leaders in the field of transfection since 1998. The company's operations focus on transfection, a field covering the introduction of genetic material (transfection) and proteins (proteofection) into eukaryotic cells. Biontex aims to continuously improve the success of this technology by advancing their synthetically produced carrier systems for nucleic acids and proteins and developing a variety of high-quality genetic engineering products. Current research focuses on the development of completely new strategies for maximising the transfection efficiency for all cell types in vivo or in vitro by utilising synthetic carrier components free from immunological effects.



Contact:
Dr. Roland Klösel

Landsberger Str. 234
D-80687 München
Phone: +49 (0) 89 324799-50
Fax: +49 (0) 89 324799-52
E-Mail: contact@biontex.com
Internet: www.biontex.com

Bio-Rad Laboratories GmbH

BIOTECH DEVICES & REAGENTS



Contact:
Sonja Fischer

Heidemannstr. 164
D-80939 München
Phone: +49 (0) 89 31884-0
Fax: +49 (0) 89 31884-100
E-Mail: info@bio-rad.de
Internet: www.bio-rad.com

Keywords: Chip/Array Technology, Peptide/Protein, Proteomics, Genomics, Gene Transfer, Laboratory, Antibody Production Service

Bio-Rad was founded in 1952 by the late David Schwartz and his wife Alice. In the 1950s, Bio-Rad introduced the first analytical grade ion exchange resins for laboratory research applications, launching the company's Life Science Group. In 1957, Bio-Rad incorporated and in 1958 relocated its headquarters to Richmond, California. By 1966 the company sold its stock to the public and expanded internationally with its first overseas office in Germany, namely in MUNICH. Over the years, Bio-Rad has evolved into a global enterprise that manufactures and distributes a broad range of products around the world. Today, Bio-Rad products are used in hospitals, universities, major research institutions, biotechnology companies, reference laboratories, pharmaceutical firms, and classrooms around the world. Bio-Rad's key competencies include separation, purification, and analysis, and the company is a leader in electrophoresis, protein assays, gel image analysis, quality controls, diabetes monitoring, autoimmune testing, blood typing, and BSE and chronic wasting disease testing.

Biosepar Ges. für Medizin- und Labortechnik mbH

PHARMA ANIMAL HEALTH



Contact:

Am Industriepark 2A
D-84453 Mühldorf
E-mail: mail@biosepar.de
Internet: www.biosepar.de

The company Biosepar GmbH was founded in 1987. It produces and markets its own developed and internationally patented products sold in the meantime globally in many countries around the world. Special emphasis is the development of new, environmentally friendly products that need to be not only hygienic but also non toxic during the diagnostic work process. The ParasiTrap® system has revolutionized the parasitological stool diagnostics. The FixSepar® ECO - system gained importance by the replacement of formalin fixative throughout the human and veterinary medicine and in the biotechnological synthesis and analysis. The company is expanding and in 2016 opened in Simbach am Inn a new head office.

bioVariance GmbH

BIOTECH BIOINFORMATICS

Keywords: Personalized Medicine, Informatics, Data Management, Biomarker Discovery & Development, Toxicology, Pharmacogenomics, NGS

BioVariance as premium provider for bioinformatics services generates insights into complex biomedical datasets that lead to testable hypotheses for our customers. We bring your data into the right context by linking DNA, RNA, proteins, metabolites & more with known biological interactions and phenotypes, generating insights to the big picture of human biology and pharmacology. We use this as fundament for our analyses helping our customers to advance projects quicker and more targeted. Our analysis capabilities are supported by biomedical software development capabilities so that we can implement our pipelines very efficiently and also deploy them to our customers.



Contact:
Dr. Josef Scheiber

Garmischer Str. 4/V
D-80339 München
Phone: +49 (0) 89 1896582-80
Fax: +49 (0) 89 1896582-99
E-Mail: josef.scheiber@biovariance.com
Internet: www.biovariance.com

BIOZOL Diagnostica Vertrieb GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Antibody, Peptide/Protein, ELISA/EIA, Proteomics, Small Molecules, Clinical Diagnostics

BIOZOL Diagnostica Vertrieb GmbH markets and distributes products for immunology, cell biology, molecular biology, biochemistry and human and veterinary diagnostics, such as antibodies, recombinant proteins, ELISA/EIA, detection kits, biochemicals and further reagents for cell culture, flow cytometry, immunohistology and cytogenetics. The company represents almost 50 different worldwide known suppliers in Germany. Biozol offers additionally different types of services such as free product search.



Contact:
Dr. Ralf Bäuerle

Obere Hauptstr. 10 b
D-85386 Eching
Phone: +49 (0) 89 3799666-6
Fax: +49 (0) 89 3799666-99
E-Mail: info@biozol.de
Internet: www.biozol.de

Breath Therapeutics GmbH

BIOTECH DEVICES & REAGENTS

Breath Therapeutics is a biotechnology company focused on the development of aerosolized drugs to improve the treatment of rare and life-threatening pulmonary diseases. Our founding and management team includes highly experienced executives and internationally renowned experts in drug aerosol and immunosuppression therapy. With our lead program, BOSTON, we are developing the first therapy for treatment of Bronchiolitis Obliterans, which is a life-threatening lung disease without approved drug therapy.



Contact:

Landsberger Straße 302
D-80687 München
Internet: www.breath-therapeutics.com



Bristol-Myers Squibb

Contact:
Eszter Viragh

Arnulfstr. 29
D-80636 München
Phone: +49 (0) 89 12142-0
Fax: +49 (0) 89 12142-392
E-Mail: info-bms-germany@bms.com
Internet: www.bms.com/de

Bristol-Myers Squibb GmbH & Co. KGaA

PHARMA & CHEMICAL INDUSTRY

Keywords: Oncology, Autoimmune Diseases, Cardiovascular Diseases, Rheumatoid Arthritis, Hematology

Bristol-Myers Squibb is a global BioPharma company firmly focused on its Mission to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Around the world, our medicines help millions of people in their fight against diseases such as cancer, cardiovascular disease and rheumatoid arthritis.

BSL BIOSERVICE Scientific Laboratories Munich GmbH

CRO

Keywords: Toxicology, Pharmacology

BSL BIOSERVICE is an internationally active Contract Research Organization. We are offering a broad range of biological safety and activity testing services for (Bio-)Pharmaceuticals, Chemicals, Medical Devices, Agrochemicals and Food. A high degree of customer orientation, high quality and flexibility are core values of our corporate philosophy. A highly experienced team of scientists and regulatory experts guarantees acceptance by national and international authorities and supports customers from early research until finalization of preclinical studies. BSL BIOSERVICE has been accredited with DIN EN ISO 17025 as well as with AAALAC and is certified in accordance with GLP and GMP. We are listed by the World Health Organization (WHO) and have successfully been audited by the FDA.



Contact:

Behringstr. 6 / 8
D-82152 Planegg-Martinsried
E-Mail: info@bioservice.com
Internet: www.bioservice.com

Carl Zeiss Microscopy GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Clinical Diagnostics, Microscopy, Tissue Engineering/Cell Culture,

Carl Zeiss Microscopy GmbH offers a broad range of modern and innovative microscope systems and solutions for different fields such as biotechnology, biomedical and clinical research as well as routine and industrial applications. Carl Zeiss MicroImaging employs about 1,750 staff worldwide and has its direct sales force in 130 countries. The company's headquarter is in Jena. At its Munich site Carl Zeiss Microscopy GmbH is focusing on software development, systems for laser microdissection and its application as well as digital slide and automation technology. In addition, in Munich the company is maintaining a unique facility hosting a modern application center and an up-to-date laboratory for biomedical and clinical research, molecular analysis and imaging. Practical courses, workshops and training are held on a regular basis and customer services are offered.



We make it visible.

Contact:
Dr. Renate Burgemeister

Kistlerhofstr. 75
D-81379 München
Phone: +49 (0) 89 909000-800
Fax: +49 (0) 89 909000-820
E-Mail: microscopy@zeiss.com
Internet: www.zeiss.com/microscopy

CASCAT GmbH

INDUSTRIAL BIOTECHNOLOGY / CHEMICAL INDUSTRY

CASCAT researches and develops processes for the production of chemicals based on chemical-enzymatic reactions. One focus is the use of renewable resources as a base. The own implementation of these processes as well as working with partners in this case represents the preferred choice of the company. In addition, the consultation of third parties in matters of biotechnology, biocatalysis, renewable resources, sustainability and bioeconomy is a main focus.



Contact:

Europaring 4
D-94315 Straubing
Internet: www.cascat.de

Celgene GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Oncology, Drug Delivery, Hematology, Small Molecules, Drug Development

Celgene is a globally acting biopharmaceutical company, founded in New Jersey (USA) in 1986. Celgene is mainly active in developing and distributing drugs in hematology, oncology and immunotherapy. Since 2006, Celgene operates a German subsidiary in Munich-Riem. For further information visit: www.celgene.de



Contact:
Gerwin Winter

Joseph-Wild-Str. 20
D-81829 München
Phone: +49 (0) 89 451519-010
Fax: +49 (0) 89 451519-019
E-Mail: info@celgene.de
Internet: www.celgene.de

cellasys GmbH - R&D

BIOTECH DEVICES & REAGENTS

Keywords: Toxicology, Tissue Engineering/Cell Culture, Drug Development, Biochips, Chip/Array Technology, In-Vitro-Diagnostics

cellasys delivers system solutions for microphysiometry. These include services such as contract research, research & development, and production & maintenance. Furthermore we offer consulting services in the area of application development, data analysis and data interpretation. Our microphysiometric systems monitor different parameters directly from living cells. These parameters include extracellular acidification (pH), cellular respiration (pO₂) and morphology (impedance).



Contact:
Dr. Joachim Wiest

Ohmstr. 8
D-80802 München
Phone: +49 (0) 89 2000110-74
Fax: +49 (0) 89 2000110-76
E-Mail: info@cellasys.com
Internet: www.cellasys.com

CellTool GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Microscopy, Devices



Contact:
Dr. Karin Schütze

Am Neuland 1
D-82347 Bernried
Phone: +49 (0) 8158 9064010
Fax: +49 (0) 8158 9042318
E-Mail info-celltool@celltool.de
Internet: www.celltool.de

CellTool is a company that develops, manufactures and distributes innovative systems for non-contact and marker-free recognition, quantitative characterization and gentle sorting of living cells based on Raman spectroscopy. CellTool systems are especially designed to meet the requirements of biologists and physicians. They are extremely user friendly. Cell handling and cell measurements are highly automated. In combination with innovative microfluidics cells can be characterized in a physiological environment keeping them viable for downstream applications. Capabilities are quality control of advanced therapeutic medicinal products, fast diagnosis of disease, patient-specific drug screening or monitoring of cell reaction upon drugs and toxins.

Centronic GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Medicinal Chemistry, Analytical Chemistry, Clinical Diagnostics



Contact:
Dr. Johannes Betz

Am Kleinfeld 11
D-85456 Wartenberg
Phone: +49 (0) 8762 7243-00
Fax: +49 (0) 8762 7243-12
E-Mail: info@centronic-gmbh.com
Internet: www.centronic-gmbh.com

Centronic GmbH is a German manufacturer, with a certified Quality Management System according to EN ISO 9001:2008 and ISO 13485:2003/AC: 2009, and distributor of a big range of high qualitative clinical chemistry reagents in fluid and lyophilised form for the determination of enzymes, electrolytes, substrates, lipids and proteins. The product range is completed by a wide range of immunoturbidimetric reagents and corresponding controls, Latex reagents, controls-calibrators, food chemistry reagents, cleaning solutions for several analysers and our registered additive for waterbaths Prothermal. The products are distributed worldwide. Our team consists of highly engaged scientists from different special fields with an experience of many years in the area of clinical chemistry.

Certara Spain SL Zweigniederlassung Deutschland

BIOTECH BIOINFORMATICS

Keywords: Pharmacokinetics, Drug Development, Medicinal Chemistry, Molecular Modelling, Data Management and Biostatistics, Informatics, Data Management

Certara is dedicated to improving human health through a broad spectrum of software products and scientific consulting services, from molecular discovery through clinical development, with special focus on supporting translational approaches to drug development. Certara was formed by uniting industry leaders Tripos®, provider of innovative scientific software solutions and services enabling life science researchers to improve the efficiency of molecular discovery; Simcyp™, a research-based company providing predictive pharmacokinetic and pharmacodynamics tools, workshops, and consultancy services; and Pharsight® Corporation, provider of software and scientific consulting services to improve productivity and decision-making in preclinical and clinical drug development.

Cfm Oskar Tropitzsch GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Fine Chemicals/Reagents, Antibiotics, Agrobiotechnology, Drug Delivery, Pharmacology, Drug Development, Natural Compounds

Cfm Oskar Tropitzsch is your reliable and GDP-Certified partner for:

- Small scale (API) manufacturing (nonGMP/cGMP)
- Contract synthesis (nonGMP/GMP)
- Small molecules (> 700 substances)
- Phytochemicals (> 1000 substances)
- Phyto-Reference Substances
- Pharmaceutical raw materials
- Excipients
- Contract manufacturing of Excipients
- Chemical specialities (Curare, Picric acid incl. DMF)
- Natural toxins - synthetically produced
- Toxins
- HPAPIs - Cytotoxins - Payloads for ADCs.
- Sourcing for all kind of chemicals in small scale
- Sourcing for APIs

In very short: Tell us what you need - we try to provide it! Finding the best solution for you! We are in business since 1788!



Contact:
Dr. Fabian Böes

Martin-Kollar-Str. 17
D-81829 München
Phone: +49 (0) 89 451030-0
Fax: +49 (0) 89 451030-30
E-Mail: fabian.boes@certara.com
Internet: www.certara.com



Oskar Tropitzsch

Contact:
Michael Schäffler

Waldershofer Str. 51
D-95615 Marktredwitz
Phone: +49 (0) 9231 9619-0
Fax: +49 (0) 9231 9619-60
E-Mail: info@cfmot.de
Internet: www.cfmot.de

Charles River Laboratories, Research Models and Services, Deutschland GmbH



Contact:

Sandhofer Weg 7
D-97633 Sulzfeld
Phone: +49 (0) 9761 406 0
Fax: +49 (0) 9761 406 60
E-mail: dbestell@de.crl.com
Internet: www.criver.com

CRO

Keywords: Drug Delivery

At Charles River, we understand that the quality of our research models has a direct impact on what truly matters to you - your research. With our core programmes - biosecurity, international standardisation, animal welfare and model quality - you can focus on your work while being assured that you are receiving the highest quality and most reliable models for your research. From standard and disease-specific models to surgically altered animals, you can trust us to be an integral part of your research programmes - now and in the future.

ChromBios GmbH

CHROMBIOS

Gesellschaft für molekulare Zytogenetik mbH

Contact:

Dr. Andrea Kofler

Hochriesweg 14
D-83131 Nussdorf
Phone: +49 (0) 8035 9849-28
Fax: +49 (0) 8035 9849-30
E-Mail: chrombios@chrombios.com
Internet: www.chrombios.com

BIOTECH DNA/PROTEIN ANALYTICS

Founded in 1998, ChromBios is focused on the field of Molecular Cytogenetics (fluorescence in situ hybridisation, FISH). The company's aims are to provide service and products for chromosome analysis tailored to the needs of the customers. We offer "FISH service" such as chromosome analysis with "chromosome painting", mapping of clones, characterisation of cancer cell lines and animal models in genome research. We especially focus on multi colour karyotyping human tumour cells and other transformed cell lines (for example for patent applications). Chrombios also offers multi colour chromosome painting of mouse cells to identify translocations in mouse tumours and to characterise mouse ES cells. Apart from human and mouse, we also provide service in the characterization of chromosomes from other animal model species including rat, hamster, cat, and various live stock animals.

ChromoTek GmbH

chromotek
new tools for better research

Contact:

Dr. Marion Jung

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 124 148 8 - 0
Fax: +49 (0) 89 124 148 8 - 11
E-Mail: info@chromotek.com
Internet: www.chromotek.com

BIOTECH DEVICES & REAGENTS

Keywords: Antibody, Proteomics, Imaging, Laboratory

ChromoTek is pioneer and leading supplier of innovative tools, reagents and assays based on alpaka single domain antibodies (also known as nanobodies). Our products simplify, accelerate and improve research applications in biochemistry, proteomics, microscopy and live cell imaging. Nanobodies provide unique properties such as small size, conformational epitope coverage, nano- to picomolar binding affinity and exceptional chemical protein stability. The latest premium tool is the Spot-Tag and Spot-Tag nanobody system - the first peptide-tag/nanobody system for demanding capture and detection applications including high resolution imaging.

Cinfa Biotech GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Cinfa Biotech is the biosimilars company of Cinfa Group, a pharmaceutical leader in Spain with more than 50 years of experience. We develop, manufacture and commercialise high-quality biosimilars for oncology and inflammatory diseases. With our headquarters in Pamplona, Spain and offices in Munich, Germany we are committed to highest European quality standards. Efficient structures in our development and manufacturing processes enable us to quickly progress on our way to market. Our lead product candidate is B12019, a biosimilar version of Neulasta® (pegfilgrastim) to treat chemotherapy-induced neutropenia. The development program for B12019 was successfully completed. The Marketing Authorisation Application for the European Union has been submitted and is under review by the EMA.



Contact:

Nymphenburger Strasse 3c
D-80335 München
Phone: +49 (0) 89 54 54 62-0
E-Mail: info@cinfabiotech.com
Internet: www.cinfabiotech.com

Cipla Europe NV

PHARMA & CHEMICAL INDUSTRY

Cipla Europe NV, a 100% subsidiary of Cipla Limited, has presence in several countries in Europe through its partners and own network. Cipla is focused on offering a new pharma concept built on layers of value such as newer products, concepts, formats, information and services to help healthcare providers across Europe.

Cipla offers a range of products in Europe – Respiratory, HIV, Vaccines, OTC, API, Plain Generics and Hospital products.



Contact:

Inselkammerstraße 4
D-82008 Unterhaching
Phone: +49 (089) 6242208 10
Fax: +49 (089) 6242208 29
E-Mail: europe@cipla.com
Internet: www.cipla.com

Clariant Produkte (Deutschland) GmbH, Group Biotechnology

PHARMA & CHEMICAL INDUSTRY

Keywords: [New Materials](#), [Agrobiotechnology](#)

Clariant is an internationally active specialty chemical company based in Muttenz, Switzerland. Clariant focuses on creating value by investing in future profitable and sustainable growth, which is based on five strategic pillars: Increase profitability, reposition of portfolio, add value with sustainability, foster innovation and research & development, and intensify growth in emerging markets. The main focus of Clariant's Group Biotechnology is on bio-catalysis and bio-refining. The company develops sustainable products and processes for bio-based chemicals and fuels. Clariant has developed a process which uses enzymatic hydrolysis followed by fermentation to produce cellulosic ethanol from agricultural residues.



Contact:

Martin Vollmer

Semmelweisstraße 3
D-82152 Planegg b. München
Phone: +49 (0) 89 710 661-0
Fax: +49 (0) 89 710 661-122
E-Mail: biotech@clariant.com
Internet: www.clariant.com

Climedo Health GmbH



Contact:

Schellingstr. 109a
D-80798 München
Phone: + 49 (0) 89 122 290 82
E-Mail: info@climedo.de
Internet: www.climedo.de

BIOINFORMATICS & DIGITAL HEALTH

Keywords: Data Management, Automation, Informatics, Cell Therapy, Gene Therapy, Personalized Medicine, Oncology

Climedo supports the research activities of the university clinics by providing an intelligent software capable to harvest, archive and analyze clinical data. Beside the internal optimization process of the software and the structured data collection, the collaboration with external research partners and production laboratories stands in the forefront.

Reference algorithms paired with functional Dashboard bring a completely new usage experience and provide the doctor with a detailed real-time inside in the ongoing clinical studies.

An IT-infrastructure which complies the data protection measures and requirements will be soon implemented and examined by the public authorities.

Through our technology/software new individualized therapies, such as cell and gene therapy, can be carried out during the clinical studies in a faster and safer way.

Clinipace GmbH



Contact:

Helfmann-Park 10
D-65760 Eschborn
Phone: +49 (0) 6196 7009 - 0
Fax: +49 (0) 6196 7009 - 120
E-Mail: contact@clinipace.com
Internet: www.clinipace.com

CRO

Keywords: R&D Service, Allergy, Clinical Trial Management and Monitoring, Oncology, Nutraceuticals, Nephrology

Clinipace Worldwide is a global-acting, mid-sized clinical research organization (CRO), specialized in serving the strategic product and clinical development needs of emerging and mid-tier biopharmaceutical companies. We are specialized in Oncology, GI, Nephrology, Nutrition, Orphan diseases and more helping you advance medicines to patients that need them the most. Regardless of where you are in your products lifecycle, Clinipace has the agility, knowledge and commitment to get you where you want to be.

Clinrex GmbH

CRO

Clinrex was founded in 2004 by Dr. Dagmar Chase to offer consulting services and training in the areas GCP, Quality Management and Project Coordination for clinical trials. The set-up and handling of DSMBs / DMCs is also one of Clinrex' core competencies.

GCP/Quality Management Consulting:

- Assessment of systems or studies regarding GCP compliance
- Inspection preparedness
- SOP development/SOP streamlining
- GCP gap analyses
- Interface sponsor/CRO
- Investigator Initiated Trials

Training:

- All areas of GCP and project management of clinical trials
- Smart Training® or customised in-house training
- Training for sponsors, CROs, investigators and study nurses



Clinrex GmbH
your clinical research experts

Contact:
Dr. Dagmar Chase

Rosenkavalierplatz 12
D-81925 München
Phone: +49 (0) 89 9292 87-0
Fax: +49 (0) 89 9292 87-50
E-Mail: info@clinrex.com
Internet: www.clinrex.com

ClinTec GmbH

CRO

Keywords: Data Management and Biostatistics, Medical Writing, Oncology, Drug Development, Regulatory Affairs, Functional Solutions, Rare Disease

Clintec International is a medium sized, global CRO which provides full and functional resourcing solutions across every trial service and stage to the pharmaceutical, biotechnology and medical device industry. Covering over 80 countries, we have a strong presence in Europe, USA and Asia-PAC as well as unique markets in Middle East & Africa, providing the global footprint to performing global trials. Clintec has a wealth of experience in conducting clinical trials in oncology and rare disease as well as other therapeutic areas. We use industry leading e-clinical technologies to support our focused, flexible and forward-thinking approach, ensuring excellence at every stage of the trial, everywhere in the world.



Contact:
Dr. Hans Wolf

Landshuter Allee 8-10
D-80637 München
Phone: +49 (0) 89 5455 8355
Fax: +49 (0) 89 5574 43
E-Mail: germany@clintec.com
Internet: www.clintec.com

COLORIMETRIX GmbH

BIOTECH ANALYTICS / INFORMATICS

At COLORIMETRIX we digitise analogue colorimetric tests. How do we do this? We can turn any smartphone into a portable spectrophotometer by using its camera and a mathematical algorithm. This way we read and interpret concentration values of the substances we measure on any colorimetric test (strips, dipsticks, lateral-flow tests, microplates, solution based assays). Our technology's advantage: # No hardware needed # Works on any high-end smartphone # Easy to use # Test results available in real time # Comparable accuracy to commercial readers # Very competitive pricing # Immediate access to the cloud # Analytics, trends, insights on the measurements.

COLORIMETRIX

Contact:

Michael-Huber-Weg 18
D-81667 München
E-Mail: contact@colorimetrix.com
Internet: www.colorimetrix.com



Contact:

Kolpingring 8
D-82041 Oberhaching
Phone: +49 (0) 89 673 4688 10
Fax: +49 89 673 4688 19
E-Mail: info@comphass.de
Internet: www.comphass.de

Compass GmbH

PHARMA SUPPLIER AND TRADE

Keywords: Logistics

Compass is a young and dynamic company in the south of Munich. As an independent service provider in the pharmaceutical setting our core business is to deal with all kinds of pharmaceutical registrations. Based on our 20 years of experience in the pharmaceutical industry we want to guarantee that the bought products are available in highest quality and as fast as possible for your sales staff and for your customers. We support you therefore in the selection of the best possible contract manufacturer and accompany you and the product up to the successful conclusion of first production



Contact:

Jürgen Schäfer

Neuhauser Str. 47
D-80331 München
Phone: +49 (0) 89 236650-0
Fax: +49 (0) 89 236650-50
E-Mail: info@conreso.com
Internet: www.conreso.com

Conreso GmbH

CRO

Keywords: Clinical Trial Management and Monitoring, Data Management and Biostatistics, Veterinary Clinical Trials

Conreso, established in 1990, BVMA member, offers a wide range of medical and clinical research services, from phase II to late phase and epidemiological studies. A particular strength, the Conreso monitoring quality, is considered by its clients to be unrivalled. Conreso shows an impressive record of successful FDA inspections and significant contributions to important new product licenses. Having recruited more than 30,000 patients between 0 and 17 years of age proves the company's unique expertise in pediatric trials. Further areas of particular expertise are oncological and vaccine studies. Quality and service of Conreso are awarded by a constant repeat business rate of 90%. The Conreso department of veterinary medicine provides all types of veterinary studies.



Contact:

Jörg Müller

Fraunhoferstr. 18b
D-82152 Martinsried
Phone: +49 (0) 89 41 77 60-0
Fax: +49 (0)89 41 77 60 8211 (222)
E-Mail: personal@coriolis-pharma.com
Internet: www.coriolis-pharma.com

Coriolis Pharma Research GmbH

CRO

Keywords: Analytical Chemistry, Antisense/Nucleotides, Vaccines, Peptide/Protein, R&D Service

Coriolis Pharma is an independent CRO specialised in formulation development for liquid and lyophilized biopharmaceutical products including vaccines and highly concentrated formulations. In this respect, Coriolis is also able to handle biosafety level S1 and S2 material. Coriolis is also a leading expert in biopharmaceutical characterization using state of the art and innovative analytical technologies to support e.g., manufacturability, trouble-shooting, comparability and higher order structure characterization studies, and forced-degradation studies. For characterization of gene therapy and viral based vaccine products Coriolis supports in particle morphology, aggregation size distribution, and purity analysis. Coriolis offers GMP-compliant testing of subvisible particles and aggregates, in the context of e.g., in-use studies, method development and validation and release testing.

Covance Clinical and Periapproval Services GmbH

CRO

Keywords: Regulatory Affairs, Oncology, Pharmacology, Medical Writing, Laboratory, Clinical Trial Management and Monitoring, Drug Development

Covance Inc., a global contract research organization (CRO), is the world's most comprehensive drug development company. We are dedicated to advancing healthcare and delivering Solutions Made Real® by providing high-quality nonclinical, preclinical, clinical & commercialization services to pharmaceutical and biotechnology companies to help reduce the time and costs associated with drug development. Because of our broad experience and deep knowledge, we are in a unique position to provide insights to our client partners that go above and beyond testing. We also offer laboratory testing services to the chemical, agrochemical and food industries and are a market leader in toxicology services, central laboratory services, discovery services and a top global provider of clinical trial services.

COVANCE

Contact:
Wolfgang Schläger

Carl-Wery-Str. 42
D-81739 München
Phone: +49 (0) 89 9210930
Fax: +49 (0) 89 913466
E-Mail: wolfgang.schlaeger@covance.com
Internet: www.covance.com



Your reliable supplier for liquid nitrogen equipment



- Cryopreservation storage, transport and supply equipment
- Cryogenic protective equipment and training courses
- Cryogenic labelling solutions
- Cryovials and Cryoboxes



Sample preparation

ice-free bench top cooling devices



Freezing

controlled rate freezing systems



Transport

cold-temperature stability devices for short and long distances



Deep cold storage

cryogenic and ultra-low storage freezers -190°C, -80°C



Thawing

automated, consistent and reproducible thawing devices



Contact:

Holzhofstr. 19
D-82362 Weilheim
Phone: +49 (0) 881 927067-60
Fax: +49 (0) 881 927067-61
E-Mail: info@creative-instruments.de
Internet: www.creative-instruments.de

Creative Instruments GmbH

BIOTECH DEVICES & REAGENTS

Keywords: PCR, Automation, Devices

Creative Instruments develops and manufactures customized solutions for laboratory automation, automation analysis for diagnostics and biotechnology as well as for measurement technology. The focus is on precision engineering, chemical and liquid handling, particularly in the optical detection and related evaluation. With a team of highly qualified and motivated specialists from the fields of physics, biology, chemistry, electronics, mechanics, optics and software, we are your partner for projects right from the design through to small series production, commissioning and maintenance. The certified and innovative company develops in close cooperation with customers tailored solutions to implement processes faster, more economically and precisely.

CRELUX GmbH - a WuXi AppTec company

BIOTECH PRECLINICAL SERVICES

Keywords: Peptide/Protein, R&D Service, Small Molecules, 3D-Structural Analysis

CRELUX is a leading expert in premium drug discovery solutions for pharma, biotech and research organizations. Our services are highly individualized for our customers. We have been delivering customized solutions in drug discovery, hit finding, validation and optimization, X-ray crystallography, biophysical screening, fragment based screening and protein supply to global pharma and biotech for more than a decade. CRELUX is part of the WuXiAppTec family and as such integrated in global R&D services.



Contact:

Dr. Michael Schäffer

Am Klopferspitz 19 a
D-82152 Martinsried
Phone: +49 (0) 89 700760-0
Fax: +49 (0) 89 700760-222
E-Mail: crelux_office@wuxiapptec.com
Internet: www.crelux.com



Contact:

Brigitte Skudelny

Arnulfstraße 19
D-80335 München
Phone: +49 (0) 89 9901649-0
Fax: +49 (0) 89 9901649-800
E-Mail: info@cri-muc.eu
Internet: www.cri-muc.eu

CRI – The Clinical Research Institute GmbH

CRO

Keywords: Devices, Medical Writing, Clinical Trial Management and Monitoring, Data Management and Biostatistics, Logistics, Pharmacovigilance, Regulatory Affairs

CRI-The Clinical Research Institute GmbH is a full-service Contract Research Organization for phase III and IV clinical trials as well as for observational clinical projects (clinical registries). We perform clinical projects within Europe but we also have reliable partners in USA, Australia and Japan to offer services in those regions in addition. We offer special experience in large-scaled non-commercial trials (IITs) and in studies with medical device companies. In addition, we support medtech companies in scientific marketing challenges or technical solutions for all aspects of clinical research.

CROMSOURCE GmbH

CRO

Keywords: Pharmacovigilance, Regulatory Affairs, Medical Writing, Devices, Drug Development, Clinical Trial Management and Monitoring, Data Management and Biostatistics

CROMSOURCE is an ISO-certified international provider of outsourced services to the pharmaceutical, biotechnology and medical device industries, specialized in clinical development and staffing solutions. A well-established full-service CRO, CROMSOURCE is unique in offering an end-to-end guarantee covering trial timelines, enrolment and contract price. This guarantees our clients that their trials are delivered on time and within the contract price with no CRO initiated change orders. CROMSOURCE supports the full spectrum of clinical development via our Pharmaceutical, Medical Device, and Staffing Solutions divisions.



Contact:
Christine Wurm

Rüdesheimer Straße 15/1
D-80686 München
Phone: +49 (0) 89 21019-10
Fax: +49 (0) 89 21019-150
E-Mail: jorge.garcia@cromsource.com
Internet: www.cromsource.com

CROS DE GmbH

CRO

Keywords: Pharmacovigilance, Medical Writing, Data Management and Biostatistics

CROS NT is an international Contract Research Organisation (CRO) specialized in clinical data services. Founded in 1992, CROS NT has completed over 800 studies and remains focused on biometrics services including clinical data management, biostatistics (analysis and programming), pharmacovigilance, medical writing and life science technology. CROS NT can also offer expert consultancy services on trial design, CDISC standards, DSMB review and regulatory submissions. With offices in Italy, Germany and the UK, CROS NT has retained 100% of its customers due to advanced internal governance and client relationships built on trust.



Contact:
Vesna Stamenkovic

Konrad-Adenauer-Allee 1
D-86150 Augsburg
Phone: +49 (0) 821 450807-4
Fax: +49 (0) 821 450807-6
E-Mail: info@crosnt.com
Internet: www.crosnt.com

CryoShop

OTHER SERVICES



Contact:

WerkStadt Sendling / Haus 2
Flößergasse 4
D-81369 München
Phone: +49 (0) 89 63 899 012
Fax: +49 (0) 89 892 94 31
E-Mail: einfachcool@cryoshop.de
Internet: www.cryoshop.de

Keywords: Logistics

SUPPLIER FOR LIQUID NITROGEN EQUIPMENT CryoShop is Munich based consulting and trading company specialising in the field of cryogenic and cold storage applications. We are supporting, serving and supplying customers in the healthcare and medical research sector. Over the years we developed an expertise in projects for ultra-cold and cryogenic preservation and storage of biological specimen. Furthermore our ,cryo‘ experienced technical crew offers services, support and maintenance, when and wherever needed. We are a reliable and skilled partner for liquid nitrogen and cold storage equipment for biotech, pharmaceutical and research companies. CryoShop is offering value added cryogenic solutions; according to our customers individual requirements it is our aim to recommend the most suitable products/solution. Our portfolio allows us to provide products and solutions along the cryopreservation (standardized) workflow: from preanalytical sample preparation, controlled rate (cell)freezing, temperature controlled transport, cryogenic archiving to controlled/automated thawing devices. Furthermore we care about your staff’s safety while working in deep cold environments, offering special cryogenic personal protective equipment as well as training courses.

CSO Pharma Consulting GmbH Compliance – Safety – Organisation Development



Contact:

Dr. Silke Ostermann

Trimburgstr. 2
D-81249 München
Phone: +49 (0) 89 20335359
Fax: +49 (0) 89 80919380
E-Mail: info@csopharma.eu
Internet: www.csopharma.eu

CRO

Keywords: Pharmacology, Data Management, Regulatory Affairs, Pharmacovigilance, Medical Writing, Laboratory

CSO Pharma provides reliable pharmacovigilance services, professional medical affairs & medical science support and successful QM/GxP consulting. Our organization is build around our customers requirements and objectives. We do not only support you as experienced service provider but always serve you as your personal business partner. Successful delivery of your projects is a personal matter for us at CSO Pharma. We run our own quality management system and offer our customers reliable services and processes based on international standards. As a professional partner CSO Pharma supports the implementation of your own Quality Management/ GxP system and you can benefit from our extensive experience from audits and inspections and our comprehensive knowledge of present legal requirements.

Curadis GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

The pharmaceutical start-up company located in Erlangen/Regensburg researches and develops steroidal medicines for breast cancer and benign enlargement of the prostate gland. Curadis GmbH was founded in 2008 in Erlangen and has S-Refit AG of Regensburg as one of its investors. The company is developing a novel substance for breast cancer and a substance for prostate cancer.



Contact:
Dr. Huber Heinrichs

Merianstraße 26
D-90409 Nürnberg
Phone: +49 (0) 700 - 1447 1447
E-Mail: info@curadis.eu
Internet: www.curadis.eu

CYTOX, biologische Sicherheitsprüfungen

BIOTECH DEVICES & REAGENTS

Keywords: Microscopy, ELISA/EIA, Toxicology, Tissue Engineering/Cell Culture

CYTOX provides biological testing service for the medical device and pharmaceutical industry by using in vitro toxicological testing procedures according to ISO 10993 as well as FDA-compliant processes. Next to classical 2D cell culture testing systems we use organotypical 3D cell culture systems especially in the area of skin irritation testing and REACH applications.



Contact:
Dr. Dietmar Scheddin

Gottlieb-Keim-Str. 60
D-95448 Bayreuth
Phone: +49 (0) 921 1511-254
Fax: +49 (0) 921 1511-255
E-Mail: info@cytox.de
Internet: www.cyttox.de

DAIICHI SANKYO EUROPE GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Cardiovascular Diseases, Drug Development, Oncology

Daiichi Sankyo is a global pharmaceutical company that focuses on researching and marketing of innovative medications. The company was created in 2005 through the merger of two traditional Japanese enterprises, Daiichi and Sankyo. With net sales of more than EUR 9.3 billion in fiscal year 2013, Daiichi Sankyo is one of the world's 20 leading pharmaceutical companies. The company's world headquarters is in Tokyo, and its European base is located in Munich. Daiichi Sankyo has established affiliates in 12 European countries since it set up European production facilities and marketing offices in 1990. The company's research activities focus on the areas of cardiovascular diseases, hematology, diabetes, anti-infectives and cancer.



Contact:

Zielstattstr. 48
D-81379 München
Phone: +49 (0) 89 7808-0
Fax: +49 (0) 89 7808-202
E-Mail: service@daiichi-sankyo.eu
Internet: www.daiichi-sankyo.eu



DATA ANALYSIS SOLUTIONS

Contact:

Dr. Jürgen von Frese

Moosstr. 36

D-82266 Inning am Ammersee

Phone: +49 (0) 8143 9977293

Fax: +49 (0) 8143 9977294

E-Mail: info@da-sol.de

Internet: www.da-sol.de

Data Analysis Solutions DA-SOL GmbH

BIOTECH BIOINFORMATICS

Keywords: Informatics, Biomarker Discovery & Development, Personalized Medicine, Molecular Diagnostics, Drug Development, Data Management and Biostatistics, Data Management

DA-SOL is a services and consulting company providing advanced multi-variate bioinformatics, biostatistics, chemometrics and data mining. Based on extensive experience in large scale industry projects and fostered by proprietary algorithms, DA-SOL develops innovative, tailored data analysis solutions for its clients and provides project support as well as training on all levels. Gene expression, proteomics, metabolomics, spectroscopy, imaging and other data – DA-SOL helps its clients to conduct their studies most efficiently and to harvest the full potential of their data. Focus areas are the analysis of process data, the development of medical diagnostics and the integration of diverse biomedical or pharmaceutical data.

Data Matrix GmbH

CRO

Keywords: Data Management and Biostatistics, Medical Writing

Data MATRIX's history goes back to 2014, when it was established as a spin-off from the data management department of OCT. As part of OCT, the team had been growing and developing constantly since 2009. With its high quality software products and professional team Data MATRIX has already successfully completed 74 projects with more than 58 current studies at different progress stages. We are trusted by such companies as Abbott, Novartis, R-Pharm and many others. - Full range of clinical data management services from study design development to preparation of clinical study report - Individual approach to every project - Team of dedicated professionals - ACDM & SCDM memberships. We are familiar with EDC, IWRS, PV, CTMS, eclinical solutions.

Davids Biotechnologie GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Allergy, Immune Therapy, Antibody, Proteomics, ELISA/EIA, Tissue Engineering/Cell Culture, Antibody Production Service

Davids Biotechnologie is a German custom manufacturer for antibodies since 1996.

- Polyclonal antibodies and monoclonal antibodies.
- Antibodies and other proteins are produced in HEK and CHO cells after transient transfection as well as in standard E.coli cells.
- Chromatographic and affinity purification services for purification of protein without a tag and with a tag.
- Cell-based natural killer cell assays for detection of active molecules and for control of human therapies.



Contact:

Neuhauserstraße 25

D-80331 München

Phone: + 49 (0) 89 122 290 82

Internet: www.dm-matrix.com/



Contact:

Dr. Michael Davids

Roentgenstr. 3

D-93055 Regensburg

Phone: +49 (0) 941 948 228

Fax: +49 (0) 941 946 8119

E-Mail: info@dabio.de

Internet: www.davids-bio.de

Definiens AG

BIOTECH BIOINFORMATICS

Keywords: Drug Development, Microscopy, Personalized Medicine, Oncology, Toxicology, Biomarker Discovery & Development, Clinical Diagnostics

Definiens is the leading provider of image analysis and data mining solutions for Quantitative Digital Pathology in the life sciences, diagnostic biomarkers and healthcare industries. Definiens software provides detailed readouts from whole tissue slides, cell-based assays and full body scans, and allows the correlation of this information with data derived from other sources. By automating analysis workflows, Definiens helps pharmaceutical and biotechnology companies, research institutions, clinical service organizations and pathologists to generate new knowledge and support better decisions in research, diagnostics and therapy. Definiens' vision is to open new fields of research, to advance personalized medicine and to significantly improve the quality of patients' lives.

DEFINIENS[®]
the tissue phenomics company

Contact:
Dr. Florian Leiss

Bernhard-Wicki-Straße 5
D-80636 München
Phone: +49 (0) 89 231180-0
Fax: +49 (0) 89 231180-90
E-Mail: fleiss@definiens.com
Internet: www.definiens.com

DelphiTest GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Laboratory, Clinical Diagnostics, Genomics, PCR, Analytical Chemistry

The company's core technology capitalizes on the revolutionary development of DNA analysis, DNA sequencing and DNA fragment analysis. Delphitest GmbH focusses on family relationship testing especially for private customers but also for courts, lawyers, medical doctors, youth welfare offices and embassies. We develop new techniques and tests, e.g. paternity tests for dogs, sibling tests etc. In addition, we offer genetic tests for hereditary diseases like Huntington, Alzheimer's Disease or Canavan Syndrome and a genetic blood group test. Delphitest provides its high level of competence in DNA techniques to scientific partners like universities, hospitals or pharmaceutical companies in Europe.



Contact:
Dr. Frank Pfannenschmid

Unter den Schwibbögen 23
D-93047 Regensburg
Phone: +49 (0) 941 2986615
Fax: +49 (0) 941 6963846
E-Mail: info@delphitest.de
Internet: www.delphitest.de

Denk Pharma GmbH & Co. KG

PHARMA & CHEMICAL INDUSTRY

In a global world it is difficult to know where a product is manufactured. Therefore all Denk Pharma products are: # Manufactured in Germany # Quality controlled in Germany # Registered in Germany. Denk Pharma, Munich, Germany (www.denkpharma.de) is a globally operating pharmaceutical company with focus on development and marketing of innovative medicine for therapy of infectious and inflammatory disease and broad range generic portfolio. Denk Pharma was founded in Munich, Germany in 1948.



Contact:
Dr. Mathias Seidel

Prinzregentenstraße 79
D-81675 München
Phone: +49 (0) 89 23 00 29-0
Fax: +49 (0) 89 2300 29-480
E-Mail: pharma@denkpharma.de
Internet: www.denkpharma.de

DiaServe Laboratories GmbH



Contact:
Dr. Ulf Henseling

Seeshaupter Str. 27
D-82393 Iffeldorf
Phone: +49 (0) 8856 8036-05
Fax: +49 (0) 8856 8036-07
E-Mail: contact@diaserve.de
Internet: www.diaserve.de

BIOTECH DEVICES & REAGENTS

DiaServe is a primary manufacturer of human and animal blood derived raw materials for diagnostic industry. Based on this raw materials DiaServe also offers tailor-made in vitro controls/calibrators for medical laboratories. The company was established in 1997 with a mission to identify, develop and manufacture in vitro diagnostics mainly on OEM basis for diagnostic manufacturers and clinical laboratories.

Dojindo EU GmbH



Contact:
Takatoshi Ezoe

Leopoldstr. 254
D-80807 München
Phone: +49 (0) 89 3540-4805
Fax: +49 (0) 89 3540-4806
E-Mail: info@dojindo.eu.com
Internet: www.dojindo.eu.com

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Fine Chemicals/Reagents

Dojindo produces over 500 well-known products used by research organizations over the world. Many of these products were developed jointly between Dojindo staff and outside researchers. Dojindo strives to expand its ability to analyze the future direction of science by maintaining continued interest in new research activities as well as improving its information-gathering network. Dojindo is ready for this shortened product cycle because our creative researchers are working continuously to meet tomorrow's research needs.

DoNatur GmbH



Contact:
Dr. Franz Kerek

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 856625-55
Fax: +49 (0) 89 856625-56
E-Mail: info@donatur.de
Internet: www.donatur.de

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Rheumatoid Arthritis

DoNatur GmbH develops new therapeutics from herbal extracts with traditionally confirmed therapeutic efficiency. The comprehensive analysis of the genuine extracts, the isolation and structural characterization of the active substances and the test of their pharmacological activities constitutes the main competence of the company. Over the last years DoNatur has successfully developed a new immunomodulatory acting natural substance which has been proved highly efficacious for the therapy of rheumatic diseases.

Dr. Nibler & Partner

CRO

Keywords: Medical Writing, Pharmacology, Devices, Drug Development

Legal requirements for pharmacovigilance are continuously rising. The fulfillment turns out to be a major burden for small and medium sized enterprises. We provide a complete pharmacovigilance full-service solution:

- 24-hours availability for receipt of adverse event reports by phone, fax or e-mail
- Literature screening and -review
- Data entry and MedDRA coding
- Follow-up by medically qualified personnel (MD, RN)
- Scientific assessment by experienced physicians
- Authority reporting either electronically or on paper
- SUSAR reporting
- Preparation of periodic reports: PSUR and ASR
- Preparation and maintenance of risk management plans
- Implementation and optimization of your pharmacovigilance system
- SOP preparation or revision
- Audits and guidance through inspection



Contact:
Dr. Reinhard Nibler

Fürstenriederstr. 105
D-80686 München
Phone: +49 (0) 89 56823726
Fax: +49 (0) 89 92185265
E-Mail: mail@dr-nibler.de
Internet: www.dr-nibler.de

Dr. R. Pflieger GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Dermatology, Antibiotics, Pharmacokinetics, Pharmacology, Drug Delivery

Dr. R. Pflieger GmbH is a medium sized German pharmaceutical company located in Bamberg (Bavaria) with a staff of 300 employees. Established in 1945 as a private company, it is nowadays exclusively owned by the Doktor Robert Pflieger Foundation, which aims are the exclusive sponsoring of charitable and social projects and the support of medical research. The company is currently selling about 35 medicinal products with emphasis in urology, gynaecology and dermatology and has GMP approved production facilities. The international business is focused on the antimuscarinic drug trospium chloride which was developed by the Dr. R. Pflieger and is approved for treatment of overactive bladder.



Contact:
Dr. Peter Topfmeier

Dr.-Robert-Pflieger-Str. 12
D-96045 Bamberg
Phone: +49 (0) 951 6043-0
Fax: +49 (0) 951 6043-29
E-Mail: info@dr-pflieger.de
Internet: www.dr-pflieger.de



Contact:
Martin Spitznagel

Am Klopferspitz 19
D-82152 Planegg-Martinsried
Phone: +49 (0) 89 339 800-510
Fax: +49 (0) 89 339 800-519
E-Mail: info@dustbiosolutions.com
Internet: dustbiosolutions.com

Dust BioSolutions GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: [New Materials](#), [Agrobiotechnology](#), [R&D Service](#), [Industrial Biotechnology](#)

Dust BioSolutions is an industrial biotechnology company that improves sustainability and profitability of its clients through the application of a natural process that solidifies permeable materials. Its international and multidisciplinary team has developed a technology platform around microbiologically induced calcite precipitation, a bio-geochemical process where bacteria precipitate calcium carbonate within the soil matrix. A first product offers various industries a customised solution to control dust more cost-efficiently and environmentally friendly than existing alternatives. Dust BioSolutions is continuously working on other applications of the technology and an expansion of its product portfolio.



Contact:
Dr. Dirk Scholl

Lochhamerstr. 15
D-82152 Martinsried
Phone: +49 (0) 89 897 4544-0
Fax: +49 (0) 89 897 4544-11
E-Mail: info@dynamic-biosensors.com
Internet: www.dynamic-biosensors.com

Dynamic Biosensors GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: [Antibody](#), [Proteomics](#), [Small Molecules](#), [Peptide/Protein](#), [Chip/Array Technology](#), [Drug Development](#), [Devices](#)

Dynamic Biosensors offers solutions for label-free molecular interaction analysis and beyond. The proprietary switchSENSE[®] technology combines unrivaled analytical content with superior sensitivity. Apart from standard binding parameters (affinity and kinetics; even in the sub-picomolar range), switchSENSE[®] allows much deeper insights into the analyte. This includes determination of the absolute size of the molecule, analysis of conformational changes, characterization of complex binders, including affinity vs. avidity, as well as thermodynamic characterization. Overall, by combining the advantages of a dynamic molecular measurement with the benefits of a chip-based biosensor system, switchSENSE[®] offers a new level of information and flexibility in biosensing.



Contact:
Rebekka Fründt

Semmelweisstraße 3
D-82152 Planegg
Phone: +49 (0) 89 3249 3670
E-Mail: info@electrochaea.com
Internet: www.electrochaea.com

Electrochaea GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

On the basis of biocatalysis, Electrochaea offers a power-to-gas key technology which has been patented internationally. It cost-effectively recycles CO₂ and simultaneously produces storable and usable biomethane from surplus electrical energy. The first industrial scale plant operates successfully in Denmark. Plants of more than one gigawatt (GW) of capacity are targeted by 2025. 20 employees work for Electrochaea in Denmark and at the head office in Munich. CEO is Mich Hein.

ELLA Biotech GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, PCR, Chip/Array Technology, RNAi & Antisense, Genomics, Antisense/Nucleotides

Our focus is the synthesis of special oligoribonucleotides for selected projects in diagnostics, chip technologies, gene synthesis and further topics - following quality standards which you would appreciate and expect in your own lab. The guidelines for the synthesis standards can be defined by our customers themselves. Through our validated technology platform, our experienced interdisciplinary team and our resolute attitude towards the highest quality in our products we offer tangible advantages to our customers and partners.



Contact:
Dr. Peter Frischmann

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 7093 9316
Fax: +49 (0) 89 7093 9440
E-Mail: info@ellabiotech.com
Internet: www.ellabiotech.com

Bayern Kapital

Venture Capital für Bayern

NEW:
Wachstumsfonds
Bayern



Your high tech enterprise is looking for equity capital?

Bayern Kapital offers:

- seed finance equity capital, for R&D, market launch and growth
- co-investments with partners
- many years of experience in financing
- access to strong network
- later stage venture capital

WWW.BAYERNKAPITAL.DE

Bayern Kapital GmbH | Ländgasse 135 a | 84028 Landshut
Phone +49 (0)871 92325-0 | info@bayernkapital.de



Contact:
Susanne Nieswandt

Am Morgenroth 6
D-97246 Eibelstadt
Phone: +49 (0) 9303 984 964
Fax: +49 (0) 700 3637 3800
E-Mail: service@emfret.com
Internet: www.emfret.com

EMFRET Analytics GmbH & CoKG

BIOTECH DEVICES & REAGENTS

emfret Analytics GmbH (founded 2002) is focussing on production, characterization, derivatization and supply of monoclonal antibodies in biomedical research, namely vascular biology.



Contact:
Dr. Franz X. Welser

Hebbelstr. 61
D-85055 Ingolstadt
Phone: +49 (0) 841 3796013
Fax: +49 (0) 841 8817185
E-Mail: info@empgenetech.com
Internet: www.empgenetech.com

EMP Genetech

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Peptide/Protein, Biomarker Discovery & Development, Antibody Production Service, Personalized Medicine, Clinical Diagnostics, Drug Development

EMP Genetech Recombinant Proteins from Human Cells Improving your Research Activities. EMP Genetech provides non-GMP services in recombinant protein production and the development of stable high producer cell lines. Protein purification to customer given purity is also conducted, as well as cell banking. We work with industrial and academical clients. Since 2000, the company has developed several dozen recombinant biomolecules.

EMP Genetech's Services:

- Gene Cloning
- Development of Stable High Producer Cell Lines
- Recombinant Protein Production
- Process Development
- Generation of Cell Banks
- Protein Purification
- Experience since 2000

EPIGENE

Contact:
Dr. Friedrich G. Felsenstein

Hohenbachernstr. 19-21
D-85354 Freising
Phone: +49 (0) 8161 4990-80
Fax: +49 (0) 8161 4990-89
E-Mail: Friedrich.Felsenstein@EpiLogic.de
Internet: www.epigenet.de

EpiGene GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: Agrobiotechnology, Genomics

EpiGene GmbH, founded in 1999, is a genomics-based research and development company focusing on applications in plant protection. The core competences comprise the molecular characterization of plant-pathogen interactions and the development of high throughput systems for molecular diagnostics of involved genetic factors. In addition, research efforts include investigations of the mode of action of plant protective agents at the molecular level and the identification of mutations or differentially expressed genes in pathogens as potential new targets.

EpiLogic GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: Agrobiotechnology, Genomics

EpiLogic is a new European wide operating company involved in product development based on genomic analysis of fungal pathogens propagated by wind in agricultural crops (at present: cereals and vine). Pathogen analysis of virulence and fungicide sensitivity are used as decision support for breeding, choice of cultivar and fungicide management to ensure sustainable agriculture. A genotype bank of several pathogens is currently being set up to offer high quality inoculum for selection in laboratory, greenhouse and field. Additionally, methods are under development for analysing and culturing new pathogens.



Contact:
Dr. Friedrich G. Felsenstein

Hohenbachernstr. 19-21
D-85354 Freising
Phone: +49 (0) 8161 4990-80
Fax: +49 (0) 8161 4990-89
E-Mail: Friedrich.Felsenstein@EpiLogic.de
Internet: www.EpiLogic.de

ethris GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Metabolic Diseases, Dermatology, Bone/Joint Diseases, Gene Therapy, Gene Transfer, Tissue Engineering/Cell Culture, Drug Development

Ethris is paving a new path from genes to therapeutic proteins using our proprietary messenger RNA technology. Developed in-house, our integrated platform enables the discovery, design and development of transcript therapies that restore missing functions in patients cells and tissues. We will advance transcript therapies to transform the treatment of disease independently and with our partners.



Contact:
PD Dr. Carsten Rudolph

Semmelweisstrasse 3
D-82152 Planegg
Phone: +49 (0) 89 8955 788-0
Fax: +49 (0) 89 8955 788-18
E-Mail: info@ethris.com
Internet: www.ethris.com

eticur) GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Based on the idea that umbilical cord blood contains multipotent adult stem cells, the cord blood is prepared and stored for potential later use. These cells might in future play an important role in therapies including regenerative medicine. Our priority is to grant the most secure storage, highest quality and extensive testing by highly qualified personnel. eticur) grants the storage of stem cells following the highest quality-standards of the Federal Board of Physicians and the Institute for Sera and Vaccine (Paul-Ehrlich-Institute).eticur) cooperates with the Department of Transfusion Medicine and Haemostaseology of the University Hospital of Erlangen.



Contact:
Felix Raslag

Landsberger Str. 406
D-81241 München
Phone: +49 (0) 89 12 59 81-0
Fax: +49 (0) 89 12 59 81-19
E-Mail: info@eticur.de
Internet: www.eticur.de

Eurofins BioPharma Product Testing Munich GmbH



Contact:
Bettina von Klitzing-Stückle

Behringstr. 6/8
D-82152 Martinsried
Phone: +49 (0) 89 899650-0
Fax: +49 (0) 89 899650-11
E-Mail: info-munich@eurofins.com
Internet: www.eurofins.de

BIOTECH PRECLINICAL SERVICES

Keywords: Toxicology, Pharmacology, Small Molecules, Bioanalytics, Laboratory

Eurofins BioPharma Product Testing is the largest network of harmonized bio/pharmaceutical GMP product testing laboratories worldwide providing comprehensive laboratory services for the worlds largest (bio-)pharmaceutical and medical device companies. Our service offerings are fully comprehensive and include testing of drug substance, final product, intermediates, and starting materials for both small and large molecule drug products as well as testing of medical devices. With a global capacity of more than 65,000 square meters and facilities located in Australia, Belgium, Denmark, France, Germany, Ireland, Italy, Netherlands, Spain, Sweden, UK and the US, our network of GMP/GLP laboratories operates under the same strict quality procedures.

Eurofins Genomics



Contact:

Anzinger Straße 7a
D-85560 Ebersberg
Phone: +49 (0) 8092 8289-0
Fax: +49 (0) 8092 21084
E-Mail: info-eu@eurofins.com
Internet: eurofinsgenomics.com

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Genomics, NGS, PCR, Antisense/Nucleotides

Eurofins Genomics is an international provider of genomic services around the core business lines next generation sequencing, genotyping, gene expression, custom DNA sequencing, oligonucleotides, siRNA and gene synthesis.

Evotec Munich GmbH

BIOTECH PRECLINICAL SERVICES

Keywords: Drug Development, Oncology, Genomics, Proteomics, Small Molecules, Inflammation, Metabolic Diseases

Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic. The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, pain, metabolic diseases as well as oncology, inflammation and infectious diseases. Evotec has long-term discovery alliances with partners including Bayer, Boehringer Ingelheim, CHDI, Genentech, Janssen Pharmaceuticals, MedImmune/AstraZeneca, Roche and UCB. In addition, the company has existing development partnerships and product candidates both in clinical and pre-clinical development. These include partnerships with Boehringer Ingelheim and MedImmune in the field of diabetes, with Janssen Pharmaceuticals in the field of depression and with Roche in the field of Alzheimer's disease. For additional information please go to www.evotec.com.



Contact:
Dr. Dirk Ullmann

Am Klopferspitz 19a
D-82152 Martinsried
Phone: +49 (0) 89 4524465-0
Fax: +49 (0) 89 4524465-20
E-Mail: info@evotec.com
Internet: www.evotec.com

EXCELLA GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Drug Development, Medicinal Chemistry, Analytical Chemistry, Small Molecules, Oncology

Excella GmbH has been serving the pharmaceutical industry for more than 35 years with high quality API's and finished dosage forms. Recent investments have directed our focus towards high containment products (including OEB5) and a one-stop-shopping approach. Excella supplies products to the generic industry but although manufactures for big pharma life cycle end products and develops processes for innovative API's and novel solid dosage forms. Services offered range from early product development through registration support to state-of-the-art manufacturing. Excella's Feucht site has an excellent track record with the FDA and other regulatory agencies since 1983 and is Safebridge certified.



Contact:
Dr. Johann Peter Mörsdorf

Nürnberger Str. 12
D-90537 Feucht
Phone: +49 (0) 9128 404-0
Fax: +49 (0) 9128 4045-81
E-Mail: info@excella-pharma-source.de
Internet: www.excella-pharma-source.de

Exosome Diagnostics GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS



Contact:
Dr. Mikkel Noerholm

Am Klopferspitz 19a
D-82152 Martinsried
Phone: +49 (0) 89 416172-70
Fax: +49 (0) 89 416172-69
E-Mail: munich@exosomedx.com
Internet: www.exosomedx.com

Keywords: Metabolic Diseases, Diabetics, CNS, PCR, Genomics, Clinical Diagnostics

Exosome Diagnostics is developing biofluid based molecular diagnostic tests for use in personalized medicine applications. Exosomes and other microvesicles are shed into all biofluids, including blood, urine, and cerebrospinal fluid, forming a highly enriched source of intact, disease-specific nucleic acids. The Company's proprietary exosome technology makes use of this natural enrichment to achieve high sensitivity and specificity for rare gene transcripts and the expression of genes responsible for cancers and other diseases. The Company is commercializing in vitro diagnostic tests for use in companion diagnostic applications and real-time monitoring of disease. The Company is located in New York, USA and Munich, Germany and is backed by an international consortium of leading VCs.

F-Select GmbH

PHARMA & CHEMICAL INDUSTRY



Contact:

Semmelweisstrasse 5
82152 Planegg
Phone: +49 (0) 89 74032330
Fax: +49 (0) 89 74033443
E-Mail: info@f-select.de
Internet: www.f-select.de

The element fluorine plays an increasingly important role in the field of high-performance materials and pharmaceuticals. The production of the necessary chemical substances remains a challenge and F-Select has the solution. F-Select offers selected fluorinating agents as well as a comprehensive know-how in the handling and production of fluorinating agents. The methods developed by F-Select provide resource-saving methods for the production of pharmacological building blocks.

FEI Munich GmbH

BIOTECH DEVICES & REAGENTS



Contact:
Erika Weber

Lochhamer Schlag 21
D-82166 Gräfelfing
Phone: +49 (0) 89 8956 62-0
Fax: +49 (0) 89 8956 62-101
E-Mail: LM.info@fei.com
Internet: www.fei.com

Keywords: Automation, 3D-Structural Analysis, Microscopy, Devices

Industry-leading FEI life sciences workflows offer a proven path to results for structural and cell biology researchers. Our commitment to innovation has resulted in many industry firsts, placing customers at the forefront of advanced research capabilities. With our comprehensive range of flexible workflows including hardware, software, and consumables researchers at any level can move from questions to answers quickly and easily. Our teams of scientists understand customers disciplines, challenges, and goals, enabling us to build long-term partnerships that advance biological research. More customers achieve results and recognition working with FEI than with any other solution provider.

FGK Clinical Research GmbH

CRO

Keywords: Drug Development, CRO/CMO, Clinical Trial Management and Monitoring, Regulatory Affairs, Medical Writing, Data Management and Biostatistics

FGK Clinical Research is a European CRO with headquarters in Munich offering full services for all phases of clinical trials. Our more than 100 highly qualified medical, scientific and regulatory experts can guide you through the clinical trial process, from planning and approval to the final report. FGK has subsidiaries in the UK, Hungary, Poland and Czech Republic. Our international client base includes biotechnology, medical device, and pharmaceutical companies. With our „all services through one company“ philosophy we are able to offer tailored approach to meet the specific requirements of each sponsor. FGK has extensive experience in all major therapeutic areas allowing it to effectively design, manage, and analyze development programs and clinical trials.



Contact:
Martin Krauss

Heimeranstr. 35
D-80339 München
Phone: +49 (0) 89 893 119-0
Fax: +49 (0) 89 893 119-20
E-Mail: info@fgk-cro.com
Internet: www.fgk-cro.com

FGK Pharmacovigilance GmbH

CRO

Keywords: Data Management and Biostatistics, Pharmacovigilance, Regulatory Affairs, Drug Development, Clinical Trial Management and Monitoring, Medical Writing

FGK Pharmacovigilance GmbH is a service provider offering the full range of services related to continuous monitoring of risk-benefit of authorized medicinal products including:

- Management of Adverse Events and Signals and of risk minimization activities including assessment of effectiveness of these activities
- Preparation of periodic safety update reports, ad hoc safety reports or statements specifically tailored to requests of CAs
- Safety profile characterization and planning of PV activities to increase knowledge about the safety profile of the medicinal product

With broad therapeutic and risk management experience of its personnel FGK PV guarantees an early recognition of potential risks and timely planning of risk minimization activities to avoid these risks while keeping the product on the market. With our daughter company, FGK Representative Service Ltd, we also provide legal representation services to our non-European customers (www.fgk-rs.com).



Contact:
Dr. Edgar J. Fenzl

Heimeranstraße 35
D-80339 München
Phone: +49 (0) 89 893 119-0
Fax: +49 (0) 89 893 119-20
E-Mail: info@fgk-pv.com
Internet: www.fgk-pv.com

Formycon AG

BIOTECH THERAPEUTICS & DIAGNOSTICS



Contact:
Iris Margraf

Fraunhoferstr. 15
D-82152 Martinsried
Phone: +49 (0) 89 864667-100
Fax: +49 (0) 89 864667-110
E-Mail: info@formycon.com
Internet: www.formycon.com

Keywords: Drug Development

Development of Biosimilars Formycon is a leading independent pure play developer of biosimilars and has become a recognized innovator in this field. The company has extensive experience in the development of complex biological molecules. Formycon's specialist expertise allows the company to develop high-quality biosimilars that meet the strict regulatory requirements of highly regulated markets such as Europe and the United States. Formycon currently has four biosimilars under development, with further product candidates already identified. Two biosimilar candidates have already been licensed out. Another project has been transferred into a Joint venture.

Freeline Therapeutics GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS



Contact:
Dr. Markus Hörer

Semmelweisstraße 3
D-82152 Planegg
E-Mail: infode@freelinetx.com
Internet: www.freelinetx.com

Freeline Therapeutics is a biopharmaceutical company focused on the development and commercialization of gene therapies for bleeding and other debilitating disorders based on a next-generation AAV gene therapy platform developed by Amit Nathwani, Professor of Hematology at UCL and CSO of Freeline Therapeutics. The German branch located in Munich was established around the Adeno-Associated Virus (AAV) manufacturing platform developed by Rentschler Biotechnologie GmbH (Rentschler) and acquired by Freeline. The focus of the Munich site is to further advance the AAV platform technologies and large-scale manufacturing processes as well as to develop a broad analytical toolbox for gene transfer vector characterization.

FreshDetect GmbH

PHARMA & CHEMICAL INDUSTRY



Contact:

Kirchplatz 1
D-82049 Pullach
Phone: +49 (0)89 324 939 210
E-Mail: info@freshdetect.com
Internet: www.freshdetect.com

FreshDetect GmbH, headquartered in Pullach, Germany, near Munich, develops and markets innovative measurement instruments and solutions for fast and reliable quality control for the food industry. Our employees are experts in the fields of spectroscopy measurement technology and microbiology. They have extensive experience in food processing technologies and the processing of microbiology data.

FRIZ Biochem Gesellschaft für Bioanalytik mbH

BIOTECH DEVICES & REAGENTS

Keywords: Chip/Array Technology, Infectious Diseases, Devices, Clinical Diagnostics

FRIZ Biochem develops and produces highly reliable user-friendly and inexpensive biochip systems for applications in medical diagnostics, food testing and pharmaceutical research. Key products are DNA-chips with direct electrical read-out where SNPs (single nucleotide polymorphism) can unambiguously be detected and time-consuming labeling of the target-DNA is no longer necessary. This enables a broad range of simple and fast analyses making the system ideal for biological medical studies. The company's proprietary combination of micro arrays, electrical detection and semiconductor technology opens the way to compact multiplex analyses directly at a PC without the expensive instrumentation commonly needed.



Contact:
Dr. Gerhard Hartwich

Floriansbogen 2 - 4
D-82061 Neuried
Phone: +49 (0) 89 7244 09-25
Fax: +49 (0) 89 7244 09-10
E-Mail: info@frizbiochem.de
Internet: www.frizbiochem.de

GBA PHARMA GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Laboratory, Analytical Chemistry, Pharmacology, R&D Service

GBA Pharma GmbH with sites in Martinsried, Gräfelfing and Ulm is an analytical full-service provider operating under cGMP. The three pharmaceutical laboratory sites offer scientific and technical solutions for international customers from both, the private industry and research institutions. Operating under cGMP with more than 150 employees and over 5,000 m² of laboratory space GBA Pharma GmbH provides scientific and technical solutions for the development, validation, approval process, and quality control throughout every step of the product lifecycle. Gas and liquid chromatography, mass spectrometry, capillary electrophoresis as well as microbiological testing and development of tests for in-vivo-in-vitro correlation belong to the core competencies of GBA Pharma GmbH.



Contact:
Ines Kipar

Fraunhoferstraße 11a
D-82152 Planegg-Martinsried
Phone: +49 (0) 89 899229-0
Fax: +49 (0) 89 8577899
E-Mail: info@gba-pharma.com
Internet: www.gba-pharma.com

GBN Systems GmbH

BIOTECH & MEDTECH DEVICES & REAGENTS

For over 20 years our challenge is to meet the outstanding demands of our clients in the fields of medical technology, biotechnology, the semi-conductor industry and automation technology. From the very start our experienced team of electro technology engineers and precision mechanics develops and manufactures a wide product range. From customized components to complete assemblies and machines from initial vision to serial end production. The Facilities are centrally located near Bavarian capital and airport of Munich. Key competencies in: Concept, development, prototyping, validation, certification, pre-series, main-serial production, quality management, fulfillment, logistics.



Performing Mechatronics
Made in Bavaria

Contact: Harry Flint

Fellnerstrasse 2
D-85656 Buch am Buchrain
Phone: +49 (0) 8124 5310-0
Fax: +49 (0) 8124 5310-20
E-Mail: info@gbn-systems.com
Internet: www.gbn-systems.com



GE imagination at work

Contact:
Michael Kaleja

Oskar-Schlemmer-Str. 11
D-80807 München
Phone: +49 (0) 7667 833-559
Fax: +49 (0) 7667 833-616
E-Mail: michael.kaleja@ge.com
Internet: www.gelifesciences.com

GE Healthcare Europe GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Fine Chemicals/Reagents, Devices, Analytical Chemistry, Genomics, Proteomics

GE Healthcare Life Sciences provides a broad range of products and services for biomolecule separations at all scales.

Chief products include:

- ÅKTAdesign™ chromatography systems and BioProcess™ media
- Filtration systems and devices
- Wave Bioreactor™ and mixers
- Cell separation for isolating and purifying cells, viruses, and sub-cellular particles
- Fast Trak™ BioPharma Services.

Our products are used in the manufacture of the majority of all FDA-approved biopharmaceuticals on the market. GE Healthcare Life Sciences is a part of GE Healthcare, a General Electric company with more than 42,000 employees, providing transformational medical technologies that are shaping a new age of patient care.



Contact:
Dr. Peter Haberl

Fürstenrieder Straße 281
D-81377 München
Phone: +49 (0) 89 4581901-0
Fax: +49 (0) 89 4581901-5
E-Mail: peter.haberl@genedata.com
Internet: www.genedata.com

Genedata Bioinformatik GmbH

BIOTECH BIOINFORMATICS

Genedata is a bioinformatics company that specializes in developing software systems for the comprehensive analysis of genomes, transcriptomes, proteomes, metabolomes, and biochemical compounds. By working closely with key partners, the company combines its extensive product portfolio with expert scientific consulting services to offer tailor-made solutions for specific applications and multiple therapeutic areas. The company's solutions are key for moving the focus of life science research from high-throughput data acquisition to high-content data interpretation. Founded in 1997 as a spin-off from Novartis, the company is headquartered in Basel (Switzerland) with branch offices in Munich (Germany), San Francisco (USA), Boston (USA), and Tokyo (Japan).

Genedia AG Biotec Services and Products

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Antisense/Nucleotides, Genomics, Medicinal Chemistry

Genedia AG Biotec Services and Products is a provider of DNA testing services including private DNA paternity testing, legal DNA paternity testing as well as other relationship testing services (full or half sibling testing, grandparents testing, aunt or uncle testing, 1st cousin testing, maternity testing as well as twin testing). An other area is DNA genealogy and anthropology, which includes ancestral origin DNA population test, Y-Chromosome Analysis, mt-DNA analysis. The forensic area includes DNA identification and banking services forensic testing services especially stain analysis. DNA molecular testing of diseases (Factor V and II, MTHFR, CFTR-Mutation). DNA testing of animals.



Contact:
Dr. Hildegard Haas

Candidplatz 13
D-81543 München
Phone: +49 (0) 89 543448-0
Fax: +49 (0) 89 543448-20
E-Mail: info@genedia.de
Internet: www.genedia.de

Genetic ID (Europe) GmbH Labor für gentechnische Analysen

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: ELISA/EIA, Genomics, PCR, Laboratory, Transgenic Plants, Agrobiotechnology

Genetic ID (Europe) GmbH provides molecular biological analysis of food and feed, plant material, and animal tissue (GMO analysis, species identification, DNA barcoding, custom contract assay development) and immunological detection of allergens in food and feed.



Contact:
Christoph Wiemer

Am Mittleren Moos 48
D-86167 Augsburg
Phone: +49 (0) 821 747 76-30
Fax: +49 (0) 821 747 76-39
E-Mail: info@genetic-id.de
Internet: www.genetic-id.de

Genomatix AG

BIOTECH BIOINFORMATICS

Keywords: Genomics, Devices, NGS, Informatics, Data Management and Biostatistics

Genomatix is one of the world's leading suppliers of technologies to analyze and interpret genomic data. As well as laying the groundwork for microarray experiments and NGS data sequencing analyses, our hardware, software & service solutions help answer the typical questions posed by systems biology. Our approach: combine multiple lines of evidence to perform an integrated meta-analysis. Instead of looking at single strands of information separately, we access an exceptionally large pool of data from different sources. This wealth of data is continually expanding, so it is continually up to date. This meta-analysis leads to more relevant results, more precise scientific knowledge and a better chance of understanding the molecular contexts of gene regulation and expression.



Contact:
Dr. Korbinian Grote

Bayerstr. 85a
D-80335 München
Phone: +49 (0) 89 599 766-0
Fax: +49 (0) 89 599 766-55
E-Mail: info@genomatix.de
Internet: www.genomatix.de

Gen-Plus GmbH & Co KG



Contact:

Staffelseestraße 6
D-81477 München
Phone: +49 (0) 89 780 179 40
Fax: +49 (0) 89 780 179 44
E-Mail: info@gen-plus.de
Internet: www.gen-plus.de

CRDO

Keywords: Drug Development

Gen-Plus was founded in 1999 and is since then engaged in research and development of innovative formulation concepts for challenging drug substances. Today Gen-Plus is a state-of-the-art contract research and development organization (CRDO) fully equipped and capable of meeting our customers' ambitious goals in formulation development. Experienced and skilled experts are our key factor of success.

Gen-Plus offers following contract services:

- Wide experience in special formulation concepts and technologies for solid and semi-solid dosage forms to increase bioavailability, stability and consumer convenience
- Sophisticated formulation technologies for oral films (ODF) and transdermal patches (TTS)
- GMP facility enabling manufacturing of investigational medicinal products for proof of concept studies in humans
- Competence Center for in vitro liberation & dissolution (USP I,II,IV,V) and performance of customized permeation tests
- Drug Development of high potent drug substances in tailor-made containment systems
- Development of formulations containing controlled substances (narcotics). – All necessary conditions as well as all legal requirements for handling narcotics are fulfilled

Gilead Sciences GmbH



Contact:

Dr. Andrea Kücherer-Ehret

Fraunhoferstr. 17
D-82152 Martinsried
Phone: +49 (0) 89 899890-0
Fax: +49 (0) 89 899890-90
E-Mail: info@gilead-sciences.de
Internet: www.gilead.com

BIOTECH THERAPEUTICS & DIAGNOSTICS

Gilead Sciences is dedicated to providing accelerated solutions for patients and the people who care for them. The evolution of Gilead - from a promising biopharmaceutical company to a leader in the international development and commercialisation of medicines for life-threatening diseases in HIV as well as in Hepatitis B and C - is testament to what the company has achieved through disciplined science, visionary thinking and diversified planning. Research and development in Gilead focusses also on hematology and oncology, liver diseases and inflammation. Gilead's headquarter is based in Foster City, California with affiliates all over the world.

GILYOS GmbH

CRO

Keywords: Small Molecules, Peptide/Protein, Antibody, Nanobiotechnology, Drug Development

GILYOS is a research-oriented, highly specialized contract service partner in the field of pharmaceutical freeze-drying. Services include, but are not limited to, formulation development for pharmaceuticals (protein, peptide), freeze-drying cycle development, optimization of processes including Quality-by-Design and scale-up from laboratory to production. GILYOS offers a variety of analytical methods to fully characterize drug formulations (liquid and solid state), with special focus on the examination of the physicochemical properties of materials. Moreover, the company offers a full range of consulting services, including technical support for freeze-dryers and sales of equipment.



Contact:
Dr. Margit Gieseler

Friedrich-Bergius-Ring 15
D-97076 Würzburg
Phone: +49 (0) 931 907056-78
Fax: +49 (0) 931 907056-79
E-Mail: info@gilyos.com
Internet: www.gilyos.com



Tel.: +49 (89) 85 89 63 - 0
kontakt@wander-immobilien.de



You are looking for suitable laboratories?

We are your specialist!

www.wander-immobilien.de

Office, laboratories and production space

from 250 sqm – 10.000 sqm

**We are looking forward to send you
an attractive offer.**



gimbio mbH Gesellschaft für Informationsmanagement in der Biotechnologie

BIOTECH BIOINFORMATICS

Keywords: Automation, Data Management

Development and application of innovative online measurement systems for biotechnical process state variables. Gimbio sees itself as a company offering innovative products and solutions in bioprocess technology, especially for companies in the food, brewing or biotechnology industry. The guiding principle of the company is, in addition to the information gathering and processing, the development and application of innovative online measurement systems for biotechnical process state variables for the purpose of process design, modeling and simulation, with the ultimate goal of optimizing underlying bioprocesses.



Contact:
Markus Fellner

Lise-Meitner-Str. 30
D-85354 Freising/Weihenstephan
Phone: +49 (0) 8161 986 4480
Fax: +49 (0) 8161 986 5661
E-Mail: info@gimbio.de
Internet: www.gimbio.de

GKM Gesellschaft für Therapieforschung mbH

CRO

Keywords: Pharmacovigilance, CRO/CMO, Medical Writing, Regulatory Affairs, Data Management and Biostatistics, Clinical Trial Management and Monitoring
GKM Gesellschaft für Therapieforschung mbH is a privately owned full service Contract Research Organisation for planning and conducting clinical trials phase II-IV as well as for post-marketing-surveillances. Since 1981, GKM is a reliable partner for pharmaceutical, biotech and medical device companies. GKM provides flexible services with expert knowledge and dedication to your projects in accordance with ICH-GCP and other applicable national and international guidelines. More than 35 years experience: cost-effective quality combined with the latest standards and technologies.



Contact:
Dr. Christian Hautmann

Lessingstr. 14
D-80336 München
Phone: +49 (0) 89 209 120-0
Fax: +49 (0) 89 209 120-30
E-Mail: mail@gkm-therapieforschung.de
Internet: www.gkm-therapieforschung.de

GlaxoSmithKline GmbH & Co. KG

PHARMA & CHEMICAL INDUSTRY

Keywords: Antibiotics, Vaccines, CNS, Dermatology, Respiratory Diseases, Urology

GSK is a research-based, globally operating healthcare company committed to improving the quality of human life by enabling people to do more, feel better and live longer. GSK is setting milestones in healthcare prevention with a comprehensive portfolio of vaccines and additionally in respiratory, urological and dermatological therapies. Via our affiliate ViiV Healthcare, we are also involved in the area of HIV. Beyond that, we are a leading manufacturer of consumer healthcare products. From clinical development to manufacturing and commercialization of our products, GSK is closely associated with Germany as a business and science location: GSK has facilities in Munich, Heidelberg, Dresden and Marburg, to name a few. We owe our success to the incredible dedication and commitment of our global workforce. We have more than 100,000 employees in 115 countries worldwide, including 3,600 employees in Germany. Social responsibility and sustainability are at the heart of our corporate philosophy. This is the reason why we place such great emphasis on promoting projects at a local level. Our global headquarter is based in London, UK.

GNA Biosolutions GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Nanobiotechnology, Clinical Diagnostics, Devices, Analytical Chemistry

GNA Biosolutions has developed a laser-based, optothermal system to provide the world's fastest DNA diagnostics. The technology is based on nanoparticles within the sample solution. These nanoparticles can be heated up with a laser, and they cool down immediately after irradiation. As a result, the heating and cooling ramps are a million times shorter than in conventional thermocyclers, leading to ultra-fast DNA amplification (Laser PCR®). The optical characteristics of the nanoparticles can also be utilized for a fluorescence-free detection (Nanostove®) that minimizes any upstream sample preparation. GNA's Pharos400 instrument will perform integrated Laser PCR® and Nanostove® read-out. The assay pipeline comprises tests for infectious diseases, with a focus on screening incoming patients for resistant micro-organisms directly during the admission. GNA was incorporated in 2010 as a spin-off from Ludwig-Maximilians-Universität, Munich and its chair for Photonics and Optoelectronics



Contact:
Claudia Kubacki

Prinzregentenplatz 9
D-81675 München
Phone: +49 (0) 89 360 440
Fax: +49 (0) 89 360 448000
E-Mail: service.info@gsk.com
Internet: www.glaxosmithkline.de



Contact:
Dr. Lars Ullerich

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 998 207-180
Fax: +49 (0) 89 998 207-188
E-Mail: info@gna-bio.com
Internet: www.gna-bio.com

GWK Präzisionstechnik GmbH



BIOTECH DEVICES & REAGENTS

Keywords: Microscopy, Chip/Array Technology, Automation, Analytical Chemistry, Devices

Contact:
Christian Heese

Gollierstr. 70
D-80339 München
Phone: +49 (0) 89 7264960-0
Fax: +49 (0) 89 7264960-29
E-Mail: info@gwk-munich.com
Internet: www.gwk-munich.de

GWK Precision Technology offers laboratory equipment and medical devices. Based in Munich we are a team of 20 specialists and serve industries since 1991. We provide special know-how in technical fields (precision mechanics, optics, image processing, sensors, microfluidics, cutting techniques, lateral flow, 3D-prototyping) and system techniques (automation, handling, electronics and machine control) as well as the certification of equipment and production systems.

Hellsicht GmbH



BIOTECH BIOINFORMATICS / DIGITAL HEALTH

Keywords: Bioinformatics, Imaging, Data Management, Informatics

Contact:

Passauerstraße 35
DE-81369 München
Phone: +49 (0)152 05390057
E-Mail: info@hellsicht.ai
Internet: www.hellsicht.ai

We build deep learning software to improve medical diagnosis by combining human expertise with machine intelligence in a unique hybrid approach.

Hematrix Wound Care GmbH



MEDTECH

Keywords: Devices

Contact:
Dr. Dr. Stefan Bertsch

Professor-Messerschmitt-Str. 3
D-85579 Neubiberg
Phone: +49 (0) 89 6008761-0
Fax: +49 (0) 89 6008761-24
E-Mail: bertsch@hematrix.de
Internet: www.hematrix.de

Hematrix Wound Care GmbH develops, manufactures and markets products in the area of wound care. Our major initial focus is the marketing of hemostatic products to control bleeding. We are experts in the field of hemostasis and wound healing. Our vision is to build up an attractive company together with our investors in this business area.

hepacult GmbH

BIOTECH PRECLINICAL SERVICES

Keywords: Toxicology, Tissue Engineering/Cell Culture, Drug Development, Analytical Chemistry

hepacult develops and markets cell culture technology based on human liver cells and other human organs. The cell culture technology is used to prognose the metabolism of novel drugs and for the in vitro simulation of liver dysfunctions. With their cutting edge cell and tissue products hepacult provides to the scientific community and pharmaceutical industry an outstanding in vitro test system coming close to the human in vivo conditions. Animal experiments can be replaced to a large extent. Results gained during the preclinical stage with hepatocytes show a better prognostic value. Partially even the cost-intensive clinical experiments on humans and related risks to humans can be reduced.



Contact:
Kurt Martin

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 95001711
Fax: +49 (0) 89 9612087
E-Mail: Liming.Ge@hepacult.de
Internet: www.hepacult.de

Hepa Wash GmbH

MEDTECH

Keywords: Multi organ failure, Respiratory Diseases, Hepatology, Devices

Hepa Wash has established the ADVOS system, the first method in the world for extended and individualized support of the human body's main detoxification organs: the liver, the lungs and the kidneys. The company was founded in Garching near Munich in mid-2005 by renowned nephrology and multi-organ support expert Dr. Bernhard Kreymann who had been instrumental in establishing the previous gold standard of organ support using single-pass albumin dialysis. Building on this expertise, Hepa Wash is developing reliable treatment methods to close the therapeutic gap in multi-organ failure.



Contact:
PD Dr. Bernhard Kreymann


Agnes-Pockels-Bogen 1
D-80992 München
Phone: +49 (0) 89 4111842-0
Fax: +49 (0) 89 4111842-09
E-Mail: info@hepawash.com
Internet: www.hepawash.com

HMNC Brain Health GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Medicinal Chemistry, Personalized Medicine, Laboratory, Biomarker Discovery & Development

HMNC is a biotech company specialised in research and development of new drugs, gene tests and biomarkers against depression and anxiety disorders, that was founded in December 2010. The objective of HMNC is to enable a more precise characterization of patients suffering from depression or anxiety disorders by means of gene tests and biomarkers, leading to an improved identification of those patients who will benefit from specific personalized treatments. Such compounds already exist but have not been marketed due to a lack of suitable gene tests and biomarkers. HMNC is in possession of such laboratory markers and is conducting clinical studies to prove that personalized treatment of depression based on laboratory markers is a progressive innovation with high market potential.



Contact:

Wilhelm-Wagenfeld-Str. 20
D-80807 München
Phone: +49 (0) 89 36090200
Fax: +49 (0) 89 360902020
E-Mail: info@hmnc.de
Internet: www.hmnc.de



Contact:
Ditte Heimberg

Am Forst 6
D-85560 Ebersberg
Phone: +49 (0) 8092 2092-0
Fax: +49 (0) 8092 2092-28
E-Mail: info@hti-bio-x.com
Internet: www.hti-bio-x.com

HTI bio-X GmbH

BIOTECH DEVICES & REAGENTS

Keywords: [Devices](#), [Automation](#)

HTI bio-X GmbH is an engineering supplier for products and technical service. We are developing customized solutions of instruments and automations. Our product portfolio covers e.g. consumables and instruments for DNA-synthesis. The biomagnetic workstation X-Tract facilitates magnetic beads applications. The main focus is a system of instruments and modules for the automation of laboratory processes. The X-TubeProcessor is based on the X-Capper for capping and of screw cap tubes. This device is expandable with many modules e.g. for labelling, barcode reading, filling reagents or powder into individual tubes or dispensing of reagents into all tubes. The X-TubeProcessor is usable for a wide range of tubes. The system will be combined with modules regarding to the market requirements.



Contact:
Dr. Margarete Martinez

Herrenwiesstr. 12
D-82031 Grünwald
Phone: +49 (0) 89 649 56 28 4
Fax: +49 (0) 89 649 5628 5
E-Mail: info@humediq.com
Internet: www.humediq.com

HumediQ

BIOTECH BIOINFORMATICS

Keywords: [Informatics](#), [Personalized Medicine](#), [Devices](#)

humediQ was founded in 2010 and has currently 10 employees. We see our mission in the development, production and sales of medical-technical systems – both software and hardware. The focus is on quality assurance systems in radiotherapy. Our vision is to develop high-quality medical devices. To achieve our product goals (transfer of scientific research results into clinical routine integration of innovation into clinical practice), we work closely together with hospitals and research institutions and form a highly qualified and motivated team.



creative bioscience solutions

Contact:
Dr. Wolfgang Mutter

Am Neuland 3
D-82347 Bernried
Phone: +49 (0) 8158 9060-0
Fax: +49 (0) 8158 9060-210
E-Mail: info@hyglos.de
Internet: www.hyglos.de

Hyglos GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: [Clinical Diagnostics](#), [Peptide/Protein](#), [Infectious Diseases](#), [Proteomics](#)

Hyglos' core competency is to exploit the principles of bacteriophage biology and the expert use of the proprietary phage-protein technology for diagnostics, antimicrobial and research applications. Hyglos' products and services are supplied to well known pharmaceutical and biotech companies as well as research institutes. Hyglos product portfolio includes the endotoxin detection assays EndoLISA® & EndoZyme®, EndoTrap®, EndoGrade®, reagents for food diagnostics, Bacteria Capture Kits. Furthermore, Hyglos offers customized services using state-of-the-art technology; Endotoxin Detection Service, Endotoxin removal Service, From Gene to Protein Service. Hyglos GmbH is certified according to ISO 9001:2008 and ISO 13485:2003 + AC:2007.

Hyperthermics Regensburg GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Hyperthermics Regensburg GmbH is a biotechnology company developing applications of hyperthermophilic organisms in renewable energy solutions and in industrial processes. In these applications hyperthermophilic microorganisms are the "software". In the initial phase we are focusing on developing applications together with international industrial partners. In an operational phase we will focus our research activities towards "software development and update".



Contact:
Dr. Stefan Miller

Am BioPark 9
D-93053 Regensburg
Phone: +49 (0) 173 8908929
Internet: www.hyperthermics.com

ibidi GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Microscopy, Chip/Array Technology, Tissue Engineering/Cell Culture, Nanobiotechnology, Devices

ibidi - cells in focus: ibidi develops, produces, and distributes innovative laboratory products, instruments, and reagents for live cell analysis and cell-based assays specifically for high-end microscopy. An extensive line of cell-culture biochips - μ -Slides, μ -Dishes, and μ -Plates- offers solutions for immunofluorescence and basic cell culture, plus complex assays, such as angiogenesis, chemotaxis, wound healing, shear stress, and flow. The instrument line includes stage top incubators, a unique perfusion system that provides continuous flow for the simulation of blood vessels, and a system for monitoring, measuring, and controlling the O₂ concentration in biological samples. The Fuse-It reagents allow for fast and efficient transport of mRNA, siRNA, and other particles into cells.



Contact:
Dr. Susanne Seifert

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 520 46 17-0
Fax: +49 (0) 89 520 46 17-59
E-Mail: info@ibidi.de
Internet: www.ibidi.de

i.DRAS GmbH

CRO

Keywords: Devices, Regulatory Affairs, Toxicology, Pharmacology, Medical Writing, Analytical Chemistry, Drug Development

i.DRAS is a service provider for international drug regulatory affairs. i.DRAS offers support and services for human and veterinary medicinal products from the preclinical/early clinical development stages to the first submission of the MA dossier throughout post marketing activities, covering the whole product life cycle. Services provided cover CTAs and MAAs and all respective documentations to be filed (IB, IMPD, CTD, NtA) for new and established drug substances and the corresponding drug products, including herbal and biological/biotechnological medicinal products. If requested i.DRAS takes over the project management for complex projects with further partners who may be assigned through us or our clients. The same applies to borderline medicinal devices and such incorporating an ancillary drug substance.



Contact:
Prof. Dr. Markus Veit

Fraunhoferstraße 9
D-82152 Martinsried
Phone: +49 (0) 89 200 0203-50
Fax: +49 (0) 89 200 0203-66
E-Mail: info@i-dras.com
Internet: www.i-dras.com



Contact:

Grillparzerstr. 18
D-81675 München
Phone: +49 (0) 89 4140 2477
Fax: +49 (0) 89 4140 4139
E-Mail: info@imevax.com
Internet: www.imevax.com

ImevaX GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Vaccines, Infectious Diseases

ImevaX develops highly specific vaccines against pathogens which cause chronic infectious diseases. Our lead candidate is a vaccine against *Helicobacter pylori*, which colonizes the stomach and is the cause of ulcer disease and gastric cancer in humans. Using an immunological screening approach, our research team was able to identify the factor responsible for the down-regulation of the immune system. Presentation of an inactivated form of this factor to the immune system led to the production of inactivating antibodies, which interfere with the mechanisms hampering the immune system, resulting in a full recovery of the immune response. It was shown that such an immune-modulatory principle is not only used by *Helicobacter pylori* but is often employed by other pathogens.

In 2011, ImevaX was awarded by the prestigious GO-Bio program, which provides essential funding for the preclinical development. As part of the GO-Bio start up program of the German Ministry of Research and Education (BMBF) further bacterial pathogens are analyzed to identify immune modulatory factors that are useful as vaccines against chronic infections. During the present funding period, our most advanced project, the *Helicobacter pylori* vaccine is envisioned to become phase I ready (IND/IMPD stage). Following the establishment of the company, we plan to transfer the vaccine candidate into phase I/II clinical development.



Contact:

Am Klopferspitz 19
D-82152 Planegg-Martinsried

E-mail: info@immunic.de
Internet: www.immunic-therapeutics.de

Immunic AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Immune Therapy

Immunic AG is a young biotech company based in the Munich biotech hub Martinsried that develops pharmaceuticals in the immunology space, in particular for autoimmune diseases or diseases that have an important immunology component in its pathogenesis. Immunic AG focuses on the development of immune modulators to block TH17- and TH1-mediated immune and autoimmune responses. The final aim is to develop these drug candidates to clinical proof of concept.



PRECISELY FOR ME.

Dedicated to giving cancer patients
better answers than „maybe“.



immatics

Contact:
Dr. Nikola Wiegeler

Machtlfinger Straße 11
D-81379 München
Phone: +49 (0) 89 540415-0
Fax: +49 (0) 89 540415-905
E-Mail: info@immatics.com
Internet: www.immatics.com

immatics biotechnologies GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Genomics, Proteomics

Immatics is a clinical-stage biopharmaceutical company active in the discovery and development of T-cell redirecting immunotherapies for the treatment of cancer. Our transformative product candidates are - best in class - Adoptive Cell Therapies and Bispecific TCR molecules, directed against targets which will transform the current landscape of tumor therapy. Two discovery platforms allow a full range of cancer therapies to be developed: (1) Immatics' proprietary and world-leading XPRESIDENT® technology is the most sensitive, unbiased and high-throughput technology capable of identifying and validating targets in virtually any type of cancer. (2) Immatics' powerful TCR discovery technology enables the generation of safer and effective T-cell-redirecting products. Quick Facts

- 150 Team members
- >100 Targets covering 20 major solid and liquid tumors
- About 80% of discovered targets are novel
- 2 proprietary technology platforms
- 8 proprietary development programs, thereof 2 in the clinic in 2017
- Best in class - Adoptive Cell Therapies and Bispecific TCR molecules
- Multiple partnered programs
- Raised more than \$230m in cash in five financings

Our mission is to bring the power of T-cell redirecting immunotherapies to cancer patients.

Immumed GmbH Gesellschaft für angewandte Immunologie

BIOTECH PRECLINICAL SERVICES

Keywords: Laboratory, Inflammation, ELISA/EIA, Clinical Diagnostics

Applied Immunology – Testing Services

We offer testing services for human, mouse or rat samples:

- Analysis of cytokines, chemokines and phosphoproteins
- Cell-characterization
- Cell-separation
- Cytotoxicity

Our team is specialized in measuring multiplex-parameter analysis with Luminex-Technology in various samples like serum, cell cultures, saliva, urine. We perform every application for flow-cytometry analysis, for example cell phenotyping, intracellular cytokine detection or cytotoxicity assays as well as positive or negative selection of cells with magnetic-bead technology.



Contact:
Wolfgang Mayer

Karlstrasse 46
D-80333 München
Phone: +49 (0) 89 5432177-89
Fax: +49 (0) 89 5432177-92
E-Mail: info@immumed.de
Internet: www.immumed.de

immunoGlobe Antikörpertechnik GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Laboratory, Antibody Production Service, Antibody

immunoGlobe® GmbH is a privately owned company, established in 1997.

Core competences are

- Manufacturing of novel research antibodies,
- Full service custom antibody production and purification,
- Marketing of own and licensed antibodies through a global network of OEM partners, wholesalers, and distributors.

Specializations:

Through sophisticated schemes of immunization, affinity purification & depletion on multiple proteins or peptides immunoGlobe® has specialized in the generation of highly specific antibodies against:

- any combination of (de)phosphorylation states of neighboring double-phosphorylation sites
- neo-epitopes (e.g. cleavage sites)
- isoforms, variants, and point mutations
- Epitope mapping services with single amino acid precision complete the service catalog.



Contact:
Dr. Matthias Reinhard

Rudolf-Diesel-Str. 8a
D-97267 Himmelstadt
Phone: +49 (0) 9364 810-610
Fax: +49 (0) 9364 810-613
E-Mail: info@immunoglobe.com
Internet: www.immunoglobe.com

Implen GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Proteomics, Nanobiotechnology, Genomics, Chip/Array Technology, Automation, Devices

Implen is a privately held corporation that is a leading supplier for spectroscopy instruments and consumables for the non-destructive analysis of ultra low volume samples. The company focuses on biological, chemical, and pharmaceutical laboratories in industry and research.



Contact:
Martin Sahiri

Schatzbogen 52
D-81829 München
Phone: +49 (0) 89 7263718-0
Fax: +49 (0) 89 7263718-54
E-Mail: info@implen.de
Internet: www.implen.de



Contact:
Patrick McManus

Robert-Koch-Allee 29
D-82131 Gauting
Phone: +49 (0) 89 8935 69-0
Fax: +49 (0) 89 8935 69-22
E-Mail: request@inamed-cro.com
Internet: www.inamed-cro.com

Inamed GmbH

CRO

Keywords: Drug Delivery, Medical Writing, Respiratory Diseases

Inamed GmbH - „THE Respiratory CRO“ INAMED was founded in 1998 and is an experienced, independent, privately owned and managed CRO with its headquarters located at the periphery of Munich, and with its roots in basic research and clinical medicine. We are an international contract research organization with true respiratory expertise. Complementing our solid experience in conducting clinical trials, INAMED’s team of inhalation and clinical experts provides our sponsors with a unique spectrum of services. Besides our clinical trial operations at all phases of development and our fully staffed, in-house Phase I-IIa unit with twenty beds, INAMED performs in-vitro studies in our own labs and is the only CRO in continental Europe able and approved to perform radio-labeling studies. Our studies deliver the highest quality data and can enhance your clinical trials and development projects for drugs and inhalation devices. INAMED offers an opportunity for sponsors to get their products to market more successfully.

INC Research GmbH - a Syneos Health Company

CRO

Keywords: CRO/CMO---, Clinical Trial Management and Monitoring, Medical Writing

The coming together of INC Research and inVentiv Health as one global company, called Syneos Health™, has created the industry’s only true end-to-end solution. This one entity combines world-renowned clinical research and commercialization capabilities with today’s most advanced science, business and data technologies to make real advances possible. We help you improve performance, reduce risk and expedite delivery of healthcare innovation to patients worldwide.



Contact:

Stefan-George-Ring 6
D-81929 München
Phone: +49 (0) 89 993913-0
Fax: +49 (0) 89 993913-160
E-Mail: reza.khosravani@syneoshealth.com
Internet: www.syneoshealth.com

Innovation and Entrepreneur Center Würzburg



- ⊙ **renting of lab and office space**
- ⊙ **coaching of start-ups**
- ⊙ **consulting on financing**
- ⊙ **support of the management**
- ⊙ **networking / business contacts**

INFORS HT

Contact:
Dr. Burkhard J. Feigel

Dachauer Str. 6
D-85254 Einsbach
Phone: +49 (0) 8135 8333
Fax: +49 (0) 8135 8320
E-Mail: infors.de@infors-ht.com
Internet: www.infors-ht.com

Infors GmbH

BIOTECH DEVICES & REAGENTS

INFORS HT is your specialist for bioreactors, incubation shakers and bioprocess control software. You benefit from sophisticated systems, in which your cell lines or microorganisms develop their full potential in a reproducible way, thus contributing to your success.

For your applications, we offer the right solutions:

- Fermentation of microorganisms (bacteria, fungi and yeasts)
- Cell culture (mammalian cells, insect cells, plant cells and algae)
- Biofuel (biodiesel and bioethanol)
- Parallel bioprocesses
- Custom-made bioreactors and incubation shakers
- Bioprocess control software
- Qualification of bioreactors and incubation shakers

Closeness to the customer, high quality, innovation and flexibility are our greatest strengths.

Institut Virion\Serion GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, ELISA/EIA, Autoimmune Diseases, Infectious Diseases, Respiratory Diseases, Automation



virion\serion

Contact:
Andrea Aelker

Friedrich-Bergius-Ring 19
D-97076 Würzburg
Phone: +49 (0) 931 3045-0
Fax: +49 (0) 931 3045-100
E-Mail: dialog@virion-serion.de
Internet: www.virion-serion.de

Institut Virion\Serion GmbH is a German in-vitro diagnostic company with more than 30 years of experience in the international market. The extensive high-quality product portfolio for the diagnosis of infectious diseases contains SERION ELISA classic tests recommended for quantified antibody detection in human serum, plasma, and, if necessary, in cerebrospinal fluid, against various viral, bacterial, fungal and parasitic infections. SERION ELISA antigen tests enable a direct antigen detection of pathogens. Our Complement Fixation Tests are featuring more than 50 different antigens. The latest developments of our particle-based SERION Multianalyt™ products allow simultaneous antibody detection against multiple antigens using flow cytometry. Parallel to immunoassays we have introduced the Immunomat™ for automated processing and analysis of SERION ELISA classic and SERION ELISA antigen tests.

InGeneron GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Cell Therapy

InGeneron is elevating the field of regenerative medicine by translating robust science into proven patient benefit. Our purpose is to set new therapeutic standards by enabling physicians to use the patients own regenerative cells at point of care. With the initial focus on key orthopedic and wound healing indications, we will make regenerative cell therapies broadly accessible across multiple medical fields.



Contact:
Sonnenstraße 24-26
D-80331 München
E-Mail: contact@ingeneron.com
Internet: www.ingeneron.com

iOmx Therapeutics GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, RNAi & Antisense, Immune Therapy

iOmx Therapeutics is a novel immuno-oncology target discovery and drug development company. Its founders have developed a high-throughput siRNA-based screening approach that allows a comprehensive identification of ligands on human cancer cells that inhibit CTL-mediated tumor cell killing. To date, this screening technology has been applied to multiple tumor entities. More than twenty novel targets have been identified which form the basis of the company's pre-clinical product portfolio. For more details, please refer to: <http://www.iomx.de/> or Follow us on: <https://www.linkedin.com/company/iomx-therapeutics>



Contact:
Angelika Geier

Fraunhoferstraße 13
D-82152 Planegg-Martinsried
Internet: www.iomx.de

Intana Bioscience GmbH

BIOTECH PRECLINICAL SERVICES

Keywords: Drug Development, R&D Service

Intana Bioscience GmbH is a privately owned service provider company. We contribute to our clients R&D programs by developing predictive assays and screens, by comprehensively understanding the behavior of their candidates, and by supporting drug discovery and development efforts from target validation to clinical testing. Intana employs single molecule sensitive fluorescence correlation spectroscopy (FCCS) to measure affinities and rate constants of drug target interactions. The method does not require protein purification and assays are carried out under physiologic conditions. In particular for challenging targets FCCS has shown to be the method of choice. Our services cover target validation, assay development, screening, support of PK/PD studies and target occupancy measurements.



Contact:
Dr. Frank Becker

Lochhamer Str. 29 a
D-82152 Martinsried
Phone: +49 (0) 89 895 572-80
Fax: +49 (0) 89 895 572-81
E-Mail: info@intana.de
Internet: www.intana-bioscience.de

Intercept Pharma Deutschland GmbH

PHARMA & CHEMICAL INDUSTRY

Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases. Founded in 2002 in New York, New York, Intercept now has operations in the United States, Europe, Canada, and Australia. Founded in 2015, Intercept Pharma Deutschland GmbH based in Munich offers medical sales and marketing support in Germany. The team has set itself the task of continuously providing high quality services to the 'liver community'.



Contact:

Rosenheimer Str. 52
DE-81669 München
Phone: +49 (0)89 4111 124 11
E-Mail: info-DE@interceptpharma.com
Internet:
www.interceptpharma.com/about/germany/



Contact:
Dr. Thomas Bruckdorfer

Waldershofer Str. 49-51
D-95615 Marktredwitz
Phone: +49 (0) 9231 9619-73
Fax: +49 (0) 9231 9619-99
E-Mail: info@iris-biotech.de
Internet: www.iris-biotech.de

Iris Biotech GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Fine Chemicals/Reagents, Peptide/Protein, Drug Development, Drug Delivery, Medicinal Chemistry, Combinatorial Chemistry, Natural Compounds

1. Starting materials for peptide synthesis, peptidomimetic and medicinal chemistry: protected amino acids, coupling reagents, linkers and resins, natural and unusual amino acids and natural compounds with physiological properties.
2. Technologies for Drug Delivery: more than 900 different carriers used in polymer therapeutics products (PEGylating reagents, PASylation, PGA Poly(glutamic acid) and multi-functional dendrimers).
3. Reagents for Life Sciences and Diagnostics: substrates, inhibitors, cross-linker, immunologic tools, carbohydrates, dyes and fluorescent labels.
4. We carry out custom synthesis in all areas above. Our strengths are compounds with one or several chiral centers.

IRUBIS

Contact:

Friedrichshafener Straße 1
D-82205 Gilching
E-Mail: info@irubis.com
Internet: www.irubis.com

IRUBIS GmbH

BIOTECH DEVICES & REAGENTS

We are innovating ATR infrared spectroscopy by making it easier, cheaper and better. Boost the performance of your ATR device with the IRUBIS crystals and accessories. The New State of the Art We developed a procedure to manufacture cost-effective and high-quality ATR crystals. Our products are made of silicon, can be functionalized and achieve spectrums comparable to results with diamonds.



Contact:
Dr. Andrea Kottke

Leopoldstraße 254-256
D-80807 München
Phone: +49 (0) 89 890 831-0
Fax: +49 (0) 89 890 831-491
E-Mail: info@isarna-therapeutics.com
Internet: www.isarna-therapeutics.com

ISARNA Therapeutics GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: RNAi & Antisense, Biomarker Discovery & Development, Drug Development

Isarna Therapeutics has an unmatched commitment to developing selective TGF- β inhibitors to fight cancer and to effectively treat ophthalmic and fibrotic diseases. We are advancing a unique pipeline of novel oligonucleotides and combination modalities to transcend clinical response and improve patient outcomes.

iThera Medical GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Nanobiotechnology, Drug Development, Devices, Cardiovascular Diseases, Inflammation, Oncology

iThera Medical develops and markets a novel in-vivo biomedical imaging technology, "MSOT" = multi-spectral opto-acoustic tomography. MSOT utilizes the photo-acoustic effect to visualize and quantify anatomical, functional and molecular information of living tissue. Today, MSOT allows the early and reliable validation of new substance efficacy in drug discovery (e.g., for oncology, neurology and cardiovascular problems). For the future, MSOT also promises to become a valuable tool for clinical diagnostics.

iTheraMedical

Listening to Molecules

Contact:
Christian Wiest

Zielstattstr. 13
D-81379 München
Phone: +49 (0) 89 700 7449-0
Fax: +49 (0) 89 700 7449-90
E-Mail: info@ithera-medical.com
Internet: www.ithera-medical.com

ITM Isotope Technologies Munich AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Delivery, Drug Development, Industrial Biotechnology, Personalized Medicine, Oncology

ITM Isotopen Technologien München AG is a privately held group of companies dedicated to the development, production and global supply of innovative diagnostic and therapeutic radionuclides and radiopharmaceuticals. Since its foundation in 2004, the ITM Group has established the GMP manufacturing and a robust global supply network. ITM is developing a proprietary portfolio and growing pipeline of targeted treatments in various stages of clinical development addressing a range of cancers such as neuroendocrine cancers or bone metastases. ITM's main objectives are to significantly improve outcomes and quality of life for cancer patients while at the same time reducing side-effects and improving health economics through a new generation of Targeted Radionuclide Therapies in Precision Oncology

The logo for ITM (Isotope Technologies Munich AG) features the lowercase letters "itm" in a bold, blue, sans-serif font. A small blue dot is positioned above the letter "i".

Contact:
Nicola Scharrer

Lichtenbergstr. 1
D-85748 Garching
Phone: +49 (0) 89 329 8986 60
Fax: +49 (0) 89 329 8986 66
E-Mail: info@itm.ag
Internet: www.itm.ag

Kantar Health GmbH Clinical Research

CRO

Keywords: Regulatory Affairs, Data Management and Biostatistics, Clinical Trial Management and Monitoring, Medical Writing, Oncology, Pharmacovigilance, Logistics

Kantar Health GmbH Clinical Research conducts phase I-IV clinical trials, retrospective and prospective non-interventional studies, patient reported outcomes and pharmaco-economic studies. Our operations span local agencies in over 45 countries worldwide. Kantar Health combines more than 30 years of CRO expertise in drug research including development of innovative web-based applications (InTrial® and InDrums®). Our services include: protocol and CRF design, eCRF solutions, feasibility and site selection, investigators training, handling of legal and ethical requirements, monitoring and site management, project management, implementation of risk management programs, data management, medical coding, pharmacovigilance, quality assurance, statistical planning and analysis, medical writing.

KANTAR HEALTH

Contact:
Mercedes Apecechea

Landsberger Str. 284
D-80687 München
Phone: +49 (0) 89 5600 1005
Fax: +49 (0) 89 5600 1400
E-Mail: info@kantarhealth.com
Internet: www.kantarhealth.com



Contact:

Dr. Klaus Hellmann

Geyerspergerstr. 27
D-80689 München
Phone: +49 (0) 89 580 082-0
Fax: +49 (0) 89 580 082-7777
E-Mail: info@klifovet.com
Internet: www.klifovet.com

KLIFOVET AG

CRO

Keywords: Pharmacovigilance, Regulatory Affairs, Drug Development, Data Management and Biostatistics, Clinical Trial Management and Monitoring

KLIFOVET AG provides high quality services for the Animal Health and Animal Nutrition Industry acting as a CRO, CMO and regulatory consultancy for the registration and marketing of all kind of veterinary medicinal products and feed additives. We offer: Project management and Regulatory consultancy from the idea to the marketed veterinary pharmaceutical or immunological product or feed additive/ feed. Regulatory strategic consultancy, dossier writing, negotiations with the authorities. CRO: Planning and conduct of veterinary clinical safety and efficacy studies in all target animal species. Full life cycle management incl. pharmacovigilance and QPPV services. CMO support for EU QP release. We handle EU, US or other projects with our partners and provide over 20 years of experience.

kmbs

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Genomics, PCR

kmbs is your service partner for organismic studies e. g. in Conservation Biology, Zoology, Phylogeny, Taxonomy, and Molecular Biology to clear up specimens' identities by means of molecular/genetic analyses (Sample preparation, PCR, DNA sequencing, Gene Fragment analysis) for purposes like resolving species relationships, detecting sibling species, delimiting species boundaries, investigating population structure and integrity, a.s.o. In addition, we are experienced in making microscopic preparations, carrying out outdoor services like mapping species inventories or searching for special organisms within a given habitat including the collection of organisms on demand, and acting as project manager and consultants.



Contact:

Dr. Michael Miller

Ferdinand-Zwack-Str. 39
D-85354 Freising
Phone: +49 (0) 8161 205957
E-Mail: info@kmbioservices.de
Internet: www.kmbioservices.de

Kalbitzer Innovations UG

BIOTECH DNA/PROTEIN ANALYTICS

Kalbitzer Innovations is a spin-off from the Institute of Biophysics and Physical Biochemistry University of Regensburg that provides novel experimental as well computational methods. It is focused on the application of high pressures on proteins in drug design, drug screening and protein refolding/renaturation. Kalbitzer Innovations develops software for specific application in NMR-based analytics. AUREMOL is a software package for automated NMR spectrum evaluation and protein structure determination, compatible with AURELIA and developed in cooperation with the University of Regensburg and Bruker BioSpin GmbH. High Pressure NMR Spectroscopy The application of high pressure (up to 200 MPa) provides very important additional information about the conformational balance of proteins, especially in the characterization of folding, dynamics and structure of folding intermediates.



Contact:

Elisabeth-Selbert-Weg 4
93055 Regensburg
Phone: +49 (0) 941 30798265
E-Mail: kalbitzer-innovations@t-online.de
Internet: www.kalbitzer-innovations.de

Laboklin GmbH & Co KG – Unternehmensbereich Labogen

BIOTECH THERAPEUTICS & DIAGNOSTICS

Our laboratory provides a complete testing service for veterinary surgeons to meet the diagnostic needs of your practice. You can find all important information and our laboratory profiles and screens (microbiology, haematology, allergy, pathology and genetic testing). Furthermore you can download submission forms or order sample collection material. If you are registered you are able to locate your samples, the stage of investigation and much more.

LABOKLIN
LABOR FÜR KLINISCHE DIAGNOSTIK GMBH & CO. KG

Contact:
Dr. Elisabeth Müller

Steubenstr. 4
D-97688 Bad Kissingen
Phone: +49 (0) 971 7202-0
Fax: +49 (0) 971 68546
E-Mail: mueller@laboklin.de
Internet: www.laboklin.com

Labor Friedle GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, Medicinal Chemistry, Allergy

Labor Friedle GmbH is an accredited analytical laboratory for analytics of chemical residues like heavy metals, pesticides, mycotoxins and radioactivity testing. Our scope includes furthermore food ingredients, nutrient content analytic, examination of human biological matrices, microbiological and molecular biological examinations and examination of indoor air pollutions.



Contact:
Albrecht Friedle

Von-Heyden-Str. 11
D-93105 Tegernheim
Phone: +49 (0) 9403 967 98-0
Fax: +49 (0) 9403 967 98-20
E-Mail: info@labor-friedle.de
Internet: www.labor-friedle.de

Labor L+S AG

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Laboratory, Clinical Diagnostics, Allergy, Medicinal Chemistry, Molecular Diagnostics, Analytical Chemistry

The Labor L+S AG is one of the leading European CROs for analytics and consulting for pharmaceuticals and medical devices. More than 1000 customers trust in the company's experience. The range of services covers microbiology, molecular-biology, biochemistry as well as physics and chemistry on raw materials and on finished products. In addition, services in industrial hygiene and clinical-microbiological diagnostic are offered. In a state of the art plant with 10,000 sqm of laboratory space, 450 experts handle more than 250,000 samples/a. Establishment of new methods is a key strategic factor of the company's success, triggered by customers requests and changes in regulatory requirements from FDA or European agencies. Both agencies successfully inspect on a regular basis.

LS|AG

Contact:
Denise Baumbach

Mangelsfeld 4, 5, 6
D-97708 Bad Bocklet
Phone: +49 (0) 9708 9100-0
Fax: +49 (0) 9708 9100-36
E-Mail: service@labor-ls.de
Internet: www.labor-ls.de

Contact:
Dr. Stefanie Zorbas-Seifried

Bunsenstr. 7a
D-82152 Martinsried
Phone: +49 (0) 89 899 480 780
E-Mail: szorbas-seifried@labpmm.de
Internet:
<https://invivoscribe.com/clinical-services>

LabPMM GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, Molecular Diagnostics

LabPMM GmbH is an ISO 15189 accredited reference laboratory focused on Personalized Molecular Medicine and Personalized Molecular Diagnostics for customers throughout Europe and surrounding regions. We offer an ever-expanding menu of internationally harmonized tests to support patient diagnosis and monitoring, stratification and enrollment of patients in clinical trials and development of companion diagnostics. Our test menu includes FLT3 and NPM1 mutational assays, B- & T-cell clonality, MRD screening and NGS gene panels, all with design-controlled reagents, kits and bioinformatics software, developed and manufactured under ISO 13485 in our FDA-registered facility. Our successful partnerships have led to the approval of the first ever AML companion diagnostic.

leon-nanodrugs

Contact:
Clarita Krüger-Crusius

Kopernikusstr. 9
D-81679 München
Phone: +49 (0) 89 4142 4889-0
Fax: +49 (0) 89 4142 4889-88
E-Mail: info@leon-nanodrugs.com
Internet: www.leon-nanodrugs.com

leon-nanodrugs GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Drug Development, Drug Delivery, Peptide/Protein, Small Molecules

Leon-nanodrugs GmbH (Munich) is a speciality pharmaceutical drug development company for oral and parenteral products. Based on its proprietary MJR-nanotechnology platform leon is focussed on the reformulation of poor / non- water soluble APIs (BCS II / IV) which reflect more than 60% of all medical drugs used worldwide. Leon's MJR-technology - a continuous solvent / antisolvent precipitation - can be applied to a wide spectrum of compounds such as small molecules and peptides; we can create API-specific crystalline and polymeric nanoparticles from 4 nm to 30µm without any limitation in capacity (>60 KG API/h). Leon can provide its industry partners a complete development range: from concept to CTM and commercial production.

Contact:
Michael Scholl

Am Klopferspitz 19
D-82152 Martinsried/Munich
Phone: +49 (0) 89 7801665-0
Fax: +49 (0) 89 7801665-11
E-Mail: info@leukocare.com
Internet: www.leukocare.com

LEUKOCARE AG

BIOTECH DEVICES & REAGENTS

- LEUKOCARE provides proprietary formulation technologies and related development services for stabilization and protection of biologics
- LEUKOCARE technologies are employed in collaborations with partners in the field of vaccines, therapeutic proteins, and biologic device combination products.
- LEUKOCARE provides development services based on fee for service during implementation of its technologies.
- LEUKOCARE's technologies provide manifold benefits:
 - Improved shelf-life / stability / quality
 - Terminal sterilization of biologics
 - Significant production cost savings

LINDIS Biotech GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Antibody

LINDIS Biotech was founded to develop ektomun[®], an innovative immunotherapeutic for the treatment of small cell lung cancer, melanoma and other neuroectodermal cancers that currently lack sufficient treatment options. The company is managed by Horst Lindhofer, inventor of the underlying trifunctional antibody technology and CEO of TRION Pharma.



Contact:

Am Klopferspitz 19 a
D-82152 Martinsried
Phone: +49 (0) 89 700 766 24
E-Mail: horst.lindhofer@lindisbiotech.com
Internet: www.lindisbiotech.com

LISANDO GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Lysando is a manufacturer of medical devices. Lysando AG and the R&D centre Lisando GmbH are owned by the TGI Group, which is specialised in environmentally supportive technologies and manufacturing.

Achievements:

In 2010 our team received the Food Safety Innovation Award for a novel method to detect bacterial contamination in food. In October 2012 LYSANDO AG has been rated with the best rating possible by Dun&Bradstreet.

Cooperations:

Lysando cooperates with various Universities and Institutes in Europe, Thailand, Japan and United States of America.



Contact:

Markus Matuschka von Greiffenclau

Am BioPark 13
D-93053 Regensburg
Phone: +49 (0) 941 28096-208
E-Mail: info@lisando.com
Internet: www.lisando.com

LivImplant GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Inflammation, Bone/Joint Diseases, Cell Therapy, Tissue Engineering/Cell Culture

LivImplant GmbH develops and sells innovative cell based therapies for lesions and diseases of tendons, joints, cartilage and bones, focusing on stimulating the self-healing powers of the body by applying stem cells and growth factors. As a spin off from the Experimental Surgery and regenerative Medicine department of the Ludwig-Maximilians-University of Munich (www.experimed.de) and a close collaboration with the Veterinary Clinic of the University of Giessen LivImplant benefits from the latest scientific proceedings. First applications are available for curing lameness with horses and dogs.



Contact:

Prof. Dr. Matthias Schieker

Truhenseeweg 8
D-82319 Starnberg
Phone: +49 (0) 8151 5590291
Fax: +49 (0) 8151 917922
E-Mail: info@livimplant.de
Internet: www.livimplant.de

lifespın GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS



Contact:

Am BioPark 13
D-93053 Regensburg
Phone: +49 (0) 941942 898 0
Fax: +49 (0) 941/942 898 29
E-Mail: info@lifespın.de
Internet: www.lifespın.de

Precision medicine tailored to the individual patient by high Level data generation and innovative software solutions. P4 medicine is predictive, preventive, personalized and participatory. Its major objectives are to quantify wellness and demystify disease. The future is NMR-based diagnostic: Fast, reliable and providing high level data for individuals to quantify health and optimize treatment.

Loewe® Biochemica GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Agrobiotechnology, ELISA/EIA

LOEWE®

Contact:

Dr. Caroline Freye-Minks

Mühlweg 2 a
D-82054 Sauerlach
Phone: +49 (0) 8104 616-20
Fax: +49 (0) 8104 616-48
E-Mail: service@loewe-info.com
Internet: www.loewe-info.com

LOEWE® is committed to the development and production of high quality reagents for the detection of plant diseases caused by bacteria, fungi, nematodes, and viruses. Furthermore we offer contract testing services for all kinds of crops and ornamentals (ELISA techniques, Immuno Fluorescence Antibody Assays, Blotting, and PCR).

Lophius Biosciences GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, Immune Therapy, Infectious Diseases

lophius

biosciences

Contact:

PD Dr. Ludwig Deml

Am BioPark 13
D-93053 Regensburg
Phone: +49 (0) 941 6309 197-0
Fax: +49 (0) 941 6309 197-9
E-Mail: info@lophius.com
Internet: www.lophius.com

Lophius Biosciences is a privately-held German biotechnology company focusing on the development and marketing of innovative immune diagnostic systems to improve therapy control and personalized treatment of patients in the area of transplantation, infectious and autoimmune diseases. The company's developments are based on its expertise in cell-mediated immunity as well as on its proprietary T-activation® and Reverse T Cell Technology platforms. Whereas the T-activation® technology platform allows an efficient stimulation of a broad spectrum of clinically relevant immune effector cells to accurately measure the cell-mediated immunity, the Reverse T Cell Technology platform can distinguish between active and memory T cells to develop innovative diagnostics. With its T-Track® CMV leading product, Lophius offers a highly sensitive, reliable and standardized CE-marked in vitro diagnostic solution to measure the functionality of CMV-specific cell-mediated immunity. T-Track® CMV assists clinicians in the risk stratification of CMV disease in immunocompromised patients, toward an improved and individualized patient management.

LRE Medical GmbH

MEDTECH

Keywords: R&D Service, Molecular Diagnostics, Other Diagnostics, Automation, Devices, In-Vitro-Diagnostics

LRE Medical GmbH is a leading developer and manufacturer of medical, in vitro diagnostic (IVD) and life sciences instrumentation for OEM customers. LRE focuses on products for Handheld, Point-of-Use and Laboratory markets based on a variety of technologies including solutions for molecular diagnostics. For more than 40 years we look for ways to optimize product design and manufacturing processes that improve product quality, reliability and performance and reduce overall program and product costs. LRE provides full turnkey projects 'One Stop Shopping' solutions (Engineering, Manufacturing, After Sales Service and Lifetime Product Support) for the Development and Manufacturing of innovative Devices in compliance with ISO 13485, ISO 14001 and FDA CFR Part 820 for Class I-III Medical Devices.



LRE Medical

Contact:
Claudia Strehle

Georg-Brauchle-Ring 89
D-80992 München
Phone: +49 (0) 89 354803-47
Fax: +49 (0) 89 354803-67
E-Mail: info@lre.de
Internet: www.lre.de/

Luye Pharma AG

PHARMA & CHEMICAL INDUSTRY

Keywords: Pharmacology, Drug Delivery, Medicinal Chemistry

Luye Pharma Group Ltd. announced the completion of its acquisition of the transdermal drug delivery systems (TDS) business from Swiss company, Acino in November 2016. The acquired business is a global leader in niche transdermal markets and will greatly enhance Luye's developmental efforts in R&D, manufacturing, international registration, and market promotion of new formulation products to international standards, thereby helping to pave the way for Luye's expansion into the global markets. The acquired business is one of the largest independent TDS manufacturers in Europe, with a product portfolio primarily focused on more sophisticated and higher margin specialty patch categories such as CNS, pain and hormone spaces under several successfully commercialised and hard-to-make formulations such as Rivastigmine, Buprenorphine, Fentanyl and fertility control patch. Luye Pharma is a leading Chinese pharmaceutical enterprise driven by innovation and primarily focuses on therapeutic areas such as Central Nervous System, Oncology, Cardiovascular, and Metabolic diseases. Since inception, Luye Pharma has adopted innovation and globalization as its core growth drivers. As one of the pioneering Chinese pharmaceutical enterprises to have conducted clinical trials in international markets, Luye Pharma currently has 5 innovative products at various stages of clinical research with significant breakthroughs in the U.S.



Contact:

Am Windfeld 35
D-83714 Miesbach
Phone: +49 (0) 8025 2867-0
Fax: +49 (0) 8025 2867-28
E-Mail: info@luyepharma.eu
Internet: www.luyepharma.eu



Contact:
Dr. Stephan Fischer

Forstenrieder Str. 8-14
D-82061 Neuried
Phone: +49 (0) 89 990 178-0
Fax: +49 (0) 89 990 178-199
E-Mail: info@mabdiscovery.com
Internet: www.mabdiscovery.com

MAB Discovery GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Antibody

MAB Discovery, based in Munich, Germany, is a provider of high quality IND ready monoclonal antibodies obtained from an unique immunization approach exploiting the natural immune system in combination with a sophisticated B-cell cloning and cultivation technique. Early functional testing allows the identification of highly potent monoclonals which eliminates the need for further time consuming affinity maturation. The diversity of the immune responses not only guarantees unprecedented epitope coverage but also ensure success against targets heretofore considered intractable. We offer simple and straightforward business terms by eschewing the traditional IP license approach.

MagForce AG

MEDTECH

Keywords: Oncology, Nanobiotechnology

MagForce AG, listed in the entry standard (MF6) of the Frankfurt Stock Exchange, together with its subsidiaries MT MedTech Engineering GmbH and MagForce USA, Inc., is a leading medical device company in the field of nanomedicine in oncology. The headquarters of the MagForce AG are in Berlin. The departments of Clinical Development, Commercial, Intellectual Property and Legal are located at the Munich site. The group's proprietary NanoTherm® therapy enables the focal treatment of solid tumors through the intratumoral generation of heat via activation of instilled superparamagnetic nanoparticles by an alternating magnetic field applicator. The nanoparticles are instilled into a tumor via a minimal invasive procedure and remain at the site of injection due to their aminosilane coating. Based on the amount and location of the instilled nanoparticle depots and the applied magnetic field strength the company's therapy planning software simulates the temperature distribution within the treatment area prior patient treatment. NanoTherm®, NanoPlan®, and NanoActivator® are components of the therapy and have received EU-wide certification (CE mark) as medical devices for the treatment of brain tumors.



Contact:

Bunsenstrasse 7
D-82152 Martinsried
Phone: +49 (0) 89 954 7795 60
E-Mail: info@magforce.com
Internet: www.magforce.de

Medical Device Services GmbH

PHARMA & CHEMICAL INDUSTRY

Biological Safety of Medical Devices. Our test laboratories at Medical Device Services have been synonymous with success for medical device manufacturers for 20 years.



Contact:
Dr. Matthias Borgmann

Lilienthalstrasse 4
D-82205 Gilching
Phone: +49 (0) 8105 7783 30
Fax: +49 (0) 8105 26152
E-Mail: pr@mdservices.de
Internet: www.mdservices.de

medicomp GmbH

CRO

medicomp GmbH was founded in 1985 and has developed ever since into a full service CRO. We offer a wide range of services for phase I-IV trials, medical device and non-interventional studies (NIS): medical and biometrical planning, protocol and CRF design, project management, data management, monitoring, statistical analysis and medical writing. medicomp is a member of the Bundesverband Medizinischer Auftragsinstitute (BVMA), which implies regular independent system audits. Furthermore, medicomp is a founding member of Pharmaceutical Service Network (PSN), a network of independent CROs, which allows us to offer services for international studies conducted in collaboration with our partners.



Contact:
Dr. Michael Gierend

Heimeranstr. 35
D-80339 München
Phone: +49 (0) 89 895286-0
Fax: +49 (0) 89 895286-66
E-Mail: info@medicomp-cro.de
Internet: www.medicomp-cro.de

Medigene AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Oncology, Personalized Medicine, Cell Therapy, Vaccines, Hematology, Immune Therapy, Gene Therapy

Medigene AG is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms of cancer. Medigene concentrates on the development of personalized T cell-based therapies, with associated projects currently in pre-clinical and clinical development. Medigene's TCR technology aims at arming the patient's own T cells with tumor-specific T-cell receptors. The receptor-modified T cells are then able to detect and efficiently kill tumor cells. This immunotherapy approach attempts to overcome the patient's tolerance towards cancer cells and tumor-induced immunosuppression by activating and modifying the patient's T cells outside the body (ex vivo).

medigene

Contact:
Julia Hofmann

Lochhamer Str. 11
D-82152 Martinsried
Phone: +49 (0) 89 2000 33-0
Fax: +49 (0) 89 2000 33-2920
E-Mail: medigene@medigene.com
Internet: www.medigene.com

Medpace Germany GmbH

CRO

Keywords: Cardiovascular Diseases, Metabolic Diseases, Oncology

Medpace, established in 1992, is a full-service Contract Research Organization (CRO), who partners with leading pharmaceutical and biotech organizations to bring promising new drugs to market. Medpace combines comprehensive regulatory consulting with efficient clinical trial management to provide sponsors with exceptional support in drug development. Proven leaders in medical and scientific research monitor every project. Medpace physicians have first-hand experience working with regulatory agencies to successfully guide projects through the complexities of the regulatory process. The medical expertise and regulatory guidance provided by Medpace leads to reduced costs and increased efficiencies for our valued customers.

MEDPACE

Contact:
Dr. Alfred Fraunhofer

Neuhauser Str. 47 / IV
D-80331 München
Phone: +49 (0) 89 895 5718-0
Fax: +49 (0) 89 895 5718-100
E-Mail: info.de@medpace.com
Internet: www.medpace.de

MedPharmTec GmbH



Contact:
Veronika Peschkes

Olschewskibogen 7
D-80935 München
Phone: +49 (0) 89 354 998-0
Fax: +49 (0) 89 354 998-199
E-Mail: office@medpharmtec.de
Internet: www.MedPharmTec.de

CRO

Keywords: Medical Writing, Pharmacovigilance, Clinical Trial Management and Monitoring, Data Management and Biostatistics, Regulatory Affairs

MedPharmTec GmbH is a Pharmaceutical Contract Service Organisation providing expert assistance in drug development, clinical research (phase II through IV), medical information, regulatory affairs and drug safety to pharmaceutical and biotechnology companies. Our clinical research services range from protocol planning, CRF design, trial management, monitoring and auditing up to data management, biometrics and report writing. Further areas of MedPharmTec activities include medical information, i.e. medical and scientific translations, Labeling Compliance Service, writing/designing of brochures, publications and scientific literature searches as well as consulting and services in terms of regulatory affairs and drug safety.

metabion



Contact:
Dr. Regina Bichlmaier

Semmelweisstr. 3
D-82152 Martinsried
Phone: +49 (0) 89 899363-0
Fax: +49 (0) 89 899363-11
E-Mail: info@mymetabion.com
Internet: www.metabion.com

BIOTECH DEVICES & REAGENTS

Keywords: PCR, Antisense/Nucleotides, Antibody Production Service, Other Diagnostics, NGS, Genomics, Proteomics

metabion is one of the globally leading suppliers of custom nucleic acids renowned for its focus on reliable supplies of consistently high quality products and services. Founded in 1997 in Munich/Martinsried, metabion keeps on expanding its product portfolio from the production of a wide range of synthetic DNA and RNA oligonucleotides according to customers' needs to the supply of standard life science products. Successfully translating highest quality standards into daily practice is the core of metabion's business philosophy and key to its popularity at the same time. Careful evaluation and implementation of new and promising technologies and products are complementing metabion's progressive and innovative approach within a healthy and sound business setup.

MetaHeps GmbH



Contact:

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 151 1799 7111
E-Mail: info@metaheps.com
Internet: www.metaheps.com

BIOTECH PRECLINICAL SERVICES

Keywords: Toxicology, Drug Development

MetaHeps® Clearing Drugs from Liver Injury Issues (DILI) = Enabling Better Therapies for Patients MetaHeps® is an innovative service provider using a technology that allows to identify or exclude drug-induced liver injury (DILI) in an individual patient using a blood sample. MetaHeps tackles DILI in clinical trials or postmarketing as a major cause of drug attrition: As a diagnosis of exclusion, DILI suspicion may be incorrect in up to 50% of cases. Now, the MetaHeps technology allows to clear a drug from DILI suspicion, or - in case DILI is confirmed - biomarker development using the cell- and databank. Customers are pharmaceutical companies and global acting CROs, using Metaheps' services in clinical phases of drug development as well as Postmarketing/Pharmacovigilance.

Metronomia Clinical Research GmbH

CRO

Keywords: Data Management and Biostatistics, Medical Writing, Clinical Trial Management and Monitoring, R&D Service

Metronomia is a specialized CRO for statistical consulting, biostatistical services and clinical data management, based in Munich (Germany). Our customers are pharmaceutical-, biotech-, and medical device companies, universities and clinical CROs. In more than 25 years, Metronomia has been successfully involved in more than 500 clinical projects. We have a proven track record in all major therapeutic areas and all clinical phases / NIS. Our customers particularly esteem the high-quality and reliability of our data, our commitment to flexibility and personal service through stable teams, and the competitive cost-benefit ratio. Our services: - Statistical consulting - Biostatistical services and statistical programming - Clinical data management - Medical Writing - IWRS.

METRONOMIA 

Contact:
Dieter Meyer

Paul-Gerhardt-Allee 42
D-81245 München
Phone: +49 (0) 89 829265-100
Fax: +49 (0) 89 829265-099
E-Mail: info@metronomia.net
Internet: www.metronomia.net

Microcoat Biotechnologie GmbH

BIOTECH DEVICES & REAGENTS

Keywords: In-Vitro-Diagnostics, Bioanalytics, PCR, Laboratory, Pharmacokinetics, ELISA/EIA

Custom Development: Development of diagnostic assays, test components and new test formats to market-ready kits. Immunological assays, molecular assays, sample and Matrix preparation protocols Contract manufacturing Diagnostik kit and component manufacturing Service. Standard kit formats comprise ELISA, ELISpot, bead-based formats, lateral-flow kits. Production, modification and conjugation of antibodies and recombinant proteins, customized solid Phase coating, filling, freeze-drying, kit-assembly, ISO 9001 and 13485. Laboratory Services: Bioanalytics, companion diagnostics and platform development support. Biomarker Services: PK/PD, immunogenicity, sample measurement, endotoxin and pyrogen testing, Assay validation, method and System benchmarking, GLP, GC(L)P, cGMP.


microcoat

Contact:

Am Neuland 3
D-82347 Bernried
Phone: +49 (0) 8158 9981-0
Fax: +49 (0) 8158 9981-10
E-Mail:
humanresources@microcoat.de
Internet: www.microcoat.de



Contact:
Dr. Martin Groher

Rupert-Mayer-Str. 44, Building 64.07
D-81379 München
Phone: +49 (0) 89 189 4253-30
E-Mail: info@micro-dimensions.com
Internet: micro-dimensions.com

microDimensions GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Informatics, Microscopy, Automation, 3D-Structural Analysis, Molecular Diagnostics

microDimensions, founded in 2011 as a spin-off of the TU München, creates solutions for the analysis and visualization of microscopic image data. Biotech and Pharma companies use microDimensions' software to gain a significant speed-up of the processes within clinical studies where histology images are involved. In the field of biomarker analysis the solution of microDimensions plays an essential role for life science companies to mitigate the risk of drug development. The patent pending technology of microDimensions for hierarchical image registration can be used to correlate histology sections automatically: analysis of multiple biomarkers, volume measurements through the reconstruction of stacks of consecutive sections, automated scoring or fast stereology are potential applications.

MIKROGEN GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: PCR, Clinical Diagnostics, ELISA/EIA, Infectious Diseases, Automation, Autoimmune Diseases, Chip/Array Technology

Founded in 1989 MIKROGEN GmbH offers innovative solutions for medical laboratories. The company's scope is the development and production of wclinical diagnostic test systems based on recombinant antigens, with the focus on bacterial, viral, parasitic and autoimmune diseases. MIKROGEN's core competencies covers genetic engineering and the scientific quality of research and development, which is reflected in various patent applications and publications in international journals. The key success factors of the company are consistent customer orientation, the strong product competence and highly skilled employees. MIKROGEN meets ongoing market demands by emphasising its activities on automation and standardisation in the in-vitro diagnostics, to improve processes in medical laboratories.



Contact:
Dr. Erwin Soutschek

Floriansbogen 2 - 4
D-82061 Neuried
Phone: +49 (0) 89 54801-0
Fax: +49 (0) 89 54801-100
E-Mail: meyer@mikrogen.de
Internet: www.mikrogen.de

MLL Münchner Leukämie Labor GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, Chip/Array Technology, Genomics, PCR, Hematology, Oncology

MLL Munich Leukemia Laboratory is working as a reference laboratory for the diagnosis of hematologic malignancies focussing on leukemia and lymphoma. All 132 coworkers (physicians, molecular biologists, biostatisticians, and technicians) have outstanding reputation in the field of comprehensive diagnostics. In parallel, cytomorphology, cytochemistry, immunophenotyping, cytogenetics, FISH, and molecular genetic techniques such as PCR as well as new techniques such as next-generation sequencing are performed. The work-flow is orientated to the clinical needs of patients and physicians. MLL serves as a reference laboratory for German and European leukemia studies and is a SME-member in the European Leukemia Network (ELN).



Contact:
Prof. Dr. Dr. Torsten Haferlach

Max-Lebsche-Platz 31
D-81377 München
Phone: +49 (0) 89 990 17-0
Fax: +49 (0) 89 990 17-111
E-Mail: info@mll.com
Internet: www.mll.com

Molecular Machines & Industries GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Microscopy, Molecular Diagnostics, Devices

Molecular Machines & Industries (MMI) is the leading provider of microscope based micromanipulation solutions for the life sciences, material sciences, and healthcare. We specialize in single cell handling, laser microdissection and optical tweezers for a wide range of clinical and research based applications. MMI is a high value partner for our customers providing worldwide unique competence in micromanipulation and single cell handling. Founded in 1998 by Prof. Dr. Stefan Seeger in Heidelberg, Germany, MMI moved in 2001 to Zurich, Switzerland. Since then, MMI emerged into the global market and today has established a broad instruments base all over the world.



Molecular Machines & Industries

Contact:
Stefan Niehren

Breslauer Strasse 2
D-85386 Eching
Phone: +49 (0) 89 319 048 40
Fax: +49 (0) 89 319 048 59
E-Mail: info@molecular-machines.com
Internet: www.molecular-machines.com

Molecular Networks GmbH

BIOTECH BIOINFORMATICS

Keywords: Molecular Modelling, Small Molecules

Molecular Networks offers innovative chemoinformatics software products, consulting, development and research services to increase the quality and productivity of discoveries in chemical, pharmaceutical and biotechnology R&D. Founded in 1997, the company established international business relationships and Molecular Networks' technology is utilized in major industrial and academic discovery laboratories worldwide to design and optimize chemical products and processes. Molecular Networks' product portfolio comprises a variety of software tools, databases and decision support applications for the design and the synthesis of chemical compounds, the prediction of their chemical, physical and biological properties, their chemical reactivity and metabolic or environmental fate.



Molecular Networks
Inspiring Chemical Discovery

Contact:
Dr. Oliver Sacher

Medical Valley Center, Henkestr. 91
D-91052 Erlangen
Phone: +49 (0) 9131 8156-68
Fax: +49 (0) 9131 8156-69
E-Mail: info@molecular-networks.com
Internet: www.molecular-networks.com



Contact:
Alena Haas

Landshuter Allee 12
D-80637 München
Phone: +49 (0) 89 360 900 900
Fax: +49 (0) 89 360 900 901
E-Mail: info@molekula.com
Internet: www.molekula.com

Molekula GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Antibiotics, Analytical Chemistry, New Materials, Medicinal Chemistry, Peptide/Protein, Fine Chemicals/Reagents

Molekula is a leading chemical supplier offering research chemicals and biochemicals sourced from production sites across the globe. Our clients ranging from university labs to big industrial players. With offices in the UK, USA, China, Germany and Italy, our global insight into the market keeps us firmly at the forefront of this constantly evolving industry. Molekula is different - we specialise in hard-to-source chemicals using production laboratories across the world. Our catalogue now holds over 8000 ex-stock products and our ability to source high-quality compounds quickly and easily means our product list is growing all the time. Since 1999 both our business and the industry have changed significantly, with Molekula evolving from a small start-up to an industry leader.

MorphoSys AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: CNS, Oncology, Infectious Diseases, Antibody, Drug Development, Inflammation, Rheumatoid Arthritis

Contact:
Anke Linnartz

Semmelweisstraße 7
D-82152 Planegg OT Steinkirchen
Phone: +49 (0) 89 89927-0
Fax: +49 (0) 89 89927-222
E-Mail: info@morphosys.com
Internet: www.morphosys.com



MorphoSys a late-stage biopharmaceutical company devoted to the development of innovative and differentiated therapies for patients suffering from serious diseases. Based on our proprietary technology platforms and leadership in the field of therapeutic antibodies, we, together with our partners, have participated in the development of more than 100 therapeutic product candidates currently in R&D, 28 of which in clinical development. Our broad pipeline spans two business segments: Proprietary Development, in which we invest in and develop product candidates, and Partnered Discovery, in which we generate product candidates for our partners in the pharmaceutical and biotechnology industries against targets identified by our partners. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR and recently also on NASDAQ.

MSD SHARP & DOHME GMBH

PHARMA & CHEMICAL INDUSTRY

Keywords: Hepatology, Rheumatoid Arthritis, Infectious Diseases, Endocrinology, Oncology, Diabetics, Cardiovascular Diseases

MSD SHARP & DOHME GMBH is the German subsidiary of Merck & Co., Inc., a research-driven, worldwide acting pharmaceutical company based in the US, which develops, produces and distributes medicines and vaccines in different therapeutic fields. MSD wants to contribute to medical care in order to guarantee and improve access to urgently needed medicines worldwide. Thus, MSD supports numerous poor countries with donations of pharmaceuticals. For more than 100 years MSD publishes the renowned „MSD-Manual“, a standard publication for physicians and pharmacists (www.msdd.de/msdmanual/). Medical knowledge and advice for the public is published in the „MSD-Manual Handbuch Gesundheit“. MSD Germany has app. 1,200 employees. The company is situated in Haar near Munich.



Contact:

Lindenplatz 1
D-85540 Haar
Phone: +49 (0) 89 4561-0
Fax +49 (0) 89 46010-10
E-Mail: infocenter@msd.de
Internet: www.msdd.de

MUC Research GmbH

CRO

Keywords: Medical Writing, Clinical Trial Management and Monitoring, Data Management and Biostatistics, Logistics, Regulatory Affairs, Hepatology, Infectious Diseases

MUC Research is specialized in clinical research, i.e. the planning, conduct and analyses of clinical and diagnostic studies. MUC Research has extensive research experience in the field of infectious diseases such as HIV/AIDS or hepatitis B and C as well as in various other therapeutic areas. The services of MUC Research include the statistical planning of interventional and observational cohort studies, the establishment of electronic study platforms involving medical data bases and electronic case report forms (eCRFs), data management, clinical monitoring, statistical analyses and medical writing.



Contact:
Dr. Eva Wolf

Karlsplatz 8
D-80335 München
Phone: +49 (0) 89 5998 933
Fax: +49 (0) 89 5998 9353
E-Mail: info@mucresearch.de
Internet: www.drevawolf.de



Contact:
Anca Todea

Maxhüttenstraße 11
D-93055 Regensburg
Phone: +49 (0) 941 3782498
Fax: +49 (0) 941 6308648
E-Mail: info@multi-service-monitoring.de
Internet: www.multi-service-monitoring.de

multi service monitoring

CRO

Keywords: Oncology, Clinical Trial Management and Monitoring, Autoimmune Diseases, Devices, Regulatory Affairs, Drug Development,

multi-service-monitoring (in the BioPark, founded in 2003, 5 employees) is a clinical research organisation (CRO) that is specialised in monitoring of non-commercial clinical trials and medical clinical trials with devices. All tasks are carried out in accordance with the appropriate national regulations and the international guidelines ICH/GCP and "DIN ISO 14155".

multimmune GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Cell Therapy, Antibody, Drug Development, Personalized Medicine, Oncology, Immune Therapy

multimmune GmbH is a biopharmaceutical company dedicated to the discovery and development of new drug candidates for treating heat shock protein 70 (Hsp70) positive tumors - surface-bound Hsp70 is a tumor-specific marker expressed on about 50-75% of various cancer entities, e.g. lung, brain, breast, colon, pancreas. Four pipelines are currently being pursued: (1) extracorporeal activation of Natural Killer (NK) cells with a synthetic peptide (currently in Phase II for lung cancer), (2) using an antibody against membrane Hsp70 (preclinical), (3) inducing tumor-specific apoptosis using a recombinant human serine protease (preclinical), (4) direct infusion of an Hsp70 peptide (preclinical).

MWM Biomodels GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Pharmacokinetics, Transgenic Animals, Cardiovascular Diseases, Diabetics, Respiratory Diseases

MWM Biomodels GmbH is a spin-off company of the LMU Munich and Minitube, specialized in the development and characterization of transgenic large animal models for biomedical research. Current projects are focused on genetically modified pigs for xenotransplantation as well as transgenic pig models of diabetes mellitus, muscular dystrophy and immunodeficiency. MWM Biomodels offers support starting from the design of a project, the development of expression and targeting vectors, the generation of genetically modified large animals, their phenotypic characterization and the performance of preclinical studies.



Contact:
Prof. Dr. Gabriele Multhoff

Kirchenstrasse 82
D-81675 München

E-Mail: graham.pockley@multimmune.com
Internet: www.multimmune.com



Contact:
Dr. Christian Simmet

Hauptstr. 41
D-84184 Tiefenbach
Phone: +49 (0) 8709 9229-0
Fax: +49 (0) 8709 9229-39
E-Mail: csimmet@minitube.de
Internet: www.mwm-biomodels.com

Myriad GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, Molecular Diagnostics, Biomarker Discovery & Development, Genomics, Personalized Medicine, Oncology

Myriad is a leading molecular diagnostic company based in Salt Lake City, Utah. Myriad's key focus is to personalize cancer therapy by the discovery and commercialization of targeted tests to assess a person's risk of developing disease, guiding treatment decisions and assessing risk of disease progression and recurrence. Originally founded in 1991, Myriad has spent more than twenty years to help patients and care givers to better understand the role genes play in hereditary cancers, such as breast, colon, endometrial, ovarian, pancreatic, and skin cancers. Since 2011/2012 Myriad is building onto its strong tradition and extending the geographic footprint in Europe. The central European laboratory of Myriad GmbH has opened in Martinsried/Munich in March 2012. The Company provides caregivers access to the technology of its BRACAnalysis[®] test for genetic predisposition to hereditary breast and ovarian cancer, Prolaris[®] - a test to assess prostate cancer aggressiveness to predict disease outcome, Colaris[®] - a test for genetic predisposition to colon and endometrial cancer, and Colaris AP[®] - a test for genetic predisposition to polyposis colon cancer. In addition to the laboratory in Munich, Myriad operates its European headquarters in Zurich, Switzerland and regional offices in Paris, Madrid, and Milan.



Contact:
Dr. Saskia Wehnelt

Bunsenstr.7
D-82152 Martinsried
Phone: +49 (0) 89 414 1424-00
Fax: +49 (0) 89 8757 8170
E-Mail: info@myriadgenetics.de
Internet: www.myriad.com

Nanon Technologies GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Nanobiotechnology, Devices

Nanon Technologies is a leading provider of automated patch clamp (APC) electrophysiology systems with throughput capabilities ranging from a single cell up to fully automated high throughput screening (HTS) instruments recording from 384 cells simultaneously. Founded in 2002 as a spin-off from the University of Munich, Center for Nanoscience (CeNS), Nanon has expanded its product range over the years to include in vitro systems for membrane pump and transporter recordings, bilayers, and contractility measurements (impedance) from beating monolayers of cells, e.g. induced pluripotent stem cell-derived cardiac myocytes (iPSC-CMs), and confluency measurements of, e.g. hepatocytes for hepatotox screening using impedance.



Contact:
Dr. Niels Fertig

Ganghoferstraße 70a
D-80339 München
Phone: +49 (0) 89 2190 95-0
Fax: +49 (0) 89 2189 97-960
E-Mail: info@nanon.de
Internet: www.nanon.de

nanoSaar AG

NANOTECHNOLOGY



Contact:
Dr. Michael Steiner

Würmstraße 4
D-82319 Starnberg
Phone: +49 (0) 8151 959022-0
Fax: +49 (0) 8151 959022-9
E-Mail: info@nanosaar.com
Internet: www.nanosaar.com

Keywords: [Nanobiotechnology](#)

nanoSaar AG, based in Starnberg, is the exclusive license owner of the patented MJR nanotechnology. Our business approach is to commercialize our proprietary economic MJR production capabilities in the following industries: pharma OTC, food & beverage, cosmetics, consumer products, medical, fragrance, (petro)chemical additives, biocides, catalyzers, paints/coatings, construction, batteries and electronics. The MJR technology can produce nano/micro-particles, emulsions and encapsulations with a highly defined size. Our MJR technology creates superior results compared to spray drying, milling, high pressure homogenization and other technologies. The continuous low cost production setup allows for an unlimited industrial scale-up. We offer product development services and buildup of MJR production capacity at the customer site. We also offer in-house production services with our proprietary products and common new business development for nano applications in licensing and joint venture models. The nanoSaar team has a long term experience and a worldwide contact network. Additional keywords: MJR nanotechnology, nanoparticle, nanoemulsion, nanoencapsulation

NanoScape AG

PHARMA & CHEMICAL INDUSTRY



Contact:
Dr. Andreas Kohl

Rupert Mayer Str. 44
D-81379 München
Phone: +49 (0) 89 4613 3443-10
Fax: +49 (0) 89 4613 3443-30
E-Mail: info@nanoscape.de
Internet: www.nanoscape.de

Keywords: [Fine Chemicals/Reagents](#), [New Materials](#)

NanoScape is a developer and producer of porous nanoscale materials, functional surfaces, and technological solutions for downstream-processing. It offers different separation and extraction techniques based on liquid membranes or microemulsions, which increase the quantity or quality of a range of products using only a single purification step. The NanoZeolite materials are cage-like structures with very high loading capacity and good thermal and mechanical resistance which, through modification of the particle size or pore diameter, and functionalisation of the surface chemistry, can be adapted to meet the requirements of the individual customer. Using such materials intelligent separation techniques can be realized, as well as bind-and-elute-applications and drug-delivery systems for functional molecules. These can be encapsulated and stabilised within NanoScapes nCAP material, allowing release profiles to be tailored to provide constant dosage levels over a tunable time period.

NanoTemper Technologies GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Bioanalytics, Devices

NanoTemper Technologies is a high-tech company providing solutions for biomolecular analytics. The company develops, produces and markets innovative technologies and instrumentation used by thousands of scientists across four continents. NanoTemper Technologies stands for strong commitment to quality and high precision instrumentation made in Germany. The deeply experienced and globally operating team of experts strongly focuses on the users benefits by ensuring maximum efficiency for research in Pharmaceutical or Biotech industries as well as in an academic basic research setting. With headquarters in Munich, Germany, and subsidiaries in the UK, Poland, US, Brazil and India, the company is rapidly expanding worldwide.

Contact:
Dr. Philipp Baaske

Flößergasse 4
D-81369 München
Phone: +49 (0) 89 4522 895-0
Fax: +49 (0) 89 4522 895-60
E-Mail: info@nanotempertech.com
Internet: www.nanotempertech.com

NDA Regulatory Service GmbH

CRO

Keywords: Regulatory Affairs, Pharmacovigilance, Drug Development

NDA Group is one of the leading Regulatory Affairs consultancies in Europe. With ~100 employees and offices in Sweden, UK and Germany, NDA has successfully provided Regulatory Support throughout Europe for over 15 years. NDA Regulatory Service GmbH in Munich was founded by a core group of regulatory experts from the European headquarter of an international pharmaceutical company. Our consultants are experienced professionals who offer expert knowledge and understanding of European regulations, guidelines and procedures. They are proficient in all regulatory activities associated with small molecules, biologicals and advanced therapies. We are dedicated to guide our clients smoothly through product development and registration in Europe.



Contact:
Dr. Rainer Paffenholz

Neumarkter Straße 18
D-81673 München
Phone: +49 (0) 89 3585-4000
Fax: +49 (0) 89 3585-4010
E-Mail: munich@ndareg.com
Internet: www.ndareg.com

Neaspec GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Devices, Analytical Chemistry, Microscopy, Nanobiotechnology, Molecular Diagnostics

Trusted to deliver cutting-edge solutions for nanoscale optical imaging & spectroscopy for research laboratories in industry and academic institutions is central to Neaspecs philosophy. Neaspec developed the neaSNOM microscope that combines the best of two worlds the nanoscale resolution of atomic force microscopy (AFM) with the analytical power of FT-IR infrared imaging & spectroscopy. neaSNOM thus allow to study chemical, structural and electronic properties of a sample at a spatial resolution up to 1000-times higher when compared to conventional technology like micro FT-IR. The non-destructive measurement method is equally suited for organic and inorganic samples and requires only standard AFM sample preparation.

Contact:
Dr. Stefan Schiefer

Bunsenstr. 5
D-82152 Martinsried
Phone: +49 (0) 89 787939-78
Fax: +49 (0) 89 787939-79
E-Mail: info@neaspec.com
Internet: www.neaspec.com



Contact:

Am Haag 6+7
D-82166 Gräfelfing
Phone: +49 (0) 89 898888-0
Fax: +49 (0) 89 898888-619
E-Mail: info.germany@neovii.com
Internet: www.neovii.com

NEOVII Biotech

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Oncology, Gene Therapy, Cell Therapy, Antibody, Immune Therapy, Hematology, Drug Development

Neovii Biotech GmbH (formerly Fresenius Biotech GmbH) is a globally operating company dedicated to deliver targeted biopharmaceutical treatment options in transplantation medicine and hematological oncology. The focus of the activities is the development and commercialization of immunologically active biopharmaceutical therapeutics based on innovative antibody technologies. Clinical and development activities as well as manufacturing are located in Germany with an additional development unit in the USA. Neovii Biotech is manufacturing and commercializing the medicinal product 1. Grafalon® and holds the EU marketing authorization for the trifunctional antibody Removab® (INN: Catumaxomab). Neovii Biotech GmbH is a company of the Neopharm Group.

NeuroProfile GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS



Contact:

Dr. Thomas Rohrmeier

Keilsteiner Breiten 6
D-93055 Regensburg
Phone: +49 (0) 941 785 369-0
Fax: +49 (0) 941 785 369-9
E-Mail: info@neuroprofile.com
Internet: www.neuroprofile.com

NeuroProfile is committed to the discovery and development of novel therapeutics for the treatment of Central Nervous System (CNS) diseases. The main objective is the identification and commercialization of novel neuronal drug targets (disease-related genes or proteins) for the most important neurodegenerative diseases Alzheimer and Parkinson and for psychiatric disorders such as schizophrenia and depression. Our targets will be the basics for forthcoming drug generations with new mechanisms of action that not only ameliorate the disease symptoms, but potentially prevent or block progression of the disease. Several patent pending target candidates are run in preclinical validation projects.

New Diagnostics GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: Toxicology, Bioanalytics, R&D Service, Endocrinology, In-Vitro-Diagnostics



bioanalytical solutions for food, the environment & medical applications

Contact:

Moosstr. 92 c
D-85356 Freising
Phone: +49 (0) 8161 8870979
Fax: +49 (0) 8161 8878332
E-Mail: mena.eidens@new-diagnostics.com
Internet: www.new-diagnostics.com

The new_diagnostics GmbH is a biotechnology company based in Freising with a subsidiary in Dresden. We are your partner for biosensor technology and effect-directed analysis in the areas of environment, food and beverages as well as medical diagnostics. With our validated yeast-based bioassays (A-YES®, A-YAS® and A-YPS), we focus on effect-related analyses of hormonally active substances in water samples and extracts. Our A-YES® is currently participating in the standardization process within the framework of the ISO working group ISO 19040-2 Water quality Determination of the estrogenic potential of water and waste water. Besides onsite trainings on how to use our assays, we also offer order analyses. With our bioanalytical expertise we offer customized solutions for your needs.

NIGU Chemie GmbH

PHARMA & CHEMICAL INDUSTRY

Nigu offers a full range of high-purity guanidine salts for biotechnological applications, which meet the supreme quality standards set by the biopharmaceutical industry. The product group includes several grades of guanidine hydrochloride for separation and purification of recombinant proteins and antibodies. Guanidine thiocyanate for nucleic acid based diagnostics is another integral part of the portfolio. A typical example is to provide guanidine-salts and recycling of used solutions as a complete package to the biopharmaceutical industry.

NIGU

AlzChem Group

Contact:
Dr. Frank Fleischer

c/o AlzChem AG
Dr.-Albert-Frank-Str. 32
D-83308 Trostberg
Phone: +49 (0) 8621 86-3029
Fax: +49 (0) 8621 86-3598
E-Mail: info@alzchem.com
Internet: www.nigu.de

Novartis Pharma GmbH

PHARMA

Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic and biosimilar pharmaceuticals and eye care. Novartis has leading positions globally in each of these areas. In 2017, the Group achieved net sales of USD 49.1 billion, while R&D throughout the Group amounted to approximately USD 9.0 billion. Novartis Group companies employ approximately 122,000 full-time-equivalent associates. Novartis products are sold in approximately 155 countries around the world.



Contact:
Angelika Gaufer

Roonstr. 25
D-90429 Nürnberg
Phone: +49 (0) 911 273-0
Fax: +49 (0) 911 273-12653
E-Mail: angelika.gaufer@novartis.com
Internet: www.novartis.de

numares AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Cardiovascular Diseases, Metabolomics, Biomarker Discovery & Development, Drug Development, Clinical Diagnostics, Nephrology, Metabolic Diseases

numares HEALTH develops and markets integrated test systems for human diagnostics. These create a detailed image of the human metabolism from bodily fluids on the basis of nuclear magnetic resonance (NMR). Diagnostic tests interpret the individual metabolic images of the patient with the help of innovative software solutions and provide valuable information about the formation, extent and severity of diseases. The ability to perform different tests on the same platform in fully automated and high throughput operations shows the efficiency and cost-effectiveness of numares systems.



Contact:

Am BioPark 9
D-93053 Regensburg
Phone: +49 (0) 941 698 091-00
Fax: +49 (0) 941 698 091-01
E-Mail: info@numares.com
Internet: www.numares.com

Nuvisan GmbH



Contact:

Wegenerstr. 13
D-89231 Neu-Ulm
Phone: +49 (0) 731 9840-0
Fax: +49 (0) 731 9840-280
E-Mail: bdinfo@nuvisan.com
Internet: www.nuvisan.com

CRO

Keywords: Oncology, Small Molecules, Peptide/Protein, Pharmacokinetics, PCR, ELISA/EIA

Nuvisan Pharma Services is a global provider of product development and support services to the pharmaceutical, biotechnology and medical device industries. We deliver services ranging from a single test to fully integrated drug development programs. Together with Focus we are pleased to offer our sponsors the complete spectrum of drug development services and assist the sponsor in bringing safe and effective pharmaceutical products to market.

Omegametrix GmbH



Omegametrix GmbH

Contact:

Adrian Passow

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 5506 300-7
Fax: +49 (0) 89 5506 300-8
E-Mail: info@omegametrix.eu
Internet: www.omegametrix.eu

BIOTECH THERAPEUTICS & DIAGNOSTICS

Prof. W.S. Harris, Sanford University - USA, and Prof. C. von Schacky, University of Munich, invented and defined the HS-Omega-3 Index in 2004. Then, in 2006 Schacky founded Omegametrix GmbH, as a Laboratory, to deal with the ever growing number of research projects, applications and samples. Initially proposed as a risk factor for sudden cardiac death, it now indicates cardiovascular risk as well. First studies have shown its association to life expectancy in general. Other applications, still in development, range from psychiatric diseases to pregnancy and lactation.

OmicScouts GmbH



Contact:

Dr. Hannes Hahne

Lise-Meitner-Str. 30
D-85354 Freising
Phone: +49 (0) 8161-976289-0
E-Mail: info@omicScouts.com
Internet: www.omicscouts.com

BIOTECH BIOINFORMATICS

Keywords: Proteomics, Bioinformatics, Drug Development, Biomarker Discovery

OmicScouts is a chemical proteomics company focused on supporting drug and biomarker discovery with its unique expertise and innovative technologies. Founded by leading proteomics researchers, the company has a track record in delivering significant collaborations with top pharmaceutical and biotechnology companies. We provide and develop proteome-wide assays that work with native proteins in a physiological setting and enable the identification of small molecule drug targets, target engagement markers, molecular mechanisms of action and drug response biomarkers. OmicScouts supports your drug and biomarker discovery projects with end-to-end solutions tailored to project specific needs.

OncoLead GmbH & Co. KG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Clinical Diagnostics, Oncology

Oncolead, is a privately owned service provider company. We offer a unique cellular screening of anticancer agents in a panel of 80-200 cancer cell lines. Routine operation and highly standardized processes guarantee our customers the results within 2-4 weeks with outstanding reproducibility for cellular screening. Customers will further benefit from a comprehensive data analysis including correlation of activity profile with mutation status and with activity profile of thousands of known anticancer agents. We provide complementary tests using a complete 80+ cell line panel: an in vitro combination of more than 500 combination pairs, development of drug tolerance or test of different drug schedules using a longer (3-4 weeks) drug treatment. All these data are requested in translational research and clinical development and help our customers to increase confidence in making drug development decisions.



Contact:
Claudia Stibi

Zugspitzstr. 5
D-85757 München-Karlsfeld
Phone: +49 (0) 151 2062 1612
Fax: +49 (0) 89 380122159
E-Mail: request4more@oncolead.com
Internet: www.oncolead.com

origenis GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Combinatorial Chemistry, Medicinal Chemistry, Automation, Combinatorics, Molecular Modelling, Small Molecules

Origenis is a leader in small molecule drug discovery with over 14 years of experience in the field. Origenis is a privately owned company based in Martinsried, Germany. Origenis runs its own patented Drug Discovery platform MOREsystem[®]. The unique platform combines state-of-the-art drug design, patent analysis, chemical synthesis and biological characterization performed in an integrated manner on 20.000 square feet of integrated lab space. Origenis runs research alliances as well as active in-house programs. Origenis is currently focusing on anti-inflammatory and CNS drugs. Origenis is offering a variety of out-licensing opportunities. Origenis offers access to its proprietary patent database Cippix[®] - www.cippix.com.

origenis

Contact:
Michael Almstetter

Am Klopferspitz 19a
D-82152 Martinsried
Phone: +49 (0) 89 7801676-0
Fax: +49 (0) 89 7801676-777
E-Mail: info@origenis.de
Internet: www.origenis.de

Oryx GmbH & Co. KG

BIOTECH THERAPEUTICS & DIAGNOSTICS



Contact:

Marktplatz 1
D-85598 Baldham
Phone: +49 (0) 8106 21 311-0
Fax: +49 (0) 8106 21 311-66
E-Mail: info@oryx-medicine.com
Internet: www.oryx-medicine.com

ORYX is a privately held Munich based biotech company. The company develops three highly innovative drug candidates for the treatment of a whole range of cancers, originating from leading research institutions like the German Cancer Research Center (DKFZ) and the University of Heidelberg. The ORYX clinical development portfolio consists of an oncolytic virus and two therapeutic cancer vaccines. In 2015, these candidates successfully completed clinical Phase I/IIa trials. Currently, the oncolytic virus ParvOryx is being further developed in a Phase I/IIa pilot study in patients with metastatic pancreatic cancer and VicOryx, one of the therapeutic vaccines, is being tested in an additional clinical Phase I trial in combination with standard cisplatin-based chemotherapy. ORYX holds exclusive, world-wide patents and utilization licenses for all its development projects.

Otsuka Novel Products GmbH

PHARMA & CHEMICAL INDUSTRY



Otsuka Novel Products GmbH

Contact:

Erika-Mann-Str. 21
D-80636 München
Phone: +49 (0) 89 2060205 30
Fax: +49 (0) 89 2060 205-55
Internet: <http://otsuka-onpg.com>

Keywords: Drug Development, Clinical Diagnostics, Antibiotics, Infectious Diseases

Otsuka Novel Products GmbH (ONPG) was founded in 2011 in Munich, as an Otsuka group company. With an international network of 145 subsidiaries and 39,000 employees in 23 countries, and regions across Europe, Asia-pacific, America and the Middle East, Otsuka researches, develops, manufactures and markets innovative and original products with a focus on pharmaceutical products for the treatment of diseases. ONPG will initially focus on infectious diseases, working in collaboration with other group companies to develop improved diagnostic tools and novel products for the treatment of tuberculosis.

Oxford BioLabs Ltd.

BIOTECH DEVICES & REAGENTS



Contact:

Am BioPark 13
D-93053 Regensburg
Phone: +44 (0) 1865 58 2004
Fax: +44 (0) 1865 41 2355
E-Mail: contact@oxbiolabs.com
Internet: www.oxbiolabs.com

Oxford BioLabs Ltd. is a science-based company tackling Androgenetic Alopecia (AGA). A small group is located in Regensburg, BioPark. Our goal is to create a new standard of care for the treatment of AGA. Oxford BioLabs is developing novel therapies for the treatment of androgenetic alopecia (AGA), which is commonly known as male and female pattern baldness. Available therapies include drugs or hair transplant surgery, which treat acute symptoms but lead to side effects, hospitalization and unsatisfactory patient outcome. Currently there is no cure against AGA and new treatment options are urgently needed.

PaediaCRO GmbH

CRO

Keywords: Pharmacovigilance, Regulatory Affairs, Drug Development, Medical Writing

PaediaCRO – your specialised CRO for your product development in paediatric use. Founded in 2007 by Prof. Dr. med., Dr. rer. nat., Dr. h. c. mult. Dieter Adam, Dr. rer. nat. Josef Hofer and Dipl.-Math. Jürgen Wyen, PaediaCRO will support you in the development of solutions for your products in paediatric use. A smile of a healthy child is our vision. To achieve this, PaediaCRO develops with its partners medicinal products to save children's life and improve their quality.



Contact:

Dachauer Str. 44a
D-80335 München
Phone: +49 (0) 89 551553-50
Fax: +49 (0) 89 551553-51
E-Mail: info@paediacro.de
Internet: www.paediacro.eu

PAN Biotech GmbH

BIOTECH DEVICES & REAGENTS

PAN-Biotech GmbH is a modern and innovative company with its headquarters in Aidenbach/Germany. PAN-Biotech was founded in 1988 and is today a major producer of biotechnological products which are worldwide distributed and used in research and industry. The product range includes new serum- and proteinfree media, sera (FCS) from different countries of origin including important special variants and a broad variety of media for cell culture. Important new product areas are our automated cell culture systems for research and industry as well as new services all around the cell culture and cell processing. As a specialist for cell culture we can offer you nearly the complete range of products and services that you need for your successful cell culture. Additional competencies: quality control of biotechnological products, practical solutions for cell culture, nutrients for cells.



Contact:

Jens Hartmann

Gewerbepark 13
D-94501 Aidenbach
Phone: +49 (0) 8543 6016-30
Fax: +49 (0) 8543 6016-49
E-Mail: info@pan-biotech.de
Internet: www.pan-biotech.de



Contact:
Gerd-Peter Heberling

Landshuter Allee 8-10
D-80637 München
Phone: +49 (0) 89 5455 83-50
Fax: +49 (0) 89 5455 83-33
E-Mail: info-de@panaceabiotec.com
Internet: www.panaceabiotec.de

Panacea Biotec GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Panacea Biotec is the third largest biotechnology company (as per ABLE Survey, 2011), as well as among the top 50 pharmaceutical companies (as per ORG IMS March 2010) of India. Panacea Biotec Germany GmbH is located in Munich and delivers and markets products in transplantation, immun-suppression and anti-infection.



Contact:
Michael Hahn

Lochhamer Schlag 21
D-82166 Gräfelfing
Phone: +49 (0) 89 742846-0
Fax: +49 (0) 89 743846-30
E-Mail: michael.hahn@pari.com
Internet: www.paripharma.com

PARI Pharma GmbH

MEDTECH

Keywords: Respiratory Diseases, Infectious Diseases, Antibiotics, Analytical Chemistry, Drug Delivery

PARI Pharma focuses on the development of aerosol delivery devices and comprehensive inhalation drug development to advance aerosol therapies where drug and device can be optimized together. PARI Pharma partners with pharmaceutical companies to develop new or improved therapies. eFlow® Technology devices are designed to significantly improve upper and lower respiratory tract deposition and reduce the burden of treatment for patients with severe respiratory conditions. Examples include Altera® for delivery of Cayston® for cystic fibrosis (Gilead Sciences) and the recently FDA approved drug device combination Lonhala®Magnair® (Sunovion) for COPD, a proprietary closed system device.

Pelo Biotech GmbH

BIOTECH DEVICES & REAGENTS

PELOBIOTECH is competent for cells and offers the broadest portfolio of animal & human cells and media. We bring your research from bench to bedside. You get the whole variety of solutions from tissue dissociation to cryopreservation for research and clinical applications.

- Tissue Dissociation Enzymes
- Defined & Xeno-free Media
- Human & Animal Primar & Stem Cells
- Diseased Human Primary & Stem Cells
- Cancer Stem Cells
- Tagged & KO Cells
- ES/iPS Cells, Media & Tools - Reprogramming Tools & Small Molecules
- Cryo-Preservation Media w/ & w/o DMSO
- Cytokines, Growth Factors & Chemokines
- 2D/3D Cell Culture Systems and 2D/3D Microfluidic Systems
- Cell based Assays
- TR-FRET Reagents
- Premium Grade & GMP Products
- High-Performance Microsphere Products for Sample Preparation



Contact:

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 51728659-0
Fax: +49 (0) 89 51728659-88
E-Mail: info@pelobiotech.com
Internet: www.pelobiotech.com

Pharma Stulln GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: [Ophtalmology](#), [Respiratory Diseases](#)

Experience in manufacturing eye drops in bottles and single-dose-units for more than 30 years. Pharma Stulln fulfills international standards in modern production of sterile preparations. Pharma Stulln has approximately fifty well established pharmaceutical customers in Germany, Europe and international countries such as Australia, China, Canada etc. Pharma Stulln is specialist in manufacturing: Eye drops, Nasal sprays, Respiratory solutions, Lens care products. In our production building in seven separate rooms high-performance bottelpack[®]-filling machines are placed for manufacturing individual products. A modern zone concept fulfills European and international standards for the production of sterile fluid pharmaceuticals. Advanced water treatment and ventilation technology combined with continuous monitoring ensure a continuous high level of quality production.

pharma **STULLN**

Contact:

Dr. Karl Luschmann

Werksstraße 3
D-92551 Stulln
Phone: +49 (0) 9435 3008-0
Fax: +49 (0) 9435 3008-99
E-Mail: info@pharmastulln.de
Internet: www.pharmastulln.de

Pharmalog – Institut für klinische Forschung GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS



Contact:

Dipl. Stat. Holger Stammer

Neumarkter Str. 18

D-81673 München

Phone: +49 (0) 89 544637-0

Fax: +49 (0) 89 544637-50

E-Mail: pharmalog@pharmalog.com

Internet: www.pharmalog.com

Pharmalog Institut für klinische Forschung GmbH acts as an European full service CRO with an excellent reputation in clinical trials phase I-IV since 1983. Our staff of 42 colleagues in our office plus further central field based monitors conducts clinical and non-interventional trials. We operate in Germany and all EU/EEU-countries, using our large pool of motivated investigators in clinics/ practices. Our local monitors are native speakers.

We work

transparent for our clients

accurate in planning, realization and evaluation of clinical trials

flexible focusing the needs of our customer

friendly to assure a long lasting and strong collaboration with our clients

We have performed more than 400 clinical trials in all medical indications for medical products/-devices/biotechnology products according to ICH-GCP and FDA-standards for more than 50 nat./internat. pharmaceutical companies.

We offer full service or modular approach (e.g. monitoring, data management/ statistics), reasonable pricing due to short contact ways and low overhead costs. Pharmalog is TÜV – certified and member of the BVMA.

PharmaZell GmbH

PHARMA & CHEMICAL INDUSTRY; CMO



Contact:

Rosenheimer Str. 43

D-83064 Raubling

Phone: +49 (0) 8035 88-0

Fax: +49 (0) 8035 88-143

E-Mail: info@pharmazell.com

Internet: www.pharmazell.com

The in-house development and production of various multi-customer active pharmaceutical ingredients is one pillar of PharmaZell API business model. A product list of currently offered generic APIs is available and information about new products under development and/or evaluation can be provided upon request. The development and production of different single-customer (exclusive) active pharmaceutical ingredients is the other pillar of our API business model. PharmaZell draws upon a long history of successful custom synthesis projects, performed on a proprietary basis for innovation driven pharmaceutical companies worldwide. The company is also diversified into finished dosage form development. Formulation and analytical development labs as well as pilot/pivotal facilities are available at its Indian site in Vizag. The site develops entire dossiers and modular services to customers.

Pharm-Olam International Deutschland GmbH

CRO

Pharm-Olam International is a global, full service, Phase I-IV CRO with offices across Europe, North America, Latin America, South Africa, and India. In Germany, we have conducted trials since 1999 and have a local office in Munich along with regional staff. Our staff are highly experienced and can provide a range of services including Marketing Surveillance (AMG § 67.6) - from protocol writing to delivery of final report, auditing, monitoring and regulatory. Our Munich office also supports neighboring Austria and Switzerland. Let us evaluate your protocol at several of the largest centers in Germany and worldwide to determine projected enrollment by contacting german.office@pharm-olam.com



Contact:
Dr. Peter Sonner

Ingolstädter Str. 20
D-80807 München
Phone: +49 (0) 89 375 0899-0
Fax: +49 (0) 89 375 0899-20
E-Mail: GermanOffice@pharm-olam.com
Internet: www.pharm-olam.com

PhaToCon (Pharm/Tox Concept)

BIOTECH PRECLINICAL SERVICES

Keywords: Toxicology, Pharmacology, Antibody, Tissue Engineering/Cell Culture, Drug Delivery, Drug Development, Regulatory Affairs

You think about Quality-Management (QM) to improve efficiency, data reliability and comparability? However, you work at full capacity and additional resources are not available? We offer individually tailored QM-Concepts in Research and Development as well as preclinical Study-Management with regard to regulatory requirements in Pharmacology / Toxicology (in vitro / in vivo). Our support is customized based on international standards like GLP/GMP, ISO, We operate from a scientific point of view and with our "hands-on" mentality we have strong execution skills. With our network of competence and capabilities we guide your project to success. Benefit from our know-how and our network of experienced partners: selected experts, toxicologists and more than 40 accredited testing laboratories.



Contact:
Dr. Thomas W. Becker

Am Klopferspitz 19
D-82152 Planegg-Martinsried
Phone: +49 (0) 89 444 899-41
Fax: +49 (0) 89 444 899-43
E-Mail: info@phatocon.com
Internet: www.phatocon.com

Phytochem Referenzsubstanzen GbRmbH

BIOTECH DNA/PROTEIN ANALYTICS

Phytochem develops, produces and markets high purified substances for the pharmaceutical industry, research, analytics and authorities (main focus over 3,000 natural compounds). Phytochem synthesizes or isolates also degradation products and impurities in remedies or other rare drugs especially for customers needs with best equipment and experience. Lot specific testing is guaranteed. Phytochem products were used as Reference Standards for research and development: (Identity standard Data File: IDF) also for quality control as Primary Standards (Reference Substance Masterfile: RMF) and full documented method validation. Additional products and consulting services in the fields of functional foods, dietary supplements, food additional and cosmetics are new focuses from Phytochem.



Contact:
Hans Rausch

Krumbacherstr. 9
D-89335 Ichenhausen
Phone: +49 (0) 731 97205-45
Fax: +49 (0) 731 97205-46
E-Mail: phytochem@t-online.de
Internet: www.phytochem-standards.de



Contact:

Lise-Meitner-Str. 30
D-85354 Freising-Weihenstephan
Phone: +49 (0) 8161 1411 400
Fax: +49 (0) 8161 1411 444
E-Mail: info@pieris.com
Internet: www.pieris.com

Pieris Pharmaceuticals GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Oncology, Respiratory Diseases, Peptide/Protein, Drug Development, Immune Therapy

Pieris Pharmaceuticals is an international Nasdaq-listed (TICKER: PIRS), clinical-stage biotechnology company that discovers and develops Anticalin protein-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes immuno-oncology multi-specifics tailored for the tumor microenvironment, an inhaled Anticalin® protein to treat uncontrolled asthma and a half-life-optimized Anticalin® protein to treat anemia. Proprietary to Pieris, Anticalin proteins are a novel class of therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. Anticalin® is a registered trademark of Pieris.



Contact:

Dr. Gudrun Vogeser

Raiffeisenstr. 31a
D-85276 Pfaffenhofen
Phone: +49 (0) 8441 87948-30
Fax: +49 (0) 8441 87948-31
E-Mail: info@pika-weihenstephan.de
Internet: www.pika-weihenstephan.de

PIKA Weihenstephan GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: Agrobiotechnology, New Materials, Analytical Chemistry, PCR

PIKA Weihenstephan was founded in 2000 as a spin-off from the Technical University of Munich-Weihenstephan. Our focus is the fast detection and identification of microorganisms which may occur as spoilers during the production process of beer and beverages, but also in a diversity of other applications. Besides offering analyses for customers, PIKA Weihenstephan is producing and selling enrichment media and kits to be used for fast and specific process control. We are specialists in microbiology, both in conventional and in DNA analyses, especially PCR based methods. All processes at PIKA Weihenstephan are certified according to DIN EN ISO 9001:2008.



Contact:

Dr. Werner Deininger

Industriestraße 1
D-93077 Bad Abbach
Phone: +49 (0) 9405 96 999-10
Fax: +49 (0) 9405 96 999-28
E-Mail: info@polyquant.com
Internet: www.polyquant.com

PolyQuant GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Proteomics, In-Vitro-Diagnostics, Laboratory, Biomarker Discovery & Development, Peptide/Protein, Clinical Diagnostics

PolyQuant offers customized solutions for quantitative proteomics, based on our proprietary QconCAT technology. Building on our expertise in design and synthesis of concatenated polypeptides, our products comprise: custom-made QconCATs as internal standards for absolute protein quantification, calibration kits for LC and MS instrument standardization, full fee-for-services: entire assay development and/or absolute protein quantification workflows and technical support for the implementation of targeted proteomics assays. Present as a polypeptide, QconCATs facilitate simultaneous multiplex absolute protein quantification by mass spectrometry. They are also well-suited to function as research tool for the identification and validation of biomarkers in disease diagnosis/prognosis.

Postnova Analytics GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Devices

Postnova Analytics is manufacturer of Field Flow Fractionation (FFF) for nanoparticle, protein and bio/polymer separation, fractionation and characterization. Postnova offers a complete FFF product range for applications in Biopharmaceutical, Nanotechnology, Environmental, Food, Cosmetics and Polymers. Field-Flow Fractionation coupled to Multi-Angle Light scattering (MALS), Dynamic Light Scattering (DLS) and ICP-MS detection offers access to high resolution size and molar mass separation, characterization and element speciation. Products are CentrifugalFFF for Nanoparticles, FlowFFF for Biopharmaceuticals and ThermalFFF for Polymers.



Contact:
Dr. Thorsten Klein

Max-Planck-Str. 14
D-86899 Landsberg a. L.
Phone: +49 (0) 8191 985 688-0
Fax: +49 (0) 8191 985 688-99
E-Mail: info@postnova.com
Internet: www.postnova.com

PPD Germany GmbH & Co. KG

CRO

Keywords: Medical Writing, Logistics, Devices, Drug Development

PPD is a leading global contract research organization providing drug discovery, development and lifecycle management services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 46 countries and more than 13,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their R&D investments.



Contact:
Dr. Peter Oberosler

Hansastr. 32
D-80686 München
Phone: +49 (0) 89 57877-0
Fax: +49 (0) 89 57877-400
E-Mail: genl.info@ppdi.com
Internet: www.ppdi.com

PreciPoint GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Microscopy, Automation, Devices

PreciPoint, located in Freising, is a manufacturer of digital microscopes and complex lab automation devices. PreciPoints core competency is combining optics, mechanics, electronics, firmware and software to modern micro imaging applications. Currently, the company is focused on Whole Slide Imaging, Digital Pathology and Virtual Microscopy. Our well-rounded engineering staff develops practical, economical and precisely manufacturable solutions for a wide array of complex problems.



Contact:
Alois-Steinecker-Str. 22
D-85354 Freising
Phone: +49 (0) 8161 976979-0
E-Mail: vertrieb@preciPoint.de
Internet: www.preciPoint.de



Contact:

Am BioPark 11
D-93053 Regensburg
Phone: +49 (0) 941 94272-100
Fax: +49 (0) 941 94272-111
E-Mail: info@presens.de
Internet: www.presens.de

PreSens Precision Sensing GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Devices, Drug Development, Tissue Engineering/Cell Culture, Analytical Chemistry

PreSens is a world leader in the field of chemical-optical sensors. It develops, manufactures and distributes sensor systems for Biotech & Pharma, Food & Beverage, Scientific Applications and Medical Devices. PreSens offers out-of-box products and engineering of customized sensors, focusing on parameters which are essential for life: oxygen, pH, carbon dioxide and biomass - and other parameters on request. Over the last 17 years, we have delivered our special microsensors and our non-invasive systems for various applications such as respirometry, biology, or medical research. We also offer imaging solutions: 2D-sensing of oxygen-, pH- and CO₂-distributions. PreSens is certified EN ISO 13485:2003 + AC:2007 and ISO 9001:2008. Together with its partners it offers service all over the world.

Pretec microbia GmbH

PHARMA ANIMAL HEALTH



Contact:

Geyerspergerstr. 27
80689 München
Phone: +49 (0) 89 58 00 82-0
Fax: +49 (0) 89 58 00 82-7777
E-Mail: info@cinfabiotech.com
Internet: www.pretecmicrobia.com/en/

Pretec microbia is an agri-food biotechnology company specialized in developing technologies and marketing products for improving the health of food animals in order to increase production performance and food safety. Pretec microbia's mission is to be a world leader in the development and commercialization of products providing an alternative to antibiotics for the prevention of bacterial infections and the improvement of food animal performance. The company has offices in Montreal and Saint-Hyacinthe, Quebec (Canada). Its German based subsidiary is run in conjunction with Klifovet AG.

PreOmics GmbH

BIOTECH DEVICES & REAGENTS



Contact:

Am Klopferspitz 19
D-82152 Planegg/Martinsried
Phone: +49 (0) 89 23 14 163-0
Fax: +49 (0) 89 23 14 163-99
E-Mail: info@preomics.com
Internet: www.preomics.com

PreOmics GmbH develops and commercializes tools for mass spectrometry-based proteomics. The main focus are easy and optimized sample preparation methods enabling fast, efficient and sensitive measurements at high throughput. PreOmics further develops instruments for automated fractionation and enrichment to achieve complete proteomics and to facilitate the analysis of signal-transduction pathways. PreOmics addresses customers in research, drug development and diagnostics.

Passion for Performance

 **Rentschler**
Biopharma



We are a biotechnology pioneer

We listen to our clients

We remain flexible

We find solutions where others don't even look

Rentschler Biopharma SE is a leading CDMO for process development and manufacturing of biopharmaceuticals as well as formulation in Strategic Alliance with Leukocare AG and fill & finish with our Strategic Partner Rentschler Fill Solutions GmbH. Long-standing experience and excellence as a solution partner for our clients ensures Rentschler Biopharma's high quality standards. Rentschler Biopharma is an independent, family-owned company employing more than 800 people.



A world-class biopharmaceutical CDMO

- Full-service provider from gene to vial and from concept to market
- Contract development and manufacturing with proven excellence
- Outstanding expertise in mammalian cell culture
- Extensive track record with more than 40 years in biopharma

Rentschler Biopharma SE

Erwin-Rentschler-Str. 21 · 88471 Laupheim · Germany

info@rentschler-biopharma.com · www.rentschler-biopharma.com



ProJect Pharmaceuticals GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS



Contact:
Dr. Andreas Schütz

Fraunhoferstr. 22
D-82152 Martinsried
Phone: +49 (0) 89 452289-700
Fax: +49 (0) 89 452289-717
E-Mail: info@project-pharmaceuticals.com
Internet: www.project-pharmaceuticals.com

Keywords: Small Molecules, Peptide/Protein, Antibody, Liposomes, Drug Delivery, Drug Development, Molecules, Vaccines

ProJect Pharmaceuticals transforms all kinds of chemical and biological ingredients into pioneering drugs. We are experts in formulation science and pharmaceutical process development for recombinant proteins, ADCs / cytotoxics and virus vaccines. We design optimized pharmaceutical formulations that provide highest safety levels at maximum convenience. Deviant from prevalent trial & error approaches, we design a quality product and its manufacturing process on a sound scientific rationale pursuant to international guidelines. New safety facilities up to GMO S2 and BSL-2 classification in dedicated labs and a profound understanding of the challenges when formulating and processing live virus vaccines enables PJP to provide specific solutions for this group of highly complex products.

Proteros biostructures GmbH

BIOTECH PRECLINICAL SERVICES



Contact:
Dr. Torsten Neuefeind

Bunsenstr. 7a
D-82152 Martinsried
Phone: +49 (0) 89 700761-0
Fax: +49 (0) 89 700761-15
E-Mail: business@proteros.com
Internet: www.proteros.com

Keywords: Oncology, Metabolic Diseases, Infectious Diseases, Cardiovascular Diseases, Small Molecules, Fine Chemicals/Reagents, 3D-Structural Analysis

Proteros is Europe's largest and most experienced biotechnology company in the field of X-ray protein structure analysis and a leading partner for fully integrated lead discovery. Successful in business since 1998, Proteros collaborates with more than 80 international pharma, biotech and agricultural companies. Proteros services delivers protein crystallography, profiling and screening and tailor-made proteins. Lead discovery combines these unique technologies and medicinal chemistry to generate novel lead compounds for a variety of therapeutically relevant target proteins. Flexible business models, makes Proteros an ideal partner to the Pharmaceutical and Biotech Industry.

PSI CRO Deutschland GmbH

CRO



Contact:

Behringstrasse 7
D-82152 Planegg-Steinkirchen
Phone: +49 (0) 89 89996080
Fax: +49 (0) 89 89996051
Internet: www.psi-cro.com

PSI is a privately-owned, full-service contract research organization (CRO) of 1,600 staff, operating globally. PSI's global reach supports the operations of clinical trials across multiple countries and continents. PSI is known to be highly selective about the work that they pursue. PSI has exceptionally high repeat and referral business rates, while maintaining minimal staff turnover indicative of its commitment to be the best CRO in the world as measured by its customers and its employees. In bi-annual CenterWatch Investigator Surveys of 2015 and 2017 PSI was repeatedly voted Number One Global CRO. Global headquarters are located in Switzerland, the German branch office is in Planegg near Munich.

quattro research GmbH

BIOTECH BIOINFORMATICS

quattro research addresses the needs of life science and chemical industry by providing state-of-the-art solutions to manage all scientific data produced in research projects. Our applications help scientists to optimise the value of their research data, e.g. the electronic lab notebook quattro/LJ or the compound management solution quattro/CM. quattro research offers software and consulting services to build and integrate heterogeneous data sources and applications, such as compound registration, HTS, LIMS or SAP, into efficient and user friendly data management platforms.



Contact:
Dr. Bernhard Schirm

Fraunhoferstraße 18a
D-82152 Martinsried
Phone: +49 (0) 89 990 1629-0
Fax: +49 (0) 89 990 1629-99
E-Mail: info@quattro-research.com
Internet: www.quattro-research.com

RAPID Biomedical GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Oncology, CNS, Cardiovascular Diseases, Bone/Joint Diseases, Devices

RAPID Biomedical GmbH is specialised in RF coils for MRI and NMR spectroscopy. The company collaborates with research institutes, hospitals and MR system manufacturers worldwide. Our products include 1H MR resonators for clinical studies at all magnetic field strengths and for all organs. We also supply multi-nuclear (e.g. 1H / 31P) MR-coils for combined MRI and MRS in clinical and basic science investigations. We offer custom made MR probeheads for routine animal research and various accessory devices. Our recent work concentrates on dual tuned coils and multi array coils for parallel MRI both for human as well as for animal studies. Our sister company RAPID MR International, LLC (www.rapidmri.com), situated in Columbus, Ohio, is contact partner for customers from the United States, Canada and South America.



Contact:
Dr. Florian Odoj

Kettelerstr. 3-11
D-97222 Rimpar
Phone: +49 (0) 9365 8826-43
Fax: +49 (0) 9365 8826-99
E-Mail: info@rapidbiomed.de
Internet: www.rapidbiomed.de

REMARK GmbH

Pharmaservices & Consulting

CRO

Keywords: Drug Development, Medical Writing, Clinical Trial Management and Monitoring, R&D Service

REMARK is a privately owned pharma services and consulting company founded in 1999. Quality and speed are the decisive factors in the success of a company involved in the healthcare market. To reach your goals our business unit Clinical Research offers the following services: - Strategic Consulting - Project Management - Sponsor Representative - Clinical Trial Liaison / Medical Science Liaison - Medical Affairs Services / Medical Writing - Quality Assurance Services Together with our unit Pharma Marketing, REMARK bridges the gap between development and marketing.



Contact:
Dr. Albrecht Pfahler

Bruckmannring 6
D-85764 Oberschleißheim b. München
Phone: +49 (0) 89 5402889 - 50
Fax: +49 (0) 89 5402889 - 60
E-Mail: info@remark-pharma.de
Internet: www.remark-pharma.de

Rigontec GmbH - a MSD Company

BIOTECH THERAPEUTICS & DIAGNOSTICS



Contact:

Am Klopferspitz 19
D-82152 Planegg/Martinsried
E-Mail: info@rigontec.com
Internet: www.rigontec.de

Keywords: Oncology, Immune Therapy, Drug Development

Rigontec is the leader in Retinoic Acid Inducible Gene I (RIG-I) targeting RNA therapeutics. The Company has first mover position in accessing the RIG-I innate immune pathway to pioneer a novel immuno-oncology approach that is designed to achieve immediate and long-term immune system activation specifically against cancer cells. Funded by premier healthcare-focused venture capital and led by an experienced leadership team and Board, Rigontec is focused on actively advancing its innovative pipeline. The first program RGT100 is expected to reach the clinic in early 2017 targeting cancer. The RIG-I pathway represents an essential part of the innate immune system that is usually activated to attack a viral pathogen. Rigontec uses a proprietary advanced RNA-based technology to direct this immune response against a patient's distinct cancer cells, thereby harnessing the body's immune reaction mechanism to efficiently destroy the cancer cells as well as enable long-term immunity against the cancer. In addition to malignant diseases, Rigontec's innovative RNA platform technology has also shown utility for the treatment of infectious diseases further broadening the applicability of this groundbreaking new class of drugs. Founded in 2014, the Company was acquired by Merck Inc. (MSD) in October 2017.

Ritter GmbH

BIOTECH DEVICES & REAGENTS



Contact:

Diplom Wirtschaftsingenieur Michael Fuchs

Kaufbeurer Str. 55
D-86830 Schwabmünchen
Phone: +49 (0) 8232 5003-0
Fax: +49 (0) 8232 5003-48
E-Mail: medical@ritter-online.de
Internet: www.ritter-medical.de

Keywords: Proteomics, Pharmacogenetics, PCR, Genomics, ELISA/EIA, Automation, Devices

Ritter GmbH was founded 1965. The company is established in Schwabmünchen, Bavaria. On 25,000 m² Ritter develops and produces with about 300 employees sterile and non-sterile laboratory equipment, high precision dispensers, tips and plates, certified according to the current DIN EN ISO 9001 and 13485 standards. In more than 50 countries, millions of Ritter medical products are used in clinical and biotechnological applications every day. Products: Robotic Consumables, Liquid Handling, Clinical Products.

Roche Diagnostics GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Peptide/Protein, Antibody, PCR, ELISA/EIA, Automation, Clinical Diagnostics, Drug Development

Roche Diagnostics GmbH is part of Roche, Switzerland, a leader in research focused healthcare with combined strength in pharmaceuticals and diagnostics. Roche is also the world's largest biotech company with medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience and is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. At Penzberg, Roche operates one of the largest biotechnology facilities in Europe for research, development and production of biotechnology based diagnostics and active pharmaceutical ingredients. The portfolio comprises test systems for the life science market, diagnosis, patient stratification and therapy monitoring. Pharma specializes in therapeutic human Proteins with focus on monoclonal antibodies and biomarkers for oncology.



Contact:
Dr. Gabriele Pestlin

Nonnenwald 2
D-82377 Penzberg
Phone: +49 (0) 8856 60-0
Fax: +49 (0) 8856 60-3896
E-Mail: penzberg.allgemein@roche.com
Internet: www.roche.de

R-Pharm Germany GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Pain, Infectious Diseases, CNS, Cardiovascular Diseases, Automation

Since many years, we manufacture and package medicinal products for patients in over 150 countries. Innovative technologies and a highly motivated and skilled team guarantee utmost reliability and quality standards as well as extraordinary value for money. Furthermore, we set ourselves the highest standards in regards to patient safety and customer satisfaction in face-to-face contact with our customers and business partners whenever possible.

We are proud to be able to look back on over 150 years of company history - both as an independent company and within the global production network of Pfizer, Inc. in the past. On October 1, 2014, a new chapter in the successful history of the company was opened. As a reliable contract manufacturer we offer excellent services and capabilities in terms of production and packaging of pharmaceutical and nutritional products.

Both, our state-of-the-art plant, as well as our ambitious services, have received numerous awards, which strengthens our reputation as innovator and „Green Manufacturer“ permanently.

We also offer additional services related to development, scale up, product launch, distribution, analytics and stability, as well as serialization. Together, we are able to master the complex challenge of handling 1.500 Stock Keeping Units (SKUs) split over 6,000 orders each year at a consistently high service level of over 99%.



R-PHARM
Germany GmbH

Contact:

Heinrich-Mack-Str. 35
D-89257 Illertissen
Phone: +49 (0) 7303 12-0
Fax: +49 (0) 7303 12-387
E-Mail: r-pharm-germany@r-pharm.com
Internet: www.r-pharm.com

SanoLiBio GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

SanoLiBio GmbH

Contact:

Walpurgisstraße 4
D-81677 München
Phone: +49 (0) 89 20 333 292
E-Mail: info@sanolibio.com
Internet: www.sanolibio.com

SanoLiBio focuses on automation in circulating tumor cells (CTC) enrichment and analysis for diagnostic standardization. Cost-efficiency, accessibility, scalability, and diagnostic precision drive our innovation. We are perfecting our magnetic bead technology that is based on the negative selection principle for highest and untouched cell recovery and unbiased cell selection. So far, we achieved significant advancement in the field as credited by a peer-reviewed process (Schreier et al. 2017) with ongoing improvements. SanoLiBio's market priority is CTC enrichment, expanding rapidly into cancer therapy support and thrive to pioneer cancer screening for cancer prevention by CTC based liquid biopsy.

Sandoz International GmbH

PHARMA & CHEMICAL INDUSTRY



Eine gesunde Entscheidung

Contact:

Ameet Mallik

Industriestr. 25
D-83607 Holzkirchen
Phone: +49 (0) 8024 476-0
Fax: +49 (0) 8024 476-2599
E-Mail: info.sandoz@sandoz.com
Internet: www.sandoz-biosimilars.com

Sandoz, the generic pharmaceuticals division of Novartis, is a global leader in the generic pharmaceutical sector. Sandoz employs over 26,500 employees across more than 160 countries, offering a broad range of high-quality, affordable products that are no longer protected by patents. With USD 9.2 billion in sales in 2013, Sandoz has a portfolio of approximately 1,100 molecules, and holds the #1 position globally in biosimilars as well as in generic injectables, ophthalmics, dermatology and antibiotics, complemented by leading positions in the cardiovascular, metabolism, central nervous system, pain, gastrointestinal, respiratory, and hormonal therapeutic areas. Sandoz develops, produces, and markets these medicines, as well as active pharmaceutical and biotechnological substances. Nearly half of Sandoz's portfolio is in differentiated products, which are defined as products that are more difficult to scientifically develop and manufacture than standard generics. In addition to strong organic growth since consolidating its generics businesses under the Sandoz brand name in 2003, Sandoz has benefitted from strong growth of its acquisitions, which include Lek (Slovenia), Sabex (Canada), Hexal (Germany), Eon Labs (US), EBWE Pharma (Austria), Oriol Therapeutics (US), and Fougera Pharmaceuticals (US).

Secarna Pharmaceuticals GmbH & Co. KG

BIOTECH THERAPEUTICS & DIAGNOSTICS



Contact:

Am Klopferspitz 19
D-82152 Planegg/Martinsried
Phone: +49 (0) 89 21546375
E-Mail: info@secarna.com
Internet: www.secarna.com

Secarna Pharmaceuticals GmbH & Co. KG ("Secarna") is a biopharmaceutical company based in Munich, Germany. The company has developed a state-of-the-art drug discovery platform, encompassing proprietary bioinformatic systems, screening platforms, as well as advanced in vitro compound characterization assays, focusing on next generation antisense molecules. Currently, Secarna has active pre-clinical programs in a range of indications including immuno-oncology, immunology, and anti-virals. Our strategy is to leverage our drug discovery platform to develop disruptive and highly differentiated therapeutics, also with industry partners.

Securetec Detektions-Systeme AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Analytical Chemistry, R&D Service, In-Vitro-Diagnostics, Infectious Diseases, Antibody, Toxicology, Small Molecules

Established in 1995, Securetec Detektions-Systeme AG provides leading edge technologies to facilitate detection of drugs, explosives, and other hazardous substances. By close cooperation with its customers Securetec understands the specific demands of traffic safety, customs, and drug enforcement authorities across the globe. Securetec's competencies cover tailor-made development and production of immunological test solutions reflecting in highly reliable products for day-to-day use. The specific technologies are successfully employed across a multitude of rapid identification applications of drugs and hazardous substances. We detect to protect - Securetec is proud to play a part in making today's world a safer one.



Contact: Dr. Torsten Stadthagen

Lilienthalstr. 7
D-85579 Neubiberg
Phone: +49 (0) 89 2030 8016-51
Fax: +49 (0) 89 2030 8016-52
E-Mail: info@securetec.net
Internet: www.securetec.net

Sension GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, ELISA/EIA, Autoimmune Diseases, Antibody

Sension develops immunoassays and rapid test systems for on-site analysis. The tests find broad applications in the fields of food analysis, environmental analysis, medical diagnostics, reproductive management in agriculture, and in the monitoring of samples for mold. Also technologies for label production to prevent products from counterfeiting are realized. Sension is realizing own product developments, but also performs R&D developments for partners and customers and specifically focus on the specific needs required.



Biologische Detektions- und Schnelltestsysteme

Contact:
Dr. Marcus Meyr

Provinostr. 52, Gebäude B14
D-86153 Augsburg
Phone: +49 (0) 821 455799-0
Fax: +49 (0) 821 455799-22
E-Mail: info@sension.eu
Internet: www.sension.eu

SequiServe GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Sequiserve offers the following custom services in molecular biology: Sanger-DNA-sequencing (plasmids, PCR-products, BACs, PACs, primer-walking, direkt sequencing of bacterial pellets). Purification of PCR products and Plamid-DNA preparation for subsequent sequencing. Sequiserve - your expert in DNA-sequencing since 1994!



Contact:
Eva Metzger

Joh.-Seb.-Bach-Str. 7
D-85591 Vaterstetten
Phone: +49 (0) 8106 8887
Fax: +49 (0) 8106 301565
E-Mail: service@sequiserve.de
Internet: www.sequiserve.de

SERVIER Deutschland GmbH

PHARMA & CHEMICAL INDUSTRY



Contact:
Arnd Prilipp

Elsenheimerstr. 53
D-80687 München
Phone: +49 (0) 89 57095-01
Fax: +49 (0) 89 57095-126
E-Mail: info@de.netgrs.com
Internet: www.servier.de

Keywords: CNS, Cardiovascular Diseases, Drug Development

Servier is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Suresnes). With a strong international presence in 148 countries and a turnover of 4.152 billion euros in 2017, Servier employs 21,600 people worldwide. Entirely independent, the Group reinvests 25% of its turnover (excluding generic drugs) in research and development and uses all its profits for development. Corporate growth is driven by Servier's constant search for innovation in five areas of excellence: cardiovascular, immune-inflammatory and neuropsychiatric diseases, cancers and diabetes, as well as by its activities in high-quality generic drugs. The German branch has been founded in 1996 in Munich. The products marketed in Germany range from cardiovascular, neuropsychiatric diseases to cancers.

Sigma-Aldrich Chemie GmbH

BIOTECH DEVICES & REAGENTS

SIGMA-ALDRICH®

Contact:
Dr. Udo Sticher

Eschenstr. 5
D-82024 Taufkirchen
Phone: +49 (0) 89 6513-0
Fax: +49 (0) 89 6513-1169
E-Mail: deorders@sial.com
Internet: www.sigma-aldrich.com

Keywords: Proteomics, Antibody, Genomics, CNS, Small Molecules, Knock Out, PCR

Sigma-Aldrich is a leading Life Science and High Technology company. Our biochemical and organic chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical and other high technology manufacturing. We have customers in life science companies, university and government institutions, hospitals and in industry. Sigma-Aldrich operates in 36 countries and has over 7,600 employees providing excellent service worldwide.

SiNatur GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS



Contact:
Dr. Franz Kerek

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 856625-55
Fax: +49 (0) 89 856625-56
E-Mail: info@sinatur.net
Internet: www.sinatur.net

Keywords: Metabolic Diseases, Diabetics

SiNatur owns the patent rights for the structure, preparation and medicinal applications Sub-Nano-Silicic Acid (SNSA). This recently discovered SNSA is the first biologically active form of silicic acid and of silicon generally. The substance is a potent inhibitor of P-type ATPases and of certain Protein-Phosphatases with IC50 in the nanomolar range. Due to the ubiquitous presence of Si in living organisms the discovery of the first biological active form of this element will have a broad scientific and practical impact. SiNatur is developing medicinal applications of SNSA first of all in the therapy of diabetes and of gastric hyperacidity.

SIRION BIOTECH GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Gene Transfer, Drug Development, Drug Delivery, Knock Out, RNAi & Antisense

SIRION Biotech was founded in 2006 in Munich. It stands for sophisticated custom virus engineering that caters to academic groups as well as the industrial gene-therapy and immune-oncology markets. All major virus systems, AAV - Lentivirus - Adenovirus, can be fully customized to the specific goals of the customer to optimize their vector strategies and increase their success in pre-clinical and clinical applications. SIRION Biotech technology has been validated in more than 250 projects with more academic and industrial organizations worldwide. Commercial arrangements range from fee-for-service over exclusive rights on specific developments, all the way to milestone & licensing arrangements. The latter are suited for longer term complex product developments in the areas of gene therapy, immune-oncology and vaccines. Molecular biologists experienced in the field stand ready for a personal project discussion.



Contact:
Dr. Christian Thirion

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 700961-999
Fax: +49 (0) 89 700961-998
E-Mail: info@sirion-biotech.de
Internet: www.sirion-biotech.com

siTOOLS Biotech GmbH

BIOTECH DEVICES & REAGENTS

siTools Biotech is a young, innovative Biotech start-up dedicated to provide innovative and superior RNAi reagents to the scientific community. siTools Biotech is located at Munich's biotech cluster in Planegg/Martinsried. "siPools" are highly complex but accurately defined pools of siRNAs. They enable highly efficient and reliable target gene silencing without detectable off-target effects.



Contact:

Lochhamer Straße 29 a
D-82152 Planegg
Phone: +49 (0) 89 4431 2584
E-Mail: info@sitoolsbiotech.com
Internet: www.sitoolsbiotech.com

SMARTEC IngenieurBüro

BIOTECH DEVICES & REAGENTS

Keywords: Devices, Automation, Chip/Array Technology, PCR, Tissue Engineering/Cell Culture

Smartec IngenieurBüro is your competent partner for individual system approaches and instrument development in the biological laboratory. Smartec IngenieurBüro convinces with know-how within the ranges biotechnology, analytics, genetic engineering, micro technology as well as micro fluidic. Smartec IngenieurBüro solves tasks of instrumentation for molecular and immunological process engineering. Smartec IngenieurBüro supports you from the idea to all stages of the product. Smartec IngenieurBüro offers complete solutions, consisting of mechanics, optics, electronics, as well as firm- and software from a single source. Smartec IngenieurBüro consists of engineers and physicists which are predominantly settled in the ranges Research and Development (R&D) of bioanalytic systems



Contact:
Ulrich Schubert

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 854 665-13
Fax: +49 (0) 89 854 665-15
E-Mail: ulrichschubert@smartecbio.de
Internet: www.smartecbio.de

Sourcia.

Contact:

Lochhamer Strasse 31
D-82152 Martinsried
Phone: +49 (0) 151 74403195
Internet: www.sourcia.eu

Sourcia

CRO

Keywords: Pharmacovigilance, Regulatory Affairs, Drug Development, Clinical Trial Management and Monitoring, R&D Service, Devices

Sourcia is your high-experienced, flexible and independent partner in clinical development. While you are focusing on sciences, we are your partner in project management, operational set-up and execution of your Clinical Development Plan.



Contact:

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 540 4134-0
Fax: +49 (0) 89 540 4134-20
E-Mail: info@spherotec.com
Internet: www.spherotec.com

Spherotec GmbH

BIOTECH PRECLINICAL SERVICES

Keywords: Drug Development, Oncology, Tissue Engineering/Cell Culture

Spherotec is a biotech company using 3D cell-culture systems that have similar properties to microtumors in cancer patients. On this basis, Spherotec offers pharmaceutical and biotech companies the opportunity to conduct functional tests of drug candidates for oncology in close to real conditions. This permits the early identification of promising substances and gives a broad profile of the effects of substances. The process also allows the definition of the kinds of tumors for which a substance or a combination of substances has the best clinical efficacy.



INTERNATIONAL CLINICAL RESEARCH

Contact:

Dr. Michael Sigmund

Landsberger Str. 23/25
D-82110 Germering
Phone: +49 (0) 89 800 650-0
Fax: +49 (0) 89 800 650-555
E-Mail: info@cro-sss.de
Internet: www.cro-sss.eu

SSS International Clinical Research GmbH

CRO

Keywords: Medical Writing, Respiratory Diseases, Oncology, Cardiovascular Diseases, Hematology

SSS International Clinical Research is a Functional Service Provider for the pharmaceutical, biotechnological and medical device industry since 1993, with headquarter in Germany and subsidiaries in Romania, Poland and UK. We provide cost-effective, high quality, comprehensive and internationally integrated Clinical Operations Services throughout Europe. Our services have been proven for nearly 20 years and through many successful projects. The services include feasibility surveys in European countries, regulatory document preparation and submissions, site identification and initiation, investigator contract negotiations, clinical trials management, monitoring, and quality assurance. Our indication focus in the past years has lied on Oncology, Neurology, Nephrology, and Pulmonology. Due to our long standing partnerships we have deep insights into the potentials of many possible study sites in these areas.

Staburo GmbH – Statistical Consulting

CRO

Keywords: Data Management and Biostatistics, Infectious Diseases, Dermatology, Oncology, Cardiovascular Diseases, Informatics

We are a biostatistics company based in Munich and are specialized in statistical consulting for clinical trials. We process your projects on a flexible basis according to your demands. Thereby your company benefits from our expertise in complex statistical questions (e.g. crossover studies in oncology). Our firm has profound knowledge in SAS programming for clinical studies - of course in compliance with ICH-GCP standards. Furthermore, we can organize statistics workshops to train your staff in statistical analysis tools (SAS, R).



Contact:
Hannes Buchner

Aschauer Str. 30a
D-81549 München
Phone: +49 (0) 89 5527 1520
E-Mail: info@staburo.de
Internet: www.staburo.de

SÜD-LABORBEDARF GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Devices

SLG is a German whole seller for molecular biology research consumables, located in Gauting near Munich since 1980. Our main business is high quality consumables such as gloves, liquid handling products, DNA/RNA kits and plastic ware like racks and cryo boxes. We sell by direct mail to Germany, Austria and Switzerland and through distributors in various European Union countries under our own brands SLG, SafeGrip, SL-Tip, SL-Pette and Hi Yield.



Contact:
Fabian Schuler

Sternberger Str. 22
D-82131 Gauting
Phone: +49 (0) 89 850 6527
Fax: +49 (0) 89 850 7646
E-Mail: info@suedlabor.de
Internet: www.suedlabor.de

Swedish Orphan Biovitrum GmbH, SOBI

BIOTECH THERAPEUTICS & DIAGNOSTICS

Swedish Orphan Biovitrum is an international company specializing in rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of these patients and their families. The Swedish Orphan Biovitrum GmbH (Sobi) has been active in Germany since 2017. The company is based in Martinsried, Bavaria. Behind the success of Sobi are the nearly 40 employees in Germany whose daily motivation is to help improve the lives of patients with rare diseases.



Contact:

Fraunhoferstr. 9a
82152 Martinsried
Phone: +49 (0) 89 550 66 760
E-Mail: mail.de@sobi.com
Internet: www.sobi.com

Syntacoll

Contact:
Dr. Alexandra Dietrich

Donaustr. 24
D-93342 Saal/Donau
Phone: +49 (0) 9441 6860-0
Fax: +49 (0) 9441 6860-30
E-Mail: info@syntacoll.de
Internet: www.innocoll.de

Syntacoll GmbH

PHARMA & CHEMICAL INDUSTRY

Syntacoll is the manufacturing division of Innocoll, Inc. and produces clinical supply or commercial product to its marketing partners and to Innocoll's two other divisions, Innocoll Technologies and Innocoll Pharmaceuticals. Using proprietary manufacturing processes, Syntacoll converts raw collagen material and incorporates medicinal compounds yielding finished pharmaceutical product in the form of a sponge or membrane. This system forms the basis of Innocoll's lead collagen-based technology, CollaRx. The sponge or membrane product format is a unique way to locally deliver a wide variety of medicinal compounds and is fully biodegradable and resorbable. The sponge and the membrane formats can be implanted at the time of surgery or applied topically to a chronic, acute or traumatic wound. Delivering drug locally to the site of action has a number of benefits, including the safe delivery of higher doses than could be achieved through systemic routes and avoidance of systemic side effects.

SynteractHCR Deutschland GmbH



Contact:

Albrechtstr. 14
D-80636 München
Phone: +49 (0) 89 126680-0
Fax: +49 (0) 89 126680-2444
Internet: www.synteracthcr.com

CRO

Keywords: [Cardiovascular Diseases](#), [CNS](#), [Metabolic Diseases](#), [Nephrology](#), [Oncology](#), [Pain](#)

Harrison Clinical Research has been an independent ISO 9001 certified CRO founded in 1987 in Munich with offices in UK, Belgium, Israel, Spain, Italy, France, Austria, Poland, Ukraine, Russia, USA and partners in Asia and Australia.

Apart from conduct of standard Phase I studies, our Phase I/IIa clinic is specialised on proof-of-concept studies in special patient populations and efficacy studies in various indications.

SynteractHCR is a multinational clinical research organization, formed from the merger of Synteract with Harrison Clinical Research in 2013, which provides global, full-service clinical trial services. We have more than two decades of experience supporting biopharma companies in all phases of clinical development across multiple therapeutic areas. We customize programs that will deliver timely, high quality data to help you get to decision points faster, taking time and cost out of drug development.

We deliver trials internationally. SynteractHCR has run trials in more than 60 countries across the globe, offering our clients strong international and regional clinical trial support throughout the world. Our geographic footprint extends from North America to Europe, and has an emerging presence in South America. We have a diverse, talented team of clinical development professionals.

Synlab Holding GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Laboratory, Bioanalytics, In-Vitro-Diagnostics

The combination of Labco and synlab has made the new SYNLAB Group the market leader in laboratory services in Europe. Combining the Europe-wide network and extensive range of diagnostic tests of both companies, SYNLAB now offers reliable and local laboratory services in more than 30 countries. SYNLAB particularly focuses on the implementation of innovative laboratory medicine methods and on networking specialist diagnostic competences (SYNLAB Centres of Excellence). SYNLAB maintains additional laboratories (strategic business units) in individual countries for veterinary medicine and environmental analysis. This services portfolio is rounded off by expert medical imaging centres in certain countries. The group works closely with research institutions and universities and also maintains an educational institution of its own, the SYNLAB Academy.



Contact:

Gubener Str. 39
D-86156 Augsburg
Phone: +49 (0) 821 521570
Internet: www.synlab.de/de/home/



Life Sciences and Pharmaceutical Law

Along the years, we consistently expanded our industry focus on the Life Science sector as well as on pharmaceutical law, with success:

“Strong position in the Life Science industry”

JUVE-Handbuch 2016/2017

“In the health sector, the focus on the industry initiated a few years ago is increasingly paying dividends.”

JUVE-Handbuch 2015/2016

RITTERSHAUS
RECHTSANWÄLTE

RITTERSHAUS Rechtsanwälte
Partnerschaftsgesellschaft mbB

OFFICE MÜNCHEN

Maximiliansplatz 10, 80333 München
Tel.: +49 (0)89 1214 05-0
Email: muc@rittershaus.net

OFFICE MANNHEIM

Harrlachweg 4, 68163 Mannheim
Tel.: +49 (0)621 4256-0
Email: ma@rittershaus.net

OFFICE FRANKFURT

Mainzer Landstr. 61, 60329 Frankfurt
Tel.: +49 (0)69 27 40 40-0
Email: ffm@rittershaus.net

www.rittershaus.net



Systasy Bioscience GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS



Contact:

Adams-Lehmann-Str. 56
D-80797 München
Phone: + 49 (0) 89 2155 3085
Fax: + 49 (0) 89 44005 5853
E-Mail: info@systasy.de
Internet: www.systasy.de

Keywords: R&D Service, Biomarker Discovery & Development, CNS, Personalized Medicine, Small Molecules, Drug Development

Systasy Bioscience GmbH, a growing start-up company founded 2012 in Munich, provides cost-effective and highly innovative solutions for the pharmaceutical industry to address critical and unmet medical needs. Systasy's products and services are ranging from the analysis of cellular target activities and specificities up to the simultaneous analysis of multiple signaling pathways in living cells. Products and services are based on Systasy's proprietary splitSENSOR and EXTassay technologies. Systasy takes advantage of their EXTassay technology to deliver profile analyses for a multitude of simultaneously occurring cellular events to customers. Thus, Systasy's services and products are designed to match customers needs in the early phases of drug discovery and personalized medicine.

T-CURX GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS



Contact:

Friedrich-Bergius-Ring 15
D-97076 Würzburg
E-Mail: info@t-curx.com
Internet: www.t-curx.com

T-CURX develops new generation UltraModularCARTM T cells for personalized cancer immunotherapy, built on cutting-edge technologies that overcome challenges in safety & efficacy, manufacture & scalability of conventional CAR-T. T-CURX's UltraModularCARTM T cells are a transformative, one-shot, chemotherapy-free cancer treatment. Patient T cells are reprogrammed using revolutionary gene transfer technology to destroy tumor cells. UltraModularCARTM T cells are living drugs that persist life-long and provide protection from relapse. T-CURX's target pipeline addresses several unique cancer indications. The lead product is targeting breast and lung cancer (oncology), chronic leukemia and mantle cell lymphoma (hematology). T-CURX has a solid IP portfolio on its platform technologies, established manufacturing capability and positive reviews from regulators, enabling rapid progress towards initiation of clinical POC studies.

TESARO Bio GERMANY GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS



Contact:

Leopoldstraße 23
D-80802 München
Phone: +49 (089) 24442-3074
E-Mail: kontakt-Deutschland@tesarobio.com
Internet: www.tesarobio.de/de/kontakt

TESARO is a biopharmaceutical company devoted to providing transformative therapies to people bravely facing cancer. We see new possibilities to responsibly develop and commercialize innovative treatments where others may not.

Therawis Pharma / Diagnostics GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Oncology, In-Vitro-Diagnostics

Therawis Diagnostics GmbH is a privately held oncology-focused company with offices located in Munich, Germany, and was founded together with clinicians and scientists of the Technical University of Munich in September 2015. Therawis Diagnostics GmbH develops and aims at to commercialize a comprehensive portfolio of predictive diagnostics to guide the optimal therapy for breast cancer patients. These predictive assays will help to address unmet medical needs and major challenges in breast cancer therapy: To predict whether a patient will respond to standard-of-care systemic cancer therapy and if not to switch to an alternative cancer treatment option

Therawis
Pharma | Diagnostics

Contact:

Grillparzerstrasse 14
D-81675 München
Internet: www.therawis.com

Thermo Fisher Scientific GENEART GmbH

BIOTECH

Keywords: Genomics, Combinatorics

Since entering the Gene Synthesis market in 2000 GeneArt has established as the global market leader. GeneArt provides key technologies for Synthetic Biology projects for example for the construction of bacteria which produce complex biopolymers such as biofuels or organisms which degrade environmental toxins. Furthermore the company contributes key technologies necessary to develop and produce new therapeutics and vaccines. Customers also rely on GeneArt services to improve enzymes, such as the ones used as additives in detergents. GeneArt was awarded the worldwide largest gene synthesis contract for the completion of the „Mammalian Gene Collection (MGC) Program“ by the U.S. National Institutes of Health (NIH). In addition, GeneArt produced subgenomic elements for the construction of the first synthetic bacterial genome by the J. Craig Venter Institute. GENEART provides the key technologies for the development and production of new medicines, services for the improvement of proteins (e.g. industrial enzymes, antibodies) or to construct cells for complex biological processes (e.g. bio-factories for the production or degradation of (bio-)polymers). The Regensburg location is now part of Thermo Fisher Scientific Inc, the world leader in serving science, with revenues of \$17 billion and 50,000 employees in 50 countries.

ThermoFisher
SCIENTIFIC

Contact:

Dr. Marcus Graf

Im Gewerbepark B35
D-93059 Regensburg
Phone: +49 (0) 941 94276-0
Fax: +49 (0) 941 94276-711
E-Mail: geneart.info@lifetech.com
Internet: www.thermofisher.com



Contact:
Dr. Pascal Schweizer

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 7167 760-31
Fax: +49 (0) 89 7167 760-49
E-Mail: info@thermosome.com
Internet: www.thermosome.com

Thermosome GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Oncology, Liposomes, Small Molecules, Drug Development, Drug Delivery

Thermosome® is leveraging its proprietary drug delivery technology platform to create products with improved therapeutic index that exploit a novel MoA called intravascular drug release. Through its TSL technology, drug-loaded nanocarriers („Thermosomes“) are created which after i.v. infusion release their content locally upon the influence of mild heat of 40-42°C achieved by various clinically established targeted heating techniques such as microwave or ultrasound. Thus, up to 15 fold higher local drug concentrations can be reached while simultaneously markedly reducing systemic exposure and potentially associated side effects. Our lead candidate is a formulation of a potent, but highly toxic chemotherapeutic agent and is envisioned to enter a FiH study in locally-advanced solid tumors.

tilibit nanosystems GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Nanobiotechnology, New Materials, R&D Service



Contact:
Jean-Philippe Sobczak

Lichtenbergstraße 8
D-85748 Garching
E-Mail: info@tilibit.com
Internet: www.tilibit.com

tilibit nanosystems specializes in the development and fabrication of nanostructures using the DNA origami method. This technology allows building discrete objects with user-defined shapes and mechanical properties on the scale of 10 to 1000 nanometers molecule by molecule from the bottom-up. User-defined chemical and mechanical features can be positioned with near-atomic control, and nanostructures can be assembled into macroscopic materials with novel mechanical or optical properties. Because of these capabilities, DNA origami is an enabling technology that creates novel and unparalleled opportunities toward the construction of „bionano“ products that promise tremendous technological progress. Tilibit nanosystems can design, assemble, purify, and characterize a fully customized nanostructure according to your specifications.

TILL I.D. GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Automation, Microscopy, Imaging, 3D-Structural Analysis

TILL I.D. GmbH is a small company at the interface of research and industry. We develop innovative concepts for light microscopy. Our aim is to take the microscope from the 19th into the 21st century by applying a scalable embedded approach rather than a modular one. Our inspiration is the smart-phone, which can be differentiated into a variety of application-specific tools (apps). Our microscopes are platforms with a common design but the flexibility to combine different imaging techniques and light sources. The idea to build an intelligent, user-friendly microscope persists not only in the microscopes hardware, but also in our newly developed software. The prototypes are validated through our partners in the field of life science and medicine, and innovative solutions are licensed to our industrial partners.



Contact: Dr. Carolina Glas

Am Klopferspitz 19
D-82152 Planegg/Martinsried
Phone: +49 (0) 89 2032 4142 20
Fax: +49 (0) 89 2032 4142 90
E-Mail: info@till-id.com
Internet: www.till-id.com

TopLab GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Proteomics

TOPLAB GmbH is a leading ISO 9001 certified service provider with high end research facilities for proteomics, protein analytics, target and biomarker discovery and validation. The company has outstanding expertise in proteome analysis, protein identification and characterisation with more than 15 years experience. A portfolio of proprietary technologies has been developed and/or licensed that is able to significantly enhance the rate of discovery of potential biomarkers and novel therapeutic targets. The vision of TOPLAB is to support our clients from pharma, biotech and academia with highest quality standards, modern technologies and an experienced and highly motivated team, to achieve confident results in compliance with the timelines of our customers with calculable costs.



Contact:
Dr. Elfriede Müller

Fraunhoferstr. 18 a
D-82152 Martinsried
Phone: +49 (0) 89 2441 45412-81
Fax: +49 (0) 89 2441 45412-86
E-Mail: info@toplab.de
Internet: www.toplab.de

TRIGA-S e.K. Scientific Support



Contact:
Dr. Yannick Böge

Mühlthal 5
D-82392 Habach
Phone: +49 (0) 8847 695 78 0
Fax: +49 (0) 8847 695 78 29

E-Mail: info@triga-s.de
Internet: www.triga-s.de

CRO

Keywords: Other Diagnostics, Logistics, Molecular Diagnostics, Clinical Trial Management and Monitoring, In-Vitro-Diagnostics

TRIGA-S Scientific Support is a Clinical Research Organization for planning and conducting clinical and technical studies phase I-IV in the In-Vitro-Diagnostics (IVD) and medical device industry. During the past 20 years, TRIGA-S supported more than 50 clinical and technical studies worldwide, including >300 sites and >60,000 patients, in accordance to ICH-GCP, international and local guidelines. TRIGA-S provides service as contract laboratory and testing site for serum and body fluids based clinical chemistry, immunology or further IVD applications, including organization and preparation of samples for technical reviews. Our services: study management/ monitoring, data management, contract laboratory, testing site, sample management/ storage/ preparation, logistics.

TRION Research GmbH



Contact:
Dr. Horst Lindhofer

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 700 766-0
Fax: +49 (0) 89 700 766-11
E-Mail: mail@trionresearch.de
Internet: www.trionresearch.com

BIOTECH PRECLINICAL SERVICES

Keywords: Drug Development, Immune Therapy, Antibody Production Service

TRION Research GmbH, founded in 1998, is a Biotech research company and a strategic partner of TRION Pharma GmbH focusing on the generation of novel Triomab[®] antibody candidates and the support of non-clinical and clinical development of Triomab[®] antibodies. The company offers Immunomonitoring Service, special antibody conjugation support, additional analytical service in tumor biology and further analytical support for reagent control to investigators, study sponsors and CROs. TRION Research is ISO 9001:2008 certified. The core competences of the company are:

- Immunomonitoring and logistical support for clinical and non-clinical studies
- Supply of purified antibodies (labeled and unlabeled)
- Development of immunological assays

UGISense AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: RNAi & Antisense

UGISense AG is a biotech company dedicated to developing new and innovative antisense therapeutic agents in collaboration with partners from the industry and academia. The developments are made on the basis of a proprietary platform technology, i.e. the Ugimeres[™].

UGISense

Contact:

Residenzstr. 18
D-80333 München
Internet: www.ugisense.com

UroQuant GmbH

BIOTECH

Transforming Cancer Diagnostics Using protein biomarkers, UROQUANT will revolutionise diagnostics. The first product, UROQUANT BC for diagnosing bladder cancer directly from urine will be established as novel gold standard for routine cancer patient care. UROQUANT BC is based on a defined protein expression pattern indicative for bladder cancer. Quantitative mass spectrometry analysis of a multimarker protein panel that is highly specific for BC diagnostics enables fast and robust diagnosis of BC. The multi-combinatorial power of the individual protein biomarkers significantly enhances sensitivity and specificity making UROQUANT BC a superior diagnostic standard in clinical routine.



Contact:

Industriestr. 1
DE-93077 Bad Abbach
Phone: +49 (0) 9405 96 999 10
Fax: +49 (0) 9405 96 999 28
E-Mail: www.uroquant.com
Internet: bcdiagnostics@uroquant.com

vasopharm GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

vasopharm is a pharmaceutical company dedicated to the discovery and development of novel therapeutics for the treatment of cerebro- and cardiovascular diseases and their consequences. The company is focused on the development of therapeutics which permits steering the bioavailability of biological NO, covering the entire NO/cGMP signal cascade and its functional counterpart NOX. vasopharm's drug candidate VAS203 represents a completely new class of NOS modulators targeting cerebral vessels and cerebral tissue, thus preventing life threatening rises in intracranial pressure after a traumatic brain injury.



Contact:

Christian Wandersee

Friedrich-Bergius-Ring 15
D-97076 Würzburg
Phone: +49 (0) 931 359099-0
Fax: +49 (0) 931 359099-12
E-Mail: office@vasopharm.com
Internet: www.vasopharm.com

Vectura GmbH

MEDTECH

Keywords: Inflammation, Respiratory Diseases, Infectious Diseases, Small Molecules, Peptide/Protein, Devices, Drug Delivery

Vectura, a FTSE250 company listed on the London Stock Exchange (LSE: VEC), is an industry-leading inhaled airways disease focused business with proprietary formulation and devices across DPI, pMDI and smart nebulisation platforms. With our extensive range of technologies, capabilities and collaborations, we believe we can become a leader in the development of inhalation products, increasing our ability to help patients suffering from respiratory diseases. In June 2016 Vectura completed a merger with Skyepharma PLC. Vectura has seven inhaled, four non-inhaled and ten oral products marketed by partners with growing global royalty streams, and a portfolio of drugs in clinical development, a number of which have licence agreements with several global pharmaceutical and biotechnology companies including Hikma, Novartis, Sandoz, Mundipharma, Kyorin, Baxter, GSK, UCB, Ablynx, Grifols, Chiesi, Almirall, Janssen, and Tianjin KingYork.



Contact:

Bernhard Müllinger

Robert-Koch-Allee 29
D-82131 Gauting
Phone: +49 (0) 89 897969-0
Fax: +49 (0) 89 897969-22
E-Mail: info@vectura.com
Internet: www.vectura.com



Contact:
Barbara Brandlhuber

Emmy-Noether-Str. 2
D-80992 München
Phone: +49 (0) 89 15882-0
Fax: +49 (0) 89 15882-100
E-Mail: info@vermicon.com
Internet: www.vermicon.com

vermicon AG

BIOTECH AGRO, FOOD, ENVIRONMENT

vermicon is an innovative and international solutions provider for microbiology. Having its roots in the original development of FISH, the company can now look back on two decades of expertise. The development of VIT® (vermicon identification technology) made FISH accessible not only for academic research but also for every industrial microbiologist or anyone relying on microbiology in their decisions. vermicon's highly qualified team of experts and its powerful technology portfolio enables the company to meet even complex microbiological challenges. Their philosophy states that only cultivation-independent methods allow real insights into microbiology. With satisfied customers worldwide, vermicon creates impressive solutions and is actively driving the evolution of modern microbiology.



Contact:

Wohraer Str. 37
D-35285 Gemünden/Wohra
Phone: +49 (0) 6453 58530 40
Fax: +49 (0) 6453 58530 50
Internet: www.ventaleon.de

Ventaleon GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Infectious Diseases, Drug Delivery

Ventaleon is developing inhaled treatments against viral infections. The Company's lead therapy, is an inhaled LASAG (D,L-lysine acetylsalicylate glycine), a lysin-salt formulation of well-known acetyl salicylic acid (Aspirin®), suitable as an ingredient for inhalable aerosol, has completed Phase II clinical trials to treat severe influenza. A proof-of-concept study in influenza patients with moderate to severe symptoms demonstrated more rapid symptom decline when administered via inhaled LASAG compared to standard of care. The Company is currently preparing to enter a pivotal clinical trial with inhaled LASAG. Ventaleon was founded as a spin-off from Activaero, a leading specialist in aerosol inhalation therapies and technologies, in 2012.



Contact:
PD Dr. Fritz Thümmeler

Lise-Meitner-Str. 30
D-85354 Freising-Weihenstephan
Phone: +49 (0) 8161 18516-11
Fax: +49 (0) 8161 18516-12
E-Mail: info@vertis-biotech.com
Internet: www.vertis-biotech.com

vertis Biotechnologie AG

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: PCR, NGS, Informatics, Genomics

VERTIS was established in 2000 as a spin off from Technical University Munich-Weihenstephan, Germany. The company offers molecular biology services in the field of functional genomics with focus on Next Generation Sequencing (NGS) especially on transcriptome sequencing (RNA-seq). The company offers a complete product line, ranging from project consulting, nucleic acid isolation, sample preparation and DNA sequencing to bioinformatic sequence analysis and data mining. The strength of the VERTIS is customer-oriented flexibility, which is based on an innovative technology platform, the company has developed in its 13-year history. VERTIS is a pioneer in the analysis of small non coding RNAs (sncRNA) and of bacterial transcriptomes.

verum.de GmbH

CRO

Keywords: Cardiovascular Diseases, CNS, Dermatology, Diabetics, Oncology, Respiratory Diseases

Verum has been the first Western-Standard CRO specializing in CEE countries, operations starting in 1992. Our core business and key competence is Full Clinical Service for Phase II-IV in CEE countries. Our team consists of about 100 experts that share our experience of more than 120 trials with some 35,000 patients in indications like cardiovascular, neurology, psychiatry, pain, CNS-diseases and oncology. With offices from Eastern Europe to the US we are pooled for the success of our trials.



Contact:
Christian Sacher

Sembdnerstr. 5
D-82110 Germering
Phone: +49 (0) 89 800777-60
Fax: +49 (0) 89 800777-88
E-Mail: verum@verum.de
Internet: www.verum.de

Viramed Biotech AG

BIOTECH DEVICES & REAGENTS

Keywords: Clinical Diagnostics, ELISA/EIA, Infectious Diseases

Based on 20 successful years on the German IVD-Market, Viramed Biotech AG produces and markets IVD-Products, based on its proprietary research and development. The company focuses on Westernblot-, Stripe- and Elisa-test kits for serological screening and confirmation of infectious and autoimmune diseases. The major products are Westernblot tests for Borrelia sp., Yersinia, Helicobacter p., Epstein-Barr-Virus, Bordetella pertussis, ENA and autoimmune liver diseases. New analytics based on purified and recombinant antigens are under development. The development of antigens and test kits for specific analytics are offered as service. The company aims to intensify export of existing products worldwide and appreciates further distribution contacts.



Contact:
Dr. Ludwig Furtmayr

Behringstr. 11
D-82152 Planegg-Steinkirchen
Phone: +49 (0) 89 899336
Fax: +49 (0) 89 8599949
E-Mail: viramed@viramed.de
Internet: www.viramed.de

Vertex Pharmaceuticals (Germany) GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases. In addition to clinical development programs in CF, Vertex has more than a dozen ongoing research programs focused on the underlying mechanisms of other serious diseases. Founded in 1989 in Cambridge, Mass., Vertex's headquarters is now located in Boston's Innovation District. Today, the company has research and development sites and commercial offices in the United States, Europe (incl. Munich/Germany), Canada and Australia. Vertex is consistently recognized as one of the industry's top places to work, including being named to Science magazine's Top Employers in the life sciences ranking for eight years in a row.



Contact:

Sonnenstr. 19/Geb. 2, 2nd floor
D-80331 München
Phone: +49 (0) 89 20602-9900
Fax: +49 (0) 89 20602-9907
Internet: www.cftr-info.de/content/vertex

vivoPharm Europe Ltd, a CGI company



Contact:
Dr. Melanie Keller

Grillparzerstr. 25
D-81675 München
Phone: + 49 (0) 89 122 287 6-90
Fax: + 49 (0) 89 122 287 6-99
E-Mail: info@vivopharm.eu
Internet: www.vivoPharm.com

CRO

Keywords: Bioanalytics, In-Vitro-Diagnostics, Pharmacokinetics, Oncology, Drug Development, Pharmacology, Toxicology

vivoPharm, a CGI company (NASDAQ:CGIX) is a successful and fast-growing precision research organization (CRO) that provides integrated preclinical services from bench to bedside (and back) worldwide. Using our experience and knowledge, we assist in the planning and performance of tailored studies, from discovery stage through to clinical development and beyond. We're a unique IO precision service organization, active in preclinical and clinical services. All work is carried out under well-defined standard operating procedures (SOPs) by highly qualified technicians in state-of-the-art laboratories in seven locations with AAALAC accredited and GLP compliant audited facilities in Australia and the US, as well as CLIA certified and CAP accredited facilities in the US.

Wacker Chemie AG



Contact:
Rachela Mohr

Hanns-Seidel-Platz 4
D-81737 München
Phone: +49 (0) 89 6279-0
Fax: +49 (0) 89 6279-1770
E-Mail: info@wacker.com
Internet: www.wacker.com

PHARMA & CHEMICAL INDUSTRY

Keywords: Fine Chemicals/Reagents, Antibody Production Service, Peptide/Protein, CRO/CMO, Nutraceuticals

WACKER is a globally active chemical company headquartered in Munich, Germany. With a wide range of state-of-the-art specialty products, WACKER is a leader in numerous industrial sectors. Its products are required in countless high-growth end-user sectors such as photovoltaics, electronics, pharmaceuticals and household/personal care products. Within its bio division, WACKER uses advanced biotech processes to offer innovative and tailored solutions and biotech products for the pharma and the food & nutrition industry. Its products include pharmaceutical proteins, cyclodextrins and fermentation-grade cysteine. The division focuses on developing customized solutions for growth sectors such as food additives and pharmaceutical actives.

Winicker Norimed GmbH Medizinische Forschung



Contact:
Jens Winicker

Deuschherrnstr. 15-19
D-90429 Nürnberg
Phone: +49 (0) 911 92680-0
Fax: +49 (0) 911 92680-8839
E-Mail: wn@winicker-norimed.com
Internet: www.winicker-norimed.com

CRO

Winicker Norimed GmbH, located in Nuremberg, is an independent, owner-operated contract research organization. Our experienced, interdisciplinary team of approximately 132 employees manages your projects from the planning through the field phase to the analysis and the clinical study report or publication. We deliver quality services according to applicable laws and international guidelines based on either our own or our clients standard operating procedures. In cooperation with hospitals and primary care physicians, we manage phase II-IV clinical trials with pharmaceuticals, studies with medical devices as well as non-interventional and epidemiological studies.

XL-protein GmbH

BIOTECH

Keywords: Drug Development, Pharmacokinetics, Peptide/Protein

XL-protein is a biopharmaceutical company utilizing its proprietary 'PASylation' technology to develop second generation biopharmaceuticals with prolonged plasma half-life. PASylation of therapeutic proteins allows less frequent and lower dosing combined with better tolerability, also opening perspectives for follow-on products of approved biopharmaceuticals. PASylation - the genetic fusion with conformationally disordered polypeptide sequences composed of the amino acids Pro, Ala, and/or Ser - provides a superior way to attach a solvated random chain with large hydrodynamic volume to a biologically active protein. Thus, its typically rapid clearance via kidney filtration can be retarded by one to two orders of magnitude while the PAS moiety is biochemically inert and easily degradable.



Contact:
Prof. Dr. Arne Skerra

Lise-Meitner-Str. 30
D-85354 Freising
Phone: +49 (0) 8161 53730-90
Fax: +49 (0) 8161 53730-99
E-Mail: info@xl-protein.com
Internet: www.xl-protein.com

XVir® Therapeutics GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Xvir Therapeutics GmbH was founded in 2004 and is focusing on the clinical development of novel cancer therapies for the treatment of various solid tumors, and in particular of drug-resistant or radiation-resistant tumors. Such cancer therapies are based on the use of oncolytic adenoviruses restoring drug sensitivity and radiation-sensitivity, respectively, of the tumors. Experimental evidence for the efficacy of Xvir's therapeutic approach has been provided in several animal studies. Xvir's therapeutic approach is covered by proprietary patents and patent applications, respectively.



Contact:
Dr. Per Sonne Holm

Nymphenburger Str. 1
D-80335 München
Phone: +49 (0) 89 9931 7446
Fax: +49 (0) 89 5155 6413
E-Mail: info@xvir.com
Internet: www.xvir.com

Zentrum für Humangenetik und Laboratoriumsdiagnostik (MVZ) Martinsried Dr. Klein, Dr. Rost und Kollegen

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Pharmacogenetics, PCR, Genomics, Chip/Array Technology, ELISA/EIA, NGS, Clinical Diagnostics

The Center for Human Genetics and Laboratory Diagnostics in Martinsried is specialized in advanced laboratory testing in genetics, clinical chemistry and immunology (in particular: HLA testing). The laboratory is accredited according to DIN EN ISO/IEC 17025 and ISO 15189. The institution's clinical consultation focuses on pediatric genetics, infertility and inherited diseases. Among the applied technologies are: PID, NIPT (Prenatalis®), Next Generation and Sanger Sequencing as well as Array technologies, Blotting, FACS, FISH, HPLC, pyrosequencing, real-time PCR and tandem mass spectrometry. One of its newly established tests is the molecular genetic analysis of the human microbiome (enteralis).

CENTER FOR HUMAN GENETICS AND LABORATORY DIAGNOSTICS
Dr. Klein, Dr. Rost and Colleagues



Contact:
Dr. med. Hanns-Georg Klein

Lochamer Str. 29
D-82152 Martinsried
Phone: +49 (0) 89 895578-0
Fax: +49 (0) 89 895578-780
E-Mail: info@medizinische-genetik.de
Internet: www.medizinische-genetik.de



Contact:

Moosburger Str. 7
D-84072 Au i.d. Hallertau
Phone: +49 (0) 8752 8656-71
Fax: +49 (0) 8752 8656-72
E-Mail: manfred.seifert@zeta.com
Internet: www.zeta.com

Zeta Biopharma GmbH

BIOTECH & PHARMA PRODUCTION

The Zeta group of companies specialises in the development and supply of tailored process and procedure solutions for sterile and aseptic applications. Zeta Biopharma: Early cooperation in all technical disciplines within the framework of projects enables us to provide customers with: reliable, high-quality and integrated process solutions and technologies a user-oriented, productivity- and maintenance-optimised layout optimum economic, functional and technical safety for the operator without interfaces, for the purpose of a simultaneous engineering concept based on our specific knowledge and our project experience from the pharmaceutical industry and biotechnology. We have made it one of our central objectives to offer our customers added value in the shortest possible time via activated technology investment in order to have a sustainable positive impact on their return (ROI). Short project accomplishment times in accordance with the schedule, predominantly through efficient project management and targeted project accomplishment at the highest technical level, and the heavy involvement of our customers and partners in the project development and accomplishment process are our strategies for fulfilling this requirement.

Zimmer BioTech GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Founded in October 2016, Zimmer BioTech, a Neu-Ulm, Germany-based drug development startup is advancing Alevin deep, a drug based on the compound 5-Aminolevulinic acid (ALA), which is used in the treatment of actinic keratoses in combination with photodynamic therapy (PDT). The spin-off also fulfils the legal requirements in the field of pharmaceuticals, as a quality management system focusing on pharmaceutical products has been put in place. In 2017 Zimmer BioTech raised 7m in funding. Investors included Zimmer MedizinSysteme GmbH, the medical device producer which spun off the company, and High-Tech Gründerfonds. The company will use the funds to continue to develop a new therapy to combat skin cancer



Contact:

Junkersstraße 9
D-89231 Neu-Ulm
Phone: +49 (0) 7304 9283270
Internet: www.zimmer.de/



FORUM

Translational Medicine

November 29, 2018

Rudolf Virchow Center
University of Würzburg

- New Technologies
- New Targets
- New Therapies

Conference Reception, November 28, 2018:
Lost in Translation?
Juliuspital-Zehntscheune, Würzburg

managed by



Bio^M for BioEntrepreneurs

we guide you from idea to success

- Mentor Circle
- Pitch Doctor
- Boot Camp
- BioAngels
- m⁴ Award
- BioEntrepreneur Lounge
- BioEntrepreneurship Summit



CONFERENCE LOCATION

AT THE INNOVATION UND START-UP CENTER FOR BIOTECHNOLOGY



Innovation and
Start-up Center
Biotechnology


Fördergesellschaft IZB mbH
Am Klopferspitz 19
82152 Planegg/Martinsried

Tel.: + 49 (0)89.55 279 48-27
Fax: + 49 (0)89.55 279 48-29
E-Mail: conference@izb-online.de

- Conference Rooms (up to 100 persons)
- IZB Residence CAMPUS AT HOME
for guests of the Campus Martinsried/
Grosshadern and conference guests only
- Restaurant SEVEN AND MORE
- Catering & Restaurant Freshmaker

www.izb-online.de

Financing Life Science Innovation



TVM Capital Life Science

TVM Life Science Management GmbH, TVM Capital GmbH, Munich
TVM Life Science Management Inc., Montréal